ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
Recently Viewed
You have not visited any articles yet, Please visit some articles to see contents here.
CONTENT TYPES

Overview of Recent Strategic Advances in Medicinal Chemistry

Cite this: J. Med. Chem. 2019, 62, 21, 9375–9414
Publication Date (Web):May 3, 2019
https://doi.org/10.1021/acs.jmedchem.9b00359
Copyright © 2019 American Chemical Society
Subscribed Access
Article Views
13799
Altmetric
-
Citations
LEARN ABOUT THESE METRICS
PDF (11 MB) OpenURL HONG KONG UNIV SCIENCE TECHLGY

Abstract

Introducing novel strategies, concepts, and technologies that speed up drug discovery and the drug development cycle is of great importance both in the highly competitive pharmaceutical industry as well as in academia. This Perspective aims to present a “big-picture” overview of recent strategic innovations in medicinal chemistry and drug discovery.

Introduction

ARTICLE SECTIONS
Jump To

The process of drug development, from identification of a new bioactive chemical entity to regulatory approval, is complex, costly, and time-consuming. It can take 10–15 years or even longer.(1−3) Thus, there is enormous pressure from the pharmaceutical industry, as well as clinicians and patients, to speed up the process. Fortunately, the extremely rapid accumulation of biological data in the postgenomic era as well as the development of computational chemical biology have stimulated an unprecedented revolution in medicinal chemistry, and the paradigm for discovery of pharmacologically interesting molecules has changed over the past few decades from a largely serendipitous, trial-and-error approach to a much more sophisticated and multifaceted approach, which has greatly improved the efficiency of drug discovery resulting in a significant acceleration of the overall process.(4−7)
This current Perspective analyzes the articles that have appeared recently in some top journals of the medicinal chemistry community (primarily in the Journal of Medicinal Chemistry), in order to provide a broad-brush picture of the trends in strategic innovations in the fields of medicinal chemistry, drug discovery, and other related fields (Figure 1), focusing in particular on drug repurposing, diversity-oriented synthesis-facilitated medicinal chemistry, structure-based drug discovery, multiparameter optimization, and biological system-mediated drug delivery. The strategy of bioorthogonal chemistry and photoactivatable-inspired medicinal chemistry with high temporal and spatial precision was first proposed by integrating related innovations in related fields.

Figure 1

Figure 1. Overview of recent strategic advances in medicinal chemistry.

1. Drug Repurposing and “Privileged Structure” Repositioning

ARTICLE SECTIONS
Jump To

Drug repurposing (also called repositioning, redirecting, reprofiling) is a polypharmacology-driven strategy for generating additional value from an existing drug by targeting diseases other than that for which it was originally intended.(8,9) This has significant advantages over new drug discovery since chemical synthesis steps, manufacturing processes, reliable safety, and pharmacokinetic properties in early clinical developmental phases (Phase I and Phase IIa trials) are already available. Therefore, repositioning of launched or even failed drugs provides unique translational opportunities, including a substantially higher probability of success to market as compared with new drugs, and a significantly reduced cost and timeline to clinical availability.(10,11)
Actually, drug repositioning is not a new strategy; many drugs have been successfully repositioned, including zidovudine (1, cancer → HIV), gemcitabine (2, viral infections → cancer), sildenafil (3, heart related chest pain → erectile dysfunction), amphotericin B (4, leishmaniasis → fungal infections), bromocriptine (5, Parkinson’s disease → type 2 diabetes), finasteride (6, enlarged prostate → scalp hair loss), methotrexate (7, chemotherapy agent → immune system suppressant), minoxidil (8, antihypertensive vasodilator medication → androgenic alopecia), ketoconazole (9, fungal infections → Cushing’s syndrome), fingolimod (10, immunomodulating drug → multiple sclerosis), raloxifene (11, osteoporosis → breast cancer), and thalidomide (12, antiemetic drug → multiple myeloma) (Figure 2).(12,13)

Figure 2

Figure 2. Examples of drugs that have been repositioned: finding and developing new uses for the approved drugs.

Additional successful examples of drug repositioning have been reported. For example, in 2017, levosimendan (13, used to treat heart failure) was identified through screening of an FDA-approved drug library as a novel and promising HIV-1 inhibitor targeting viral transcription. Levosimendan displayed robust potency against TNFα-induced HIV-1 reactivation in many cell lines with HIV-1 latency via the HIV-1 Tat-LTR transcriptional axis. Moreover, it inhibited not only acute viral replication but also the reactivation of latent HIV-1 proviruses in primary CD4+ T cells.(14)
In recent years, many chemically diverse FDA-approved drugs with potency for inhibiting the cell entry of Ebola virus have been identified; these include benztropine (14), bepridil (15), paroxetine (16), sertraline (17), toremifene (18), imipramine (19), clomipramine (20), and thioridazine (21), which directly bind with Ebolavirus glycoprotein.(15)
In 2018, pharmacological inhibition of neuraminidase by two anti-influenza agents, oseltamivir (22) and zanamivir (23), was found to protect cardiomyocytes and the heart from myocardial injury. Subsequently, a key role of Neu5Ac in acute myocardial infarction was confirmed by functional metabolomics studies, and neuraminidase-1 was identified as a previously unrecognized therapeutic target for coronary artery diseases.(16)
In 2018, through screen of a fragment library (2500 compounds), Urquiza et al. identified the antifungal ciclopirox as a binder to and stabilizer of uroporphyrinogen III synthase, a drug target of congenital erythropoietic porphyria (CEP), thereby restoring activity of the enzyme. Also, ciclopirox exhibits orally effective in vivo activity and low toxicity, in a genetic mouse model of CEP.(17)
In 2019, via cell-based reporter assays, primary cell culture, and multiple mouse models, it was found that non-nucleoside HIV-1 reverse transcriptase inhibitor efavirenz is a potent pregnane X receptor (PXR)-selective agonist that can efficiently activate PXR to induce hypercholesterolemia and hepatic steatosis.(18)
Via screening 2486 FDA-approved drugs, new Na+/K+ ATPase inhibitors were identified, which enable the dissociation of circulating tumor cells clusters into single cells, resulting in DNA methylation remodeling at critical regions and metastasis suppression.(19)
In 2019, it was reported that three salicylanilide anthelmintic drugs, namely, niclosanide (24), oxyclozanide (25), and rafoxanide (26), showed significant antiadenovirus potency at low micromolar concentrations with little cytotoxicity. Furthermore, the mechanistic assays show differences in the way the drugs exert antiadenovirus potency. Compounds 24 and 26 target transport of the human adenovirus type (HAdV) particle from the endosome to the nuclear envelope, while 25 specifically targets the early gene E1A transcription step of adenovirus.(20)

1.1. New Developments on Drug Repurposing

Today, most strategies for repositioning are based on phenotypic screening and systematic screening (robotic high-throughput screening, HTS) using a panel of approved drugs.(21,22)
Identifying the molecular targets of compounds from phenotypic screening is a challenging but crucial step toward understanding their mechanisms of action. In this context, many target identification methods have been used to successfully elucidate the target proteins of a variety of compounds. For example, chemoproteomics has proven an effective tool to identify protein targets from phenotypic assay and to understand on- and off-target engagement of potential bioactive agents. Mass spectrometry (MS)-based proteomics is the primary technology for target identification.(23) Moreover, photochemistry (live-cell photoaffinity labeling) has been employed recently to identify novel targets for known molecules.(24−26)
In recent years, with the continuous development of bioinformatics and cheminformatics, drug repurposing has gradually developed into a data-driven innovative drug development strategy. Recent work has demonstrated that bioinformatics-based methodologies have the potential to provide the kind of systematic insights into the complicated relationships among diseases, targets, and drugs that are needed for successful repositioning.(27,28)
With the guidance of bioinformatics and cheminformatics, recent progress has also been made in exploration of the chemical space of existing drugs for novel bioactivities with translational potential (Figure 3). For example, zileuton (27, trade name ZYFLO) is an orally bioavailable inhibitor of 5-lipoxygenase and thus inhibits formation of leukotrienes (LTB4, LTC4, LTD4, and LTE4); it is used for the treatment of asthma. Based on previous studies indicating that the leukotriene pathway is involved in human tauopathy (bioinformatics), it was recently shown that aged tau transgenic mice treated with zileuton exhibit reversal of learning impairments, memory deficits, and neuropathology.(29)

Figure 3

Figure 3. Identifying and developing new uses from existing (investigational) drugs via new approaches or further optimization.

Suberanilohydroxamic acid (SAHA, vorinostat, 28), an approved histone deacetylase (HDAC) inhibitor, was used for treating cutaneous T cell lymphoma. Previous studies suggested that 28 showed potential anti-inflammatory activity (cheminformatics), though the underlying mechanisms remained unclear. Based on this, Lu et al. reported drug repurposing of HDAC inhibitors as agents to alleviate neutrophilic inflammation in idiopathic pulmonary fibrosis and acute lung injury via binding with leukotriene A4 hydrolase, thereby inhibiting leukotriene B4 biosynthesis.(30)
Integrating computational prediction and experimental validation has great potential to improve the success of drug repositioning.(31,32) In 2014, Huang et al. reported a combination of systems biology and multiple microarray experimental approaches to find and characterize the function of novel oncogenes associated with hepatocellular carcinoma and lung cancer. This was helpful in drug repositioning discovery.(33)
A plethora of in silico approaches have been developed to facilitate the repositioning of drug-like molecules, including virtual screening, reverse pharmacophore profiling, or binding pocket comparisons. For example, NorA is the most important efflux pump of Staphylococcus aureus as it confers multidrug resistance. Astolfi et al. constructed a ligand-based 3D-pharmacophore model of efflux pump inhibitors (EPIs) based on the S. aureus (ModB and ModC) NorA EPIs library. The best model was screened against approved drugs, leading to the discovery of novel and potent NorA EPIs, including three nonantibiotic approved drugs dasatinib (29, used to treat certain cases of chronic myelogenous leukemia and acute lymphoblastic leukemia), gefitinib (30, used for certain breast, lung, and other cancers), and nicardipine (31, used to treat high blood pressure and angina) that were able to restore the antibacterial activity of ciprofloxacin against resistant S. aureus strains overexpressing NorA.(34)
Using a computational screen of an FDA-approved drug library, the proton pump inhibitor lansoprazole (32) was repositioned as an anticancer drug by binding to the thioesterase domain of human fatty acid synthase.(35)
Multiple ligand simultaneous docking (MLSD) is a computational tool used to investigate interactions between a biotarget and substrate in the presence of an inhibitor. In 2011, Li et al. described a novel approach to drug discovery by combining fragment-based drug design with drug repositioning using MLSD. This led to the identification of celecoxib and its analogues as new inhibitors of signal transducer and activator of transcription 3 (STAT3).(36a) In 2014, they further reported the identification of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 protein–protein interaction through MLSD-derived drug-repositioning methodology.(36b) Novel in silico drug design approaches, especially those related to machine-learning algorithms, are being utilized for in silico drug repositioning, as exemplified by drug profile matching,(37) topological graph theory,(38) and other computational methodologies.(39−41)
Because of the limited variety of drugs on the market, it is necessary to expand the selection of drugs or drug-like molecules (investigational compounds). As we know, development of repurposed drugs is also limited by challenges in the regulatory path.(42) Widening the scope of compound library beyond approved drugs can help overcome this shortcoming.
For example, three pyrimidinone derivatives 33ac, previously known as nonapproved HIV-1 non-nucleoside reverse transcriptase inhibitors, were reported to inhibit cell proliferation and facilitate cell differentiation via inhibiting (a nontelomeric) endogenous reverse transcriptase.(43)
Robotic HTS of a natural compound library (Spectrum), a library of pharmacologically active compound (LOPAC), and an FDA-approved drug library (Prestwick) against Plasmodium falciparum Hsp90 (PfHsp90) resulted in three hits: (±)-2-amino-3-phosphonopropionic acid (34) (APPA) from LOPAC and harmine (harmaline) (35) and acrisorcin (36, a combination of the active ingredients 9-aminoacridine and 4-hexylresorcinol) from Spectrum. These compounds were identified as selective PfHsp90 inhibitors, with IC50 values in the nanomolar level in a cell-based antimalarial assay, and showed synergistic potency in the presence of chloroquine, a drug used to prevent and to treat malaria.(44)
Selective optimization of off-target activities represents an original alternative to HTS. For example, the 1,2,4-triazol-3-ylthioacetanilide RDEA806 (37) was once advanced into phase IIa clinical trials as a promising novel anti-HIV-1 drug candidate in Ardea Biosciences (a subsidiary of AstraZeneca). Meanwhile, it also showed uric acid lowering potency and potential for the chronic management of hyperuricemia and gout. In a follow-up study, 1,2,4-triazol-3-ylthioacetic acid RDEA594 (38), a major metabolite of RDEA806 was identified, which retained all the uric acid lowering effects of RDEA806, but no antiviral potency. Compound 38 is an orally bioavailable inhibitor of urate-anion exchanger transporter 1. In December 2015, 38 was approved by the FDA, named Lesinurad, ZURAMPIC as combination therapy with a xanthine oxidase inhibitor for treating hyperuricaemia and gout.(45,46)
Depending on the new indication, the repurposed (experimental) drugs may need further medicinal chemistry optimization to improve their potency and selectivity as potential clinical candidates for clinical therapy. For example, Itraconazole (ITZ, 39) is a clinically efficacious antifungal agent. Recent drug-repurposing projects identified ITZ as a potent anticancer agent through its off-target activity, including the vascular endothelial growth receptor 2 (VEGFR2), mTOR signaling and hedgehog (Hh) signaling pathways. To fully investigate the structural requirements for these anticancer properties, various ITZ derivatives were prepared and evaluated for anti-Hh and antiangiogenic activities (exemplified by 40a). The results suggest that the triazole functionality is indispensable to ITZ-mediated inhibition of angiogenesis, but that it is not required for inhibition of Hh signaling.(47) Further optimization suggested that modification of the sec-butyl side chain of ITZ can result in improvement of the pharmacological activity (HUVEC proliferation or VEGFR2 glycosylation) of itraconazole.(48a) In an effort to eliminate ITZ’s inhibition of CYP3A4 (the drug metabolizing enzyme) while retaining antiangiogenic activity, a series of derivatives were designed and prepared in which the 1,2,4-triazole ring was replaced with a set of azoles and other rings. Among these analogues, 40b with tetrazole in place of 1,2,4-triazole displayed the best effect on HUVEC proliferation with an IC50 of 73 nM with extremely weak inhibition of CYP3A4 (EC50 > 20 μM). Similar to itraconazole, 40b could induce Nieman-Pick C phenotype and inhibit AMPK/mTOR signaling.(48b)
Pretomanid (41, PA-824) is an experimental antituberculosis drug. Phenotypic screening of pretomanid derivatives toward kinetoplastid diseases unexpectedly resulted in the discovery of DNDI-VL-2098 (42) as a promising first-in-class drug candidate for visceral leishmaniasis. Additional SAR studies led to the discovery of phenylpyridine derivatives (43, 44) with significantly improved potency in a mouse model of acute Leishmania donovani infection.(49)
Tozasertib (45) was originally developed as an anticancer agent targeting AurA. One iteration of automated multiobjective in silico design (computational chemistry and machine learning) was sufficient to shift the selectivity of tozasertib toward the pain target TrkA. Compound 46 was selected as a top-ranked molecule from a focused library derived from tozasertib, which showed 10,000-fold improved selectivity versus AurA, cellular activity at nanomolar concentration, and high selectivity for TrkA versus a kinase panel.(50)
A HTS approach identified the antihistamine terfenadine (47) as possessing previously unreported antimicrobial potency against Staphylococcus aureus (S. aureus) and other Gram-positive bacteria. Mechanism of action investigations by Perlmutter et al. indicated that terfenadine-based analogues (exemplified by 48) displayed antibacterial potency, at least in part, through inhibition of bacterial type II topoisomerases.(51)
The nucleoprotein (NP) of influenza A virus is a promising target for new antivirals. Previously, naproxen (49) was disclosed as a dual inhibitor of NP and cyclooxygenase cyclooxygenase-2 (COX2), with antiviral and anti-inflammatory potency by in silico screening. Very recently, further optimization using traditional medicinal chemistry strategies to remove COX2 inhibition potency afforded derivatives 50a and 50b with improved antiviral potency in infected cells, without inhibiting COX2. This improved antiviral potency probably results from these two derivatives inhibiting the interactions between NP and RNA and polymerase acidic subunit N-terminal, respectively.(52)
Biology-oriented drug synthesis has great potential to explore compounds derived from commercial pharmaceutical drugs for new and diversified biological potential by adopting simple chemical transformations.(53)
Overall, drug repurposing, combined with innovative methods for drug validation, has greatly contributed in recent years to the discovery of novel antiviral molecules, broad-spectrum antiviral agents (BSAA), and targets for therapeutic intervention.(54)
In particular, the discovery and development of BSAA has been a key aim of antiviral research,(55) and various broad-spectrum nucleoside derivatives, host-targeting antiviral agents, and immune-modulating agents have been reported (Figure 4). For example, ribavirin (51), a nucleoside analogue with broad-spectrum antiviral potency, is effective against a mammalian bornavirus, avian bornaviruses, and Borna disease virus.(55) Sofosbuvir (52), a clinically approved anti-HCV drug, also inhibits Zika virus RNA polymerase.(56) Favipiravir (53, T-705), a broad-spectrum antiviral compound approved in Japan for treating influenza virus infection, has already been used off-label to treat patients infected with Ebola virus and Lassa virus.(57) Nitazoxanide (54), a FDA-licensed drug for treatment of enteritis due to protozoa, parasites, and anaerobic bacteria, also displays a variety of antiviral potencies and is currently in phase II/III clinical trials for treatment of infections caused by influenza viruses, HCV, norovirus, and rotavirus.(58)

Figure 4

Figure 4. Representative broad-spectrum antiviral drugs.

Host-based antiviral agents could interfere with viral pathogenesis by targeting host cellular factors required for viral infections or innate immune responses.(59) Several potent inhibitors of inosine-5′-monophosphate dehydrogenase(60−63) and inhibitors of phosphatidylinositol 4-kinase IIIβ(64) have in vitro antiviral potency against a range of DNA and RNA viruses (HCV, human rhinovirus, and coxsackievirus B3, Zika virus, norovirus, influenza virus, and dengue virus). Recently, it was reported that ITZ also displayed broad-spectrum antiviral potency against enteroviruses, cardioviruses, and HCV, via targeting oxysterol-binding protein, a cellular lipid shuttling machinery. The core structure bearing five rings and the sec-butyl chain are crucial to antiviral potency, whereas the triazole ring, which is indispensable to antifungal potency, is not.(65)

1.2. “Privileged Structure” Repositioning

The hit rates by repositioning of commercially available approved or experimental drug libraries are usually quite low, and the hits often have low structural diversity. As a supplement, compound collections based on privileged structures offer the potential of libraries encompassing favorable physicochemical profiles and containing privileged scaffolds known to target various cellular targets, thereby increasing the success rate of discovering selective molecules that inhibit specific targets. In this section, it is intended to be illustrative rather than comprehensive, and the examples are chosen to convey the range of opportunities available and the current state of the art of “privileged structure” repositioning, highlighting its contributions to new drug discovery.

1.2.1. Diversity-Oriented “Privileged Structure” Repositioning

Diversity-oriented synthesis (DOS) based on privileged structures employed in existing drugs frequently have other, undiscovered activities. This observation highlights opportunities for drug discovery through screening of drug (lead)-like compound libraries; the resulting hits are likely to be safer and less expensive to develop than conventional hits, as well as having a shorter development timeline.(66,67)
1,6-Naphthyridine-7-carboxamide (in pink) has been regarded as a promising motif with drug-like properties. Among structurally diverse HIV-1 integrase inhibitors, the 8-hydroxy[1,6]naphthyridine L-870,810 (55) was a promising anti-HIV drug candidate, but in spite of its pharmacological activity, the development of 55 was halted during phase I clinical studies (reasons unknown). Nevertheless, because of its desirable drug-like properties, novel derivatives of 55 (substitutions at the 5- and 8-positions) were designed to overcome the limitations of naphthyridine-7-carboxamides as antiviral compounds and to reposition them as novel cytotoxic anticancer agents. Finally, further structural decoration of the 5,8-disubstituted-[1,6]naphthyridines (on 7-carboxamide) afforded novel molecules 56ac with remarkable cytotoxicity toward a set of cancer cell lines and high potency against selected oncogenic kinases (Figure 5).(68)

Figure 5

Figure 5. Discovery of bioactive molecules via diversity-oriented “privileged structure” repositioning approach.

In addition, a newly synthesized tractable tricyclic scaffold has been incorporated into new analogues of bioactive drug candidates across multiple target families, affording the potent serine peptidase DPP-4 inhibitor 57, a CCR5 receptor antagonist 58, and the highly selective PI3K δ isoform inhibitor 59.(69) Overall, the platform described in this section is widely applicable to accelerate drug discovery by using privileged structures from drugs approved for other indications.

1.2.2. Target Similarity-Inspired “Privileged Structure” Repositioning

Taking into account the structural understanding of targets, the design and screening of focused libraries (target-oriented synthesis, TOS) based on privileged structure platforms provide an efficient strategy to explore chemical space and to discover novel hits. For example, α-carboxynucleoside phosphonate (α-CNP) 60 with a cyclopentyl linker between the nucleobase and α-carboxyphosphonate inhibits HIV-1 reverse transcriptase preferentially (50 to 100 fold) over herpetic DNA polymerases. Interestingly, modifications in the linker moiety (compound 61) resulted in pronounced shift of the inhibition target (∼50 to 100 fold) from HIV reverse transcriptase to herpetic DNA polymerases (Figure 6).(70)

Figure 6

Figure 6. Discovery of bioactive molecules via target similarity-inspired “privileged structure” repositioning.

Ribonuclease H (RNase H)-like superfamily, also called retroviral integrase superfamily (including some metalloenzymes: HIV integrase, HIV RNase H, HBV RNase H, human cytomegalovirus pUL89 endonuclease, the NS1 protein of parvovirus B19, influenza virus polymerase acidic endonuclease), has attracted great attention as a potential drug target. The metalloenzyme activity is dependent on metal ions located in the catalytic site.(71) The shared enzymatic mechanism employed by many dication-dependent polynucleotide metabolizing enzymes provides a huge opportunity for a multipronged drug discovery effort. Divalent metal ion chelators, such as N-hydroxyimide, diketo acid, α-hydroxytropolone, pyrimidinol carboxylic acid chemotypes, etc., were reported as broad-spectrum antiviral agents via chelation of active-site divalent metal ions of metalloenzymes (as exemplified by 62 and 63).(72−74) For example, some anti-HIV RNase H compounds can inhibit HIV integrase, and vice versa.(72,74) Compounds prepared during anti-HIV RNase H screening should be screened against HBV; moreover, toxicity data of some of these molecules is known.(72) The endonuclease domain (pUL89-C) has an ribonuclease H/integrase-like fold. Like ribonuclease H, pUL89-C endonuclease function is dependent on metal ions in the catalytic site. pUL89-C endonuclease function was inhibited by HIV integrase inhibitor raltegravir.(73e)
Baloxavir marboxil (66, trade name Xofluza) is a cap-dependent endonuclease inhibitor for treatment of influenza A and influenza B, FDA-approved in October 2018 and given via oral single dose once/day. It shares a similar metal-chelating pharmacophore (red) in the structures of HIV integrase inhibitors dolutegravir (64) and bictegravir (65), which was prepared from readily derivatizable building blocks with well-established preparation methods.(75)
Analogously, based on integrase inhibitor-like pharmacophore (N-alkyl-5-hydroxypyrimidinone carboxamide in Raltegravir (67)), target similarity-inspired “privileged structure” repositioning resulted in the discovery of N-alkyl-5-hydroxypyrimidinone carboxamide 68 as a novel antitubercular agent against Mycobacterium tuberculosis.(76)

2. Bioorthogonal Chemistry-Inspired Drug Discovery

ARTICLE SECTIONS
Jump To

Bioorthogonal chemistry, referring to the chemical reaction that can occur at physiological conditions without interference from biomolecules, has been widely used in chemical biology and gradually used in drug discovery.(77) Several chemical reactions have been developed that fulfill the criteria of bioorthogonality, as exemplified by commonly used Cu(I)-catalyzed or strain-promoted azide–alkyne cycloaddition, Staudinger ligation, or the 1,3-dipolar cycloaddition between cyclooctynes and nitrones, thiol–ene click chemistry, and oxime/hydrazone formation from ketones and aldehydes, which have greatly facilitated the hit identification.

2.1. Rapid Assembly and Screening of Focused Combinatorial Fragment Libraries

In current drug discovery, parallel HTS or phenotypic screening of large compound collections is considered an effective approach to exploit chemical space and rapidly find hit compounds. However, the time-consuming and labor-intensive compound separation processes prior to evaluation have been bottlenecks in drug discovery.(78) In recent years, the rapid assembly and direct screening of focused combinatorial fragment collections in microtiter plates (or in parallel reactors) using bioorthogonal reaction (predominantly, click chemistry) has been developed as a robust and efficient method to establish structure–activity relationships (SARs) and for discovering bioactive molecules (Figure 7),(79) as exemplified by the discovery of HIV-1 PR inhibitors 6971,(80) highly selective and potent epigenetic inhibitors 7276 (HDACs and SIRTs),(81) JAK inhibitor 77,(82) and glucocerebrosidase inhibitor 78.(83) In our recent review, the inherent limitations and challenges facing this methodology were critically discussed.(79)

Figure 7

Figure 7. Discovery of highly potent and selective inhibitors through click chemistry-based combinatorial fragment assembly. CuAAC: copper(I)-catalyzed azide–alkyne [3 + 2] dipolar cycloaddition.

Undoubtedly, the success rate of this fragment-based drug discovery methodology relies on the information on detailed binding conformation and binding affinity of a range of small fragments bind to their respective targets. Besides, exploration of other HTS-amenable organic reactions suitable for efficient synthesis and screening of diverse chemical libraries, such as copper-free click chemistry, is crucial in overcoming these problems.(84−86)

2.2. Target-Guided Synthesis (TGS) Approaches

Target-guided synthesis (TGS) has proven a robust strategy in recent years for its original concept: using the biological target itself to assemble its selective ligands directly from a pool of fragments bearing complementary reactive functional groups. The approaches, bridging the gap between chemical synthesis and bioactivity assays, are divided into two major approaches: the kinetic TGS (KTGS) approach (Figure 8A), namely, the kinetically controlled reactions involving irreversible bond formation,(87) and the thermodynamically controlled reactions involving reversible reactions (also known as dynamic combinatorial chemistry, DCC) (Figure 8B).(88) Both strategies have been extensively and successfully implemented for hit finding for receptors and enzymes,(89) such as neuraminidase,(90) carbonic anhydrase,(91) kinase/phosphatase,(92) cyclooxygenase-2,(93) etc.

Figure 8

Figure 8. (A) KTGS principle. Best building blocks from each binding pocket of the biomolecule would preferentially react together because of their spatial proximity and afford the corresponding dimeric binder displaying synergistic bioactivity. (B) Thermodynamically controlled TGS or DCC principle. From appropriate fragments under equilibrium conditions, suitable dynamic combinatorial libraries (DCLs) are built up, allowing the generation of all possible library members in a thermodynamically controlled distribution (via selection pressure of the biotarget).

Particularly, structure-guided fragment linking of precursors that display weak affinity to the target (the KTGS approach) is considered a robust way to rapidly find potent inhibitors, based on cooperative binding. In KTGS approach, the biotarget accelerates the irreversible reaction (in situ click chemistry) between complementary fragments by bringing them into close proximity in proper orientation.(89) In 2017, Wang et al.(94) reported two cell-permeable O-GlcNAc transferase (OGT) inhibitors (79 and 80, IC50 = 139 and 66.7 μM, respectively), developed from low-activity components (IC50 > 1 mM) via a kind of dynamic combinatorial chemistry, namely, “tethering in situ click chemistry” (Figure 9A). The discovery of these compounds supports the idea that tethering in situ click chemistry can be utilized to search novel lead molecules from weak-binding fragments.(94)

Figure 9

Figure 9. Kinetic target-guided synthesis of (A) cell-permeable O-GlcNAc transferase inhibitors and (B) Bcl-X(L)/BH3 protein–protein interaction modulators.

In 2011, Manetsch et al. reported the use and validation of KTGS via the sulfo-click reaction between sulfonyl azides and thio acids as a valuable tool for the discovery of potent modulators targeting protein–protein interaction (as exemplified by Bcl-X(L)/BH3), acylsulfonamides 8184 (Figure 9B).(95,96) These results demonstrated that KTGS based on the sulfo-click reaction is a screening and synthesis platform for the straightforward identification of high-quality modulators.(96)
However, in most cases, target-guided synthesis requires purified proteins, which limits its application. In 2018, by applying metabolomics methods, Antti et al. demonstrated that target-guided synthesis with target proteins can also be achieved directly in cellular environments.(97) This method opens up new possibilities to screen drug candidates for difficult target proteins in cell-based systems.
Recently, the tetrazine bioorthogonal reaction has been used by Astex Pharmaceutical to stitch together functional proteolysis targeting chimeras (PROTACs) for degrading anticancer drug targets BRD4 and ERK1/2 within living cells (Figure 10). Notably, in situ assembly of two small compounds within a cell demonstrated higher efficacy than simply adding the preassembled compound.(98)

Figure 10

Figure 10. Tetrazine bioorthogonal reaction was used to form drug-like heterobifunctional molecule 87 inside cells, as the BRD4 degrader via the ubiquitin pathway.(98)

However, DCC represents a promising approach for a highly efficient generation of libraries.(89) As yet, however, this approach is limited by the techniques used for the analysis of protein–binder complexes and the few appropriate reactions. Several techniques have been used to the analysis of protein-directed DCL. These include X-ray crystallography, NMR spectroscopy, HPLC, and mass spectrometry. X-ray crystallography and NMR spectroscopy are high-resolution techniques, but are time-consuming. Notably, competitive MS binding assays have proved to be an effective method for the affinity determination of single molecule toward a protein of interest, which has been readily extended to the screening of compound collections as well. In the search of new γ-aminobutyric acid transporter 1 (GAT1) inhibitors, an exploratory research was undertaken in which pseudostatic hydrazone libraries were generated by DCC and screened against GAT1 using MS binding assays (Figure 11). Hydrazone 88 bearing a 2′,4′-dichlorobiphenyl moiety was identified as a robust binder with low nanomolar affinity (pKi = 8.1). Further optimization afforded 89 (pKi = 6.9) as a stable carba analogue of hydrazone.(99)

Figure 11

Figure 11. GAT1 inhibitor hits 88 and 89 were obtained by means of library screening and further optimization.

Besides, the efficient dynamic-combinatorial MS technique has the advantages of providing detailed information on mass shifts. In recent years, the disulfide or boronic acid/boronate ester dynamic systems coupled with protein MS analysis has been employed in the rapid discovery of JmjC histone demethylases and nucleic acid demethylases.(100)
To expand the potential and scope of DCC, very recently, a novel multiprotein DCC strategy was developed, which combines the sensitivity of differential scanning fluorimetry and the discriminatory power of a zwitterionic “thermal-tag”. This methodology enables simultaneous identification of subfamily selective inhibitors against several targets of interest.(101) It was illustrated that from aldehyde and amine fragments a quadruplex nanotemplate can dynamically select and amplify selective G quadruplex DNA binders, which further enriched the literature in this area and indicate the increasing level of interest in this field.(102)

2.3. Bioorthogonally Activated Chemotherapy (Bioorthogonal Uncaging Strategies)

Complementary to bioorthogonal reactions that ligate two molecules, there is an increasing interest in reactions that cleave a linker or release a molecule. Such dissociative bioorthogonal reactions have a broad spectrum of uses, including in drug delivery.(103)
To avoid toxic side effects on healthy cells and tissues, much research has been directed at the design of cancer-specific strategies (selective delivery of chemotherapeutic drugs to cancer cells), for example, by using prodrugs via controlled activation, which are inactive precursors of cytotoxic agents, but can be biochemically converted into their active forms in a spatially controlled manner. Recent advances in bioorthogonal catalysis are increasing the ability of medicinal chemists to manipulate the fate of molecules in complex biological systems. Consequently, bioorthogonal uncaging (bioorthogonally activated chemotherapy, also termed “click to release”) have been recently reported as an experimental prodrug therapeutic strategy to control drug release by the application of solid metals (mainly palladium) as implantable activating devices to catalyze various chemical reactions in biocompatible environments and to modulate the cytotoxicity of anticancer agents in specific biological settings.(104,105) While soluble palladium species such as Pd2+ complexes exert inherent cytotoxicity, Pd(0) catalysts are biocompatible and seem to be the safer agents.(105)
Recently, Unciti-Broceta reported palladium-labile biorthogonal prodrugs (9295) of several anticancer drugs, including cytotoxic gemcitabine (2),(105d) 5-fluorouracil (90, 5FU),(105e,f) floxuridine (91),(105g) and vorinostat (28)(105h) by introducing a Pd(0)-cleavable group (N-propargyloxycarbonyl (N-Poc) promoiety) at positions that are mechanistically relevant for the bioactivity of the original anticancer agents. As shown in Figure 12, such prodrugs are converted into cytotoxic agents selectively in the presence of Pd(0). For example, a Pd(0)-functionalized device could be surgically implanted in the affected area of tissue or organ, enabling local treatment of the disease with prodrugs, while reducing side effects in distant tissues and organs.(105) Very recently, new Pd-labile NO precursors were reported, which can be effectively uncaged by a biocompatible Pd(0) catalyst via bioorthogonal bond cleavage to release NO in living cancer cells, eliciting a potent antiproliferative effect.(106)

Figure 12

Figure 12. Bioorthogonally activated palladium-labile prodrug strategy and toxigenic mode of action (Prototype drugs were highlighted in blue).

There remains great interest in novel bioorthogonal uncaging strategies, as exemplified by the newly disclosed inverse electron-demand Diels–Alder reaction and gold-triggered uncaging chemistry.(107,108)
Another prominent example is the application of the highly strained alkene transcyclooctene and ene ether to mask functional groups, including amines and alcohols (Figure 13), which is then liberated upon reaction with a tetrazine.(109) In 2018, the group of Wang reported a concentration-sensitive bioorthogonal prodrug activation approach by taking advantage of reaction kinetics-controlled tetrazine–cyclooctyne click reaction, and spontaneous cyclization-based release. This study robustly demonstrated the concept of enrichment-triggered prodrug activation specifically in mitochondria and the critical feasibility of treating the related clinical diseases such as cancer and acute liver injury.(110)

Figure 13

Figure 13. Schematic illustration of the application of the highly strained alkene transcyclooctene and ene ether to mask an amine or alcohol.(109)

In summary, the use of bioorthogonal reactions to trigger caged groups furnishes a great opportunity to activate on the human body and could be translatable to patients in theory. We anticipate that more and more investigators will apply “click to release” approaches to trigger the release of drugs in vitro and in vivo.(110b)

3. Photoactivatable Medicinal Chemistry

ARTICLE SECTIONS
Jump To

Light has been used to suddenly liberate a ligand or substrate by removing a photolabile-protecting group (PPG) from a suitable precursor molecule to produce reactive oxygen species from photosensitizers or to control the activity of ligands in precise spatiotemporal manner to investigate the structure and function of important biotargets, and different concepts may be followed, as exemplified by photoactivatable caged (phototriggering) prodrug, photodynamic therapy, and photoswitchable ligands. These are collectively referred to as “photoactivatable medicinal chemistry”.

3.1. Photoactivatable Caged Prodrug

A newly emerging approach to regulate the action of bioactive compounds in a spatial and temporal control manner employs PPGs.(111) The PPG is a chromophore covalently linked to the pharmacophoric group of the bioactive compound, thus inhibiting its bioactivity, a concept known as “caging” (the photo prodrug). The covalent bond between the PPG and the drug molecule is broken by irradiation with ultraviolet light, resulting in the formation of the parent drug molecule (“uncaging”).
The off-target effects of systemically administered anticancer drugs heavily constrained their efficacy and tolerability. The photocaging concept has been used in the delivery of drugs across membranes; it reduces off-target effects, as exemplified by photoactivatable prodrug (97) of the antimelanoma agent vemurafenib (96),(112) caged RET kinase inhibitor 99,(113) photoactivatable caged prodrugs (101 and 102) of imatinib (100),(114) photocontrolled HDAC inhibitors 103, 104,(115,116) and 106, a photoactivatable prodrug of doxazolidine (105) targeting exosomes (Figure 14).(117)

Figure 14

Figure 14. Photoactivatable caged kinase inhibitors, HDAC inhibitors, and photoactivatable prodrug of doxazolidine targeting exosomes. Essentially, the photo prodrug concept is based on the mask of a pharmacophoric moiety. The PPG (pink) is therefore attached to the bioactive compound by a covalent bond. The parent bioactive molecules can be released by irradiation with ultraviolet light. Therefore, this method might improve higher drug concentrations in the area of interest sparing other compartments (such as cancer-afflicted tissues) in a rapid and efficient manner with lower side effects.

Meanwhile, a number of PPGs have been exploited for this purpose, including p-nitrobenzyl, 4,5-dimethoxy-2-nitrobenzyl, 7-diethylaminocoumarin-4-ylmethyl, and 6-bromo-7-hydroxycoumarine-4-ylmethyl. The successful application of the photoactivation concept to some kinase inhibitors and HDAC inhibitors afforded further evidence for this concept as a feasible approach in many other fields.(118,119) These photoactivatable caged prodrugs can be useful as pharmacological probes to investigate the impact of the parent molecules toward biological systems.

3.2. Photodynamic Therapy

Photodynamic therapy (PDT) is well studied and established in clinical application since the approval of the first drug, porfimer sodium, based on the characteristics of strong metabolism of tumor cells, after injection of photosensitizers (drugs), the concentration of tumor tissue is notably higher than that of neighboring normal tissues. At appropriate time, light irradiation with specific wavelength could activate photosensitizers, produce reactive oxygen species (such as singlet oxygen), and specifically kill cancer cells and destroy neovascularization.(120) PDT has proven a promising treatment option for various kinds of cancers and nonmalignant diseases including infections. Even though several photosensitizers have been clinically approved already, the development of additional photosensitizer with high phototoxicity, low dark-toxicity, and favorable aqueous solubility is very challenging for PDT.(121−123)
Several methods have been employed to obtain more efficient and less toxic photosensitizers. For example, conjugation with tumor-specific ligands (including small molecules, peptides, and proteins) significantly improves the selectivity of the active photosensitizer toward specific cells. In 2017, the conjugates 107 and 108 were synthesized by coupling zinc phthalocyanine to gonadotropin-releasing hormone (GnRH) analogues. Compared to unmodified zinc phthalocyanine, conjugates 107 and 108 demonstrated higher and more specific phototoxicities against breast cancer cells and robust in vivo anticancer efficacies (in animal model). Conjugate 108 exhibited a high safety profile for its low retention in brain and skin (Figure 15).(124)

Figure 15

Figure 15. Photosensitizers 107 and 108 mediated by GnRH receptors, and 109, the far-red light-activatable prodrug of PTX.

In 2016, compound 109, the far-red light-activatable prodrug of paclitaxel (PTX), was prepared by conjugating the photosensitizer via singlet oxygen-cleavable aminoacrylate linker (Figure 15). Through the combined effects of site-specific paclitaxel chemotherapy and photodynamic therapy, the cytotoxicity was significantly reduced.(125)
A recent study shows that hydroxypyridinone and 5-aminolaevulinic acid conjugates could substantially enhance the formation of phototherapeutic metabolite and phototoxicity.(126) In 2018, a novel series of porphyrin-based water-soluble derivatives were reported as potential sensitizers for effective PDT against breast cancer.(127) In 2018, two advanced boron dipyrromethene (BODIPY)-based photosensitizers with a glibenclamide-derived moiety were reported to behave as singlet oxygen provider with high photostability.(128)
This direction will continue to be a hot topic in the field of anticancer drugs.(129) In the future, it would be of high interest to explore if the photodynamic effectiveness may be improved and, at the same time, if the systemic toxicity may be reduced by photosensitizers that circulate in their inactive form in the normal tissues and are activated only by specific conditions in cancer cells (e.g., lower pH value, reducing environment). Furthermore, research in this direction should pay attention to questions like: a high concentration of glutathione present in the tumor tissues can consume reactive oxygen species; PDT is often followed by recurrence because of incomplete ablation of tumors.

3.3. Photoswitchable Ligands: Azobenzenes

There is growing interest in designing spatiotemporal control over enzyme activities using noninvasive stimuli, as exemplified by light.(130) Photoswitchable ligands, also termed photochromic ligands, are a class of molecules whose activity at a target of interest can be controlled precisely in a reversible manner by light. When irradiated with light of a certain wavelength, such molecules undergo a configurational change in their structure in a reversible way, which may substantially alter their binding affinity to a specific target.(131)
In recent years, azobenzenes were used as photoswitch due to favorable geometric and photochemical properties. This approach resulted in discovery of potent photoswitchable inhibitors (110 and 111) of γ-aminobutyric acid transporter,(132) a potent photochromic antagonist 112 that selectively targets the calcium ion permeable AMPA-type of ionotropic glutamate receptors,(133) and phototrexate (114), a photochromic analogue of methotrexate (113) as the human dihydrofolate reductase inhibitor (Figure 16).(134) All in all, this design approach opens new avenues for optically controlling enzyme function and optochemical biology.(135)

Figure 16

Figure 16. Chemical structures of phototrexate in the trans (in the dark and under blue/white light illumination) and cis (under UVA illumination) configurations.

4. Lead Diversification via Late-Stage Functionalization

ARTICLE SECTIONS
Jump To

Several strategies have been employed to generate collections of compounds with complex scaffolds, including diversity-oriented synthesis (DOS).(136) The direct functionalization of complex scaffolds at a late stage, namely, late-stage functionalization (LSF), is another often used approach to build derivatives efficiently with precise and substantial modifications to the platforms of these molecules without resorting to de novo synthesis.(137) In recent years, there is a lot of research on LSF, which has enabled rapid diversification of drug-like molecules or drug candidates to improve their potency and drug-likeness. Many innovative methods have been developed for this endeavor, including late stage C–H functionalization, nucleophilic aromatic substitution, etc.
C–H activation reactions are valuable tools for medicinal chemists to directly introduce functional groups into a bioactive compound at a late stage of synthesis.(138) For example, in the optimization of NCH-31 (115), a histone deacetylase (HDAC) inhibitor, a late-stage C–H coupling approach enabled rapid identification of novel derivatives IYS-10 (116a) and IYS-14 (116b), as a potent pan-HDAC inhibitor and an HDAC6-insensitive inhibitor, respectively (Figure 17).(139)

Figure 17

Figure 17. Late-stage functionalization using C–H diversification reactions and cytochrome P450 enabled rapid identification of HDAC inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, and phosphodiesterase 2 inhibitors.

In 2015, a stereodivergent and step-economical diversification of the privileged 2-arylcyclopropylamine motif by sequential C(sp3)-H borylation and Suzuki–Miyaura coupling was developed.(140) Then, in 2017, El Marrouni et al. described the successful application of a palladium-catalyzed C(sp2)–C(sp3) cross-coupling reaction of a fully elaborated inactivated organostannane compound 118 with a range of aryl halides to achieve rapid, parallel synthesis of HIV non-nucleoside reverse transcriptase inhibitor 119 from doravirine (117) (Figure 17).(141)
The palladium-catalyzed cross-coupling reaction between N-tosylhydrazones and heteroaryl halides constitutes a rapid and efficient approach to the preparation of 1,1-diarylethylenes as novel heterocyclic analogues of iso-Combretastatin-A4 (isoCA-4). Among them, 120 induced G2/M cell cycle arrest. It also exhibited interesting potency against CA-4-resistant colon carcinoma cells and multidrug-resistant leukemia cells, high human microsomal stability (in comparison to isoCA-4), and central nervous system (CNS) permeability.(142)
Direct functionalization of complex molecules still faces several challenges as chemical reactions with high selectivity, high yield, and mild reaction conditions are required. Somewhat unexpectedly, it was found that the number of reactions, dominating the chemical landscape of contemporary medicinal chemistry, is very limited.(143) To expand the chemical space and structure diversity of compound libraries and to facilitate the late-stage derivatization of several complex pharmaceutical compounds, there is a need to develop more LSF compatible reactions that prepare functional compounds with desirable properties.(144,145) Novel organic catalysts and synthetic methodology (including photochemistry and electrochemistry) are particularly promising for late-stage derivatization of complex molecules.(146−148) Sulfur(VI) fluoride exchange (SuFEx) reaction, which relies on readily available building blocks to afford molecules with the sulfonyl fluoride motif, has also expanded the toolbox of organic and medicinal chemists.(149−151)
Metabolomics has been applied not only in the drug discovery process and personalized medicine but also in lead diversification.(152) In 2018, Obach et al.(153) described a rapid and cost-effective late-stage lead functionalization method, whereby lead compounds can be converted into new derivatives by using liver microsomes at a submicromolar scale. Several representative human phosphodiesterase-2 inhibitors were incubated with liver microsomes from various organisms to afford multiple products, which were isolated and analyzed by quantitative cryomicroprobe NMR (qNMR) spectroscopy. The diluted solutions from qNMR analysis were subjected to biochemical assays, which yielded compounds PF-06815189 (124), 125, and 126 with improved potency inhibiting phosphodiesterase-2, physicochemical profile, and favorable metabolic properties, compared with the respective parent molecules 121123 (Figure 17).(153) The examples highlighted herein illustrate the value of organic and biocatalytic C–H functionalization methods in drug discovery.(154)

5. Multiparameter Optimization

ARTICLE SECTIONS
Jump To

A high-quality drug should exhibit a good balance of efficacy against its therapeutic targets, physicochemical properties, ADME properties (absorption, distribution, metabolism, and elimination) and safety.(155,156) In other words, drug discovery is a multiparameter optimization (MPO) process in which the aim is to find novel pharmaceutical molecules that meet the multiple drug-like criteria. Examples are “rule of 5”, “beyond rule of 5”, and “lead-like drugs”(157−160) and ligand efficiency metrics (such as lipophilic efficiency).(161) Half of all therapeutic targets cannot be modulated with small-molecules that comply with the rule of 5. Macrocycles have been found to be in “beyond rule of 5” space and were especially useful in drugging targets that have large, flat, or groove-shaped binding sites.(158)
Avoidance of toxicity and optimization of drug-like properties is a critical issue at the late stage of drug discovery.(162) Thus, in drug optimization, structure–property (or toxicity) relationship studies should be focused on a range of targets, not merely activity.(163,164)
Drug discovery for the CNS disorders still faces huge challenges, for example, the optimization of lead compounds into drug candidates is difficult due to the strict physicochemical properties required to penetrate the blood–brain barrier. In 2010, a druglikeness CNS MPO algorithm was designed by Pfizer, which has parametrized medicinal chemistry design space for CNS drug candidates.(165a) Since then, significant progress has been made in application of this simple-to-use design algorithm.(165b,c)
The significance of understanding the kinetics of the interaction between a ligand and its target has been acknowledged for a long time. Ligand–target residence time (structure–kinetic relationship, SKR) has also been valued as a key drug discovery parameter, and it is still receiving sustained attention. Numerous recent research articles from the medicinal chemistry community provide compelling arguments for more widespread assessment of binding kinetics and discussion of SKR.(166−169)
The binding of ligand with target is influenced by multiple factors, including hydrogen bonds and hydrophobic interactions, residual mobility, desolvation, dynamics, and the local water molecule.(170) Experimental tools to (un)binding kinetics are nowadays available,(171) but reliable computational methods for predicting kinetics and residence time are still lacking. Most attempts have involved molecular dynamics (MD) simulations, which are CPU-intensive and not yet particularly accurate.(172,173)
In 2016, Mollica et al. reported a new scaled-MD-based protocol, verified by directly comparing computational predictions, experimental kinetics measurements, and X-ray crystallography, which seems to have potential for predicting kinetics and drug residence times in drug discovery.(174) In considering structure–property–activity relationships, multiple aspects of ligand–protein binding need to be considered, including surface water networks coating protein-bound ligands(175) and water-mediated ligand functional group cooperativity.(176)
Off-rate screening by surface plasmon resonance (SPR) is an efficient approach to kinetically sample the hit-to-lead chemical space using unpurified reaction products.(177,178) Recent study demonstrated that the lifetime of the drug–target complex is governed by interactions in the transition state for ligand binding rather than the ground state of the enzyme–ligand complex, and the on-rates can play a key role in drug–target residence time.(179) In 2018, an efficient computational method, for the ranking of drug candidates by their residence time and giving insights into ligand–target dissociation mechanisms, was reported.(180)
Innovations in characterizing lead quality and compound prioritization have allowed more informed decision-making by medicinal chemists.(181) We anticipate that these new methodologies and technologies will dramatically improve the efficiency of early stage drug discovery.

6. Biological System-Mediated Drug Delivery

ARTICLE SECTIONS
Jump To

6.1. Antibody-Recruiting Molecules

Synthetic immunology, i.e., the development of synthetic systems to modulate immunological functions, is a newly established field. One focus of research has been to find synthetic small-molecular agents, named antibody-recruiting molecules (ARMs), that can enhance antibody binding to disease-relevant viruses or cells, thus promoting their immune-mediated clearance.(182,183)
Early in 2009, Spiegel et al. reported several ARMs that target prostate cancer.(184) They designed new bifunctional ARMs to bind to HIV-1 gp120 and antidinitrophenyl (DNP) antibodies, simultaneously. Anti-DNP antibodies are abundant in the human bloodstream. By connecting these two fragments together, ARMs (exemplified by 128, derived from the existing molecule 127 (BMS-378806)) could mediate the formation of a ternary complex, leading to blocking virus entry and antibody-mediated immune clearance of gp120-bearing cells (Figure 18).(185a)

Figure 18

Figure 18. Antibody-recruiting small molecules 128 and 130 that target HIV gp120 and 131 that targets prostate-specific membrane antigen.

In 2014, computationally driven modification of ARMs targeting HIV-1 gp120 gave an optimized molecule 130 (derived from 129), which was almost 1000-fold more potent than 128 in gp120-binding and cell-based antiviral assay. It was also effective against multiple HIV pseudotypes in laboratory and clinic.(185b)
In 2016, Genady et al. reported the discovery of radiolabeled ARMs (exemplified by 131) that target prostate-specific membrane antigen and anti-DNP antibodies for combined immunotherapy and radiotherapy.(186)

6.2. Human Serum Albumin-Derived Drug Delivery

Human serum albumin (HSA) is the most abundant protein in sera (30–50 g/L human serum), where it primarily functions as a natural transporter for a myriad of molecules. Being an intrinsic protein of the human blood, it exhibits no immunogenicity. It also has a long circulatory half-life (about 19 days) due to its binding affinity for the recycling neonatal Fc receptor. Thus, HSA is an ideal drug carrier for targeted delivery and for improving the pharmacokinetic profile (half-life extension) of drugs.(187−190) Several albumin-related small-molecular drug delivery technologies have been developed, including in vivo noncovalent or covalent endogenous HSA targeting, coupling of small molecule drugs to exogenous albumin, and encapsulation of drugs into albumin coated nanoparticles.(187)
Most small-molecular drugs are short-lived species in the circulatory system and can be rapidly eliminated via glomerular filtration. Noncovalent binding of small-molecular drugs to HSA could protect them against enzymatic degradation and renal clearance, affording slower clearance and a prolonged half-life in vivo.
For example, FMS(3)-gentamicin (133) was developed as a long-acting prodrug derivative by linking three (2-sulfo)-9-fluorenylmethoxycarbonyl (FMS) moieties to three amino moieties of gentamicin (132) to provide increased affinity for albumin.(191) Compound 134 is a fatty acid-like platinum(IV) prodrug designed to improve drug delivery via enhanced interaction with HSA.(192) The clinically relevant glucagon-like peptide 1 (GLP-1) was functionalized with diflunisal (135, albumin binder) and indomethacin (136, albumin binder) to afford a divalent GLP-1 analogue 137 with a longer circulatory half-life and absorption time compared to its monovalent equivalent (Figure 19).(193)

Figure 19

Figure 19. Examples of the in vivo noncovalent endogenous HSA targeting approach.

Kratz et al. established an in vivo covalent conjugation strategy that exploits endogenous HSA as a drug carrier. In this approach, the prodrug binds selectively and rapidly to the cysteine-34 residue on the surface of HSA after intravenous administration, thereby generating an in situ transport form of the drug in the blood (Figure 20A,B).

Figure 20

Figure 20. (A) X-ray structure of human serum albumin (bound with diflunisal, PDB ID 2BXE): the position of cysteine-34 is highlighted. (B) Schematic illustration of in vivo thiol–maleimide conjugation. (C) Chemical structure of doxorubicin-maleimide derivative 138, gemcitabine-maleimide derivatives 139 and 140, and albuvirtide.

A proof-of-concept was obtained with the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (138, DOXO-EMCH, INNO-206), which is the first albumin-binding prodrug of doxorubicin to enter clinical trials. Compound 139 selectively binds to circulating albumin within just a few minutes (Figure 20C).(194) Inspired by translational research with 138, many albumin-binding prodrugs have been developed, as exemplified by recently reported in situ covalent-albumin-binding gemcitabine prodrugs 139 and 140, which offer improved bioavailability and tumor accumulation (Figure 20C).(195) Notably, compound 139 demonstrated remarkably increased bioavailability (21-fold higher than gemcitabine) and efficient tumor accumulation of free-gemcitabine (8-fold greater than gemcitabine).
On 6 June 2018, Albuvirtide (141, ABT), a HIV fusion inhibitor developed by Frontier Biotech, was approved as a new anti-HIV drug in China, with long half-life in vivo (suitable for injection once a week) and potent and broad-spectrum potency against HIV-1 variants resistant to T20.(196) ABT is a 3-maleimimidopropionic acid-modified peptide that can irreversibly conjugate to HSA.(197)
The macromolecular prodrug strategy of in vivo HSA conjugation is effective to overcome rapid enzyme inactivation, extended half-life (exemplified by ABT), and poor tumor targeting of cytotoxic anticancer agents. It also offers several advantages over in vitro-synthesized drug albumin conjugates: (a) it avoids the need for carefully controlled purification of commercial albumin; (b) the prodrug is relatively inexpensive to manufacture and convenient to store and use; and (c) quality control is simple, being comparable to that needed for any other small-molecular drug candidate.

6.3. “Bio-oxidizable” Prodrug Strategy

To improve the efficiency and reduce side effects (arising from peripheral cholinergic activation) of approved acetylcholinesterase (AChE) inhibitors during symptomatic treatment of Alzheimer’s disease (AD), Levacher et al. reported a biological investigation of new AChE inhibitors based on a novel “bio-oxidizable” prodrug approach.(198) The design of this “bio-oxidizable” prodrug originates from an insight into the action mechanism of AChE inhibitors. Whereas donepezil (142) and galanthamine (143) are competitive inhibitors, rivastigmine (144) is a pseudoirreversible inhibitor via the carbamylation of the serine-OH located at the “esterasic site” of AChE. All these drugs share in common a tertiary amine moiety that plays an important role in the inhibition of AChE. At physiological pH, this amine was protonated as a positive charge bioactive form, which binds to the “catalytic anionic site” of AChE (Figure 21). Generally, the charged form cannot cross the blood–brain barrier through passive diffusion; the acid–base equilibrium permitted the neutral inactive form to penetrate this physiological barrier, which resulted in both central and peripheral cholinergic effects often observed with these drugs. Based on these mechanistic insights, by temporarily masking the positive charge at the periphery, a “bio-oxidizable prodrug” strategy was envisaged to design central specific AChE inhibitors, which afforded dihydroquinoline carbamate 1a and donepezil-based “bio-oxidizable” prodrugs 1r.

Figure 21

Figure 21. (A) Approved AChE inhibitors for the symptomatic treatment of AD and schematic representation of the ligand binding site of AChE; the “anionic” and “esterase” sites are highlighted. (B) Rational design of central selective AChE inhibitors via a “bio-oxidizable” prodrug approach.

Putatively, once in the CNS, the prodrugs 145a and 146a should be converted into the parent compounds 145b and 146b through a redox-activation process mediated by the NAD(P)H/NAD(P)+ coenzyme system. It is expected that the presence of a permanent positive charge in 145b and 146b could not only act as AChE inhibitors in the CNS through “locked-in” effect but also facilitate rapid elimination of the quinolinium salt form in the peripheral system. These studies strongly prove that this attractive “bio-oxidizable” prodrug strategy is ingenious and practical.

6.4. Mitochondrial-Targeted Agents

Cancer cells principally show higher mitochondrial transmembrane potential and abnormal metabolic pathways. Thus, the targeting and delivery of anticancer agents to the mitochondria could improve therapeutic efficacy.(199) This mitochondrial-targeted strategy was exemplified by introduction of delocalized lipophilic cations to the parent compounds. The most investigation-delocalized lipophilic cation is the triphenylphosphonium cation, and several successful examples have been reported with remarkable cytotoxicity and selectivity, including chlorambucil derivative 148 (Mito-Chlor)(200) and lupane triterpenoid derivative 150 (Figure 22).(201a) Additionally, a recent study demonstrated that conjugation with triphenylphosphonium cation can restore the antifungal activity of some natural terpenes.(201b)

Figure 22

Figure 22. Mitochondria-targeted anticancer agents.

7. Structure-based Drug Discovery

ARTICLE SECTIONS
Jump To

Structure-based drug discovery is a fundamental strategy for finding and optimizing lead compounds of therapeutic importance. This section will discuss the following topics: covalent inhibitors or probes, bisubstrate inhibitors, exploration of water-binding pockets, and drug design to stabilize inactive protein conformations, as these have been highlighted in very recent literature.

7.1. Covalent Inhibitors or Probes

An attractive increase in the potency and pharmacokinetics of a drug-like compound is to evoke the formation of a covalent bond. Compared with noncovalent inhibitors, the advantages of covalent compounds lie in the following aspects: higher potency, long residence time, and decreased drug resistance. In the past several years, many covalent drugs such as telaprevir, abiraterone, carfilzomib, and afatinib have been used in clinical, ushering in a new era for covalent modifiers.(202,203)
Covalent inhibitors should remain a key focus of contemporary drug discovery, especially in the initial structure-based design optimization, as exemplified by human tissue transglutaminase inhibitor 151,(204) c-Jun N-terminal kinase 3 inhibitor 152,(205) janus kinase 3 selective inhibitor 153,(206) KRAS inhibitor ARS-853 (154),(207) FGFR inhibitor 155 (PRN1371),(208) mitogen-activated protein kinase kinase 7 (MKK7) inhibitor 156,(209) EGFR inhibitor 147,(210) histone lysine demethylase KDM5A inhibitor 158,(211) pyruvate dehydrogenase kinase 1 (PDK1) inhibitor 159,(212) and monoacylglycerol lipase (MAGL) inhibitors 160 and 161(213) (Figure 23).

Figure 23

Figure 23. Covalent inhibitors in drug discovery: typical examples. The warheads for covalent binding are highlighted in red.

Complementarily, allosteric modulators are sought after as a means to avoid undesirable side effects of covalent or active site inhibitors. In 2016, the first covalent and potent cannabinoid 1 receptor (CB1R) allosteric modulator 162 was reported, which can be used as an effective chemical probe for characterizing CB1R allosteric ligand-binding motifs.(214) In 2018, the first covalent positive allosteric modulator 163 for the metabotropic glutamate receptor 2 (mGlu2, a class C GPCR) was reported, which advanced the understanding of the mGlu2 PAM interaction.(215)
The main hurdle for covalent inhibitors is the lack of selectivity. Apart from selecting a warhead or modulating of electrophilic warhead reactivity, substantial efforts are required to optimize noncovalent reversible interactions to facilitate target-selective recognition and the overall potency. For example, through crystallography, kinetic, and molecular simulation studies, interaction of cyanamide-based covalent JAK3 inhibitor 164 with residue Cys909 was optimized affording potent and selective JAK3 inhibitors as exemplified by 165, with substantially enhanced activity and selectivity (Figure 24A).(216)

Figure 24

Figure 24. Discovery of covalent inhibitors via (A) optimization of noncovalent reversible interactions and (B) diversity-oriented modification of warheads.

Y181C-mutated HIV-1 strain is one of the key clinically observed mutants. In 2017, Jorgensen’s group took Y181C-mutated HIV-1 reverse transcriptase as the target for drug design.(217) Based on the protein crystallography, it was found that the carbon–chlorine bond catechol in diethers compound 166 is oriented toward Tyr181, and its replacement with an electrophilic warhead could make covalent binding of Cys181 variants. Consequently, electrophilic group-bearing compounds 167170 were designed and synthesized. Especially, compounds 168 and 170 are covalent inhibitors of HIV-1 RT mutants (Y181C and K103N/Y181C) through in vitro assays (MT-2 cells), mass spectrometry, and protein crystallography. This is the first successful application of the irreversible covalent inhibition strategy to HIV-1 reverse transcriptase (Figure 24B).(217) Based on activity results, it is found that small chemical alterations of warheads often cause significant differences in activity. Therefore, diversity-oriented selection of warheads make possible the systematic exploration of the chemical space.(218)
Besides the most popular acrylamide, additional electrophilic traps have undergone considerable development as “privileged warheads” in chemical biology (exemplified by sulfonyl fluoride and isothiocyanate).(215,219) The exploration of warheads with chemical reactivity toward target enzymes for incorporation into parent compounds is expected to afford novel covalent drugs.
Design of boron-containing molecules has recently attracted much attention. Boron differs from carbon in that it has a vacant p-orbital that is receptive to a reversible covalent bond formation with a Lewis base under physiological conditions. Recently, boronic acid was proven a structurally and mechanistically differentiated electrophile from other cysteine reacting moieties, arising from the ability of boronic acids to generate a reversible covalent bond with oxygen nucleophiles (Lewis base) of the target protein. Boronic acid-based covalent agents have received widespread attention in the drug design community, with several boron-containing drugs (including bortezomib and ixazomib, tavaborole, and crisaborole) and other recent successful examples that have demonstrated their therapeutic effects (Figure 25).(220)

Figure 25

Figure 25. Structures of boron-containing drugs.

For many years, Raines and his team has been engaged in the research of boric acid based drug discovery and chemical biology.(221) In 2017, Raines et al. reported on boronic acid-substituted stilbenes that limit transthyretin (TTR) amyloidosis in vitro. X-ray crystallographic analysis of TTR/175 complexes (PDB code 5U4F) demonstrated that a boronic ester was reversibly formed with Ser117, which has a great contribution to the thermodynamics and kinetics of binding (Figure 26).(221a)

Figure 26

Figure 26. Structure of stilbene boronic acid 175 and its binding mode with TTR (PDB code 5u4f).

In 2018, based on the three-dimensional structure and mechanism of HIV-1 protease, this group replaced the aniline group of darunavir (176) with phenylboronic acid moiety, which led to the identification of 177 with increased affinity with the protease by 20 times and a high affinity for HIV-1 protease-resistant strain D30N (Figure 27). X-ray cocrystallization structure demonstrated that the boric acid group participated in triple hydrogen bonding, which was superior to the amino group in darunavir and other derivatives. The hydrogen bond distance between Asp30 (or Asn30) of protease and hydroxyl group of boric acid was shorter than orthodox hydrogen bonding, which had a certain degree of covalence. This is a reasonable explanation for high potency and remarkable antiresistance profiles of boric acid derivatives.(221b)

Figure 27

Figure 27. Discovery of boronic acid-bearing subpicomolar inhibitors of HIV-1 protease.

In 2007, a 100-fold affinity gain was achieved by introduction of a C-terminal boronic acid group into dipeptidic inhibitors (178a,b) of the West Nile, Zika, and dengue virus proteases. The resulting molecules (as exemplified by 179) have high binding affinity with Ki values in the two-digit nanomolar level, low cytotoxicity, and virus-inhibitory potency (Figure 28). SARs and a X-ray cocrystal structure of 179 with West Nile virus NS2B-NS3 protease pave the way for the design of advanced covalent-reversible inhibitors targeting emerging flaviviral pathogens.(222)

Figure 28

Figure 28. Discovery of 179 as a capped peptide–boronic acid inhibitor of flaviviral proteases and its binding mode with West Nile virus NS2B-NS3 protease (PDB code 5IDK).

Boronic acid transition-state inhibitors proved to be one of the most promising classes of serine amidohydrolase inhibitors, including β-lactamase inhibitors. In 2001, an unexpected tricovalent binding mode of boronic acids within the catalytic site of a penicillin-binding protein was reported.(223) The boron usually adopts a tetrahedral conformation, binds to the nucleophilic serine of the active site, and mimics the transition state of the catalytic reaction. Compound 180 (Ki = 44 nM) represented a promising lead compound against ADC-7 (Acinetobacter-derived cephalosporinase), one of the most critical resistance determinants in A. baumannii. The cocrystal structure of the ADC-7/180 complex suggested that the inhibitor was covalently linked to the catalytic residue Ser64 (Figure 29), highlighting the significance of key structural factors for recognition of the boronic acid moiety.(224)

Figure 29

Figure 29. Cocrystal structure of 180 in complex with ADC-7 β-Lactamase (PDB code 4U0X).

The risk of indiscriminate reactivity of active warheads and the resulting adverse effects can be reduced by incorporating latent electrophiles into irreversible covalent inhibitors. In general, a terminal alkyne is considered “inert” toward cellular components and is therefore often applied in bioorthogonal reactions. Recently, an alkyne moiety was introduced as a less reactive electrophilic moiety into cathepsin K inhibitors. Notably, based on crystal structure analysis, alkyne-based compounds 181 and 182 (Figure 30) effectively inhibit the activity of cathepsin K protease by formation of an irreversible covalent bond with the cysteine residue in the catalytic site in a proximity-driven manner. Just because of this, they did not show indiscriminate thiol reactivity. More importantly, based on these proof-of-concept studies, it is foreseeable that latent electrophiles such as the alkyne may be of important prospects in further design of cysteine-targeting irreversible covalent drugs with an improved safety profile.(225) Interestingly, a warhead moiety is not necessary for covalent inhibitors. For example, the cyclic piperidine and piperazine aryl ureas (piperidine-bearing PF750 (183) and piperazine-bearing JNJ1661010 (184)), without any warhead moiety, were reported as potent fatty acid amide hydrolase (FAAH) inhibitors (Figure 30) because FAAH could efficiently hydrolyze the amide bond of these molecules, forming a covalent enzyme-binder adduct.(226)

Figure 30

Figure 30. Covalent small molecule inhibitors with a latent electrophile or via a proximity-driven mode.

The binding process of covalent inhibitors with related targets consists of multiple processes, which are not necessarily independent of each other. Thus, computer-aided prediction of binding affinity for covalent inhibitors presents a great challenge. The free energy perturbation combined with λ-exchange molecular dynamics technique provided particular advantages in predicting binding selectivity among protein isoforms, which is a major challenge in covalent inhibitor design.(227) We envision that the continued interest in covalent drug discovery will propel further development of new computer programs to predict the binding energetics and binding mode of covalent drugs.(228)
Generally speaking, diversity-oriented structural modification can compensate for the shortcomings of target-based drug design and computational prediction. Under this situation, a fragment-based method combined with a MS covalent ligand screening was developed to discover irreversible covalent inhibitors of cysteine proteases, such as ubiquitin ligase.(229,230)

7.2. Bisubstrate Inhibitors

A bisubstrate inhibitor consists of two covalently connected fragments, each targeting either the substrate or the cofactor binding pocket, thus potentially mimicking the ternary transition state of a bireactant catalytic reaction. This drug design approach has the potential to obtain high potency and selectivity. More than a decade ago, several bisubstrate inhibitors were successfully developed for several proteins, including kinases and acetyltransferases.(231,232)
There have been some new developments in recent years. Mycobacterial biotin protein ligase (MtBPL) is an indispensable enzyme in Mycobacterium tuberculosis (Mtb) and regulates lipid metabolism via the post-translational biotinylation of acyl coenzyme A carboxylases (ACCs). The enzymatic reaction proceeds in two steps by sequential adenylation of biotin (185) to generate Bio-AMP (186), followed by acylation of the biotin carboxylase carrier protein domain of ACCs to afford holo-ACC (187). In 2015, nucleoside-based bisubstrate adenylation MtBPL inhibitors 188 and 189 were discovered, through modifications on the ribofuranosyl ring of the nucleoside (Figure 31A).(233)

Figure 31

Figure 31. (A) Targeting MtBPL with nucleoside-based bisubstrate adenylation inhibitors. (B) Schematic representation of the transition state of DNMT (DNMT1 and DNMT3A) catalytic site and the chemical modulation strategy. In red is depicted the methyl-donor AdoMet and its mimic 4-aminoquinazoline, in blue the deoxycytidine in the DNA and its analogues, and in pink the linker between the two moieties. Besides, the amino moiety in C4 position of the quinazoline was substituted by phenylpropylamine as a hydrophobic group on the amine at C4 position of the adenosine in AdoMet analogues, which was probably favorable for DNMT inhibition potency. (C) Discovery of a bisubstrate inhibitor of NNMT.

In 2017, on the basis of the structure of the catalytic pocket of DNMT (Figure 31B), the bisubstrate analogues-based inhibitors were designed, by mimicking each substrate of DNA methyltransferases (DNMT3A and DNMT1), the S-adenosyl-l-methionine (190, SAM), and the deoxycytidine, and linking them together, which resulted in quinazoline-quinoline-derived DNMT3A and DNMT1 inhibitors 191 and 192, some showing certain isoform selectivity.(234)
Inspired by the recently published ternary crystal structure of human nicotinamide N-methyltransferase (NNMT) in complex with the substrate nicotinamide (193) and the cofactor SAM as the methyl group donor, a bisubstrate NNMT inhibitor MS2734 (194) was discovered and characterized (Figure 31C). Furthermore, a cocrystal structure of 194 in complex with hNNMT was obtained, which paved the way for further developing more potent and selective NNMT inhibitors.(235)

7.3. Exploring Water-Binding Pockets (Structural Water Molecules) in Structure-based Design

Water molecules are important components in protein channels and are often found around ligands in protein crystal structures. Water-mediated interactions, especially hydrogen bonds, play key roles in drug binding.(236,237) Careful examination of these water molecules and their energetics can contribute to successful drug design, as exemplified by neuronal nitric oxide synthase inhibitors, nonpeptidic urea HIV protease inhibitors, and benzoxaborole non-nucleoside polymerase inhibitors of HCV.(238−240)
Recently, several structural and computational studies to explore water-binding pockets have been reported.(241−244) One way to systematically improve existing weak binders could focus on identifying and later chemically optimizing those moieties with a particular proximity or orientation to water molecules in the protein–binder complex. For example, the X-ray structure of the antiviral drug Arbidol (195) with influenza hemagglutinin revealed a highly ordered water molecule adjacent to Arbidol, and this was exploited in the structure-based design of Arbidol analogues (Figure 32). Addition of a meta-hydroxyl group to the thiophenol group of Arbidol to replace the water molecule in the binding pocket afforded 196, which showed significantly increased affinity for both H1 (98-fold) and H3 (1150-fold) hemagglutinin subtypes.(245)

Figure 32

Figure 32. Structure-based optimization based on the X-ray structure of Arbidol bound to influenza virus hemagglutinin (H3-HK68: A/Hong Kong/1/1968; PDB code 5T6N).

A recent study indicated that the introduction of a hydroxyl group to form a water-mediated hydrogen bond may not necessarily improve the binding affinity between ligand and target because hydrophobic effects also play an important role in ligand binding affinity in some cases.(246)
The M2 proton channel of influenza A is a well-validated target for the antiviral drugs, such as amantadine and rimantadine. Recent disclosed X-ray crystal structures of the M2 proton channel with bound inhibitors reveal that the inhibitors engage in and disrupt transmembrane networks of hydrogen-bonded water and that small molecules can enable potent inhibition by targeting key water molecules.(247)
Generally, it is thought that a protein binder can achieve affinity by extending into a region occupied by unfavorable water molecules or lose affinity by displacing water molecules from a region where it was relatively stable. However, the real situation is much more complicated. The prevailing thermodynamic theories of the past few years claim that water was observed largely in terms of an entropic gain after it was displaced by a ligand, which are now known to be too idealistic. In most cases, as water molecules can be difficult to locate by X-ray diffraction methods, especially when they are not tightly bound to biomacromolecules, NMR spectroscopy can be used as a valuable technique to assess those water molecules. By increasing the (perdeuterated) protein concentration, WaterLOGSY titration experiments help to get useful information about the location of protein-bound water in the surroundings of the ligand and ligand binding modes even in the case of weak binders, which are extremely beneficial to specific optimization of the ligand to enhance binding affinities.(248)
In view of the complexity and uncertainty of water-mediated interaction, the understanding of water’s roles in the underlying structural protein–ligand complexes came at the expense of very careful and detailed dissections of the relevant scenarios with new computational methodologies and isothermal calorimetric, spectroscopic, and crystallographic experiments.(249)

7.4. Stabilization of Protein Inactive Conformations or Protein–Protein Interactions

A large number of medicinal chemists have engaged in the design and development of protein kinases inhibitors. However, in comparison, targeting protein kinases with small compounds that bind outside the highly conserved ATP pocket to stabilize inactive protein conformations has been regarded as a fresh approach in kinase-targeted drug design that is worthy to be promoted because these compounds often have improved pharmacological profiles compared to inhibitors exclusively targeting the ATP pocket. However, traditional screening approaches for kinase inhibitors are often based on enzyme activity, and it has been recognized that they may miss ligands that stabilize inactive protein conformations. An example of a way to overcome this issue is provided by a study to find selective Met tyrosine kinase inhibitors in which a high-throughput virtual screening of a ChemNavigator compound database was employed for directed discovery of inhibitors targeting the Met tyrosine kinase domain (i.e., compounds that stabilize the kinase domain in its inactive conformation).(250)
In 2010, Klüter et al. reported a kinase binding assay using a pyrazolourea type III inhibitor and enzyme fragment complementation technique that is suitable to screen stabilizers of enzymatically inactive kinases.(251) In the same year, Whelligan et al. reported the first systematic exploration of compounds binding to an unusual, inactive conformation of the mitotic kinase Nek2.(252)
Recently, a novel series of competitive shikimate kinase inhibitors that stabilize an inactive open conformation of the enzyme by targeting the dynamic apolar pocket surrounding the natural substrate was disclosed.(253)
Novel pleckstrin homology domain-dependent covalent-allosteric inhibitors of the kinase Akt were identified via structure-based design, which bind covalently to a distinct cysteine residue of the kinase and stabilize the inactive protein conformation.(254) To sum up, stabilization of an inappropriate and inactive conformation for enzymatic catalysis seems an innovative and promising approach for dissecting conformation-dependent signaling of protein kinases and finding drug candidates.(252) Certainly, there is a significant challenge to adapt screening methodologies and downstream techniques to identify and optimize stabilizers of inactive conformations.
Similarly, stabilization of protein–protein interactions is also a viable strategy for drug discovery but has not been exploited in a systematic manner. Ottmann’s lab has pioneered this field.(255) The potential for high selectivity, the ability to gain access to previously undruggable targets, and the list of impressive compounds were reviewed recently.(256)

8. Conclusions and Prospects

ARTICLE SECTIONS
Jump To

Contemporary drug discovery still faces major scientific and economic challenges to identify and provide lead compounds in an efficient manner. The classical methods of drug design, preparation, and evaluation lead to substantial time delays, resulting in inefficient usage of data in the complex drug design process. This Perspective has focused on exploring strategic approaches to solving issues in lead identification and optimization projects that affect candidate development and quality and that are frequently encountered in drug development campaigns (Figure 33).

Figure 33

Figure 33. Schematic diagram of interdisciplinary teamwork at the interface between the field of chemistry and biology with the aid of informatics.

Structure-based drug design intends to generate the protein and ligand molecules that have high affinity and specificity. Since the binding cavity of an identified drug is usually large and their possible protein interactions are still required to be explored, detailed understandingd of drug–protein interactions or selectivity-determining features are needed to increase the effectiveness of structure-based drug design. Precise knowledge of (non)covalent interactions between proteins and binders provides good foundations for rational design of covalent inhibitors, bisubstrate inhibitors, stabilizers of protein inactive conformations, and exploitation of the water-binding pocket (structural water molecules) for structural modification. Notably, covalent inhibitors attract tremendous attention. One advantage of covalent drugs is a reduced risk for the development of resistance, which is a major challenge in the treatment of cancer and infectious diseases. The key factor affecting the target specificity of covalent inhibitor is the warhead moieties’ reactivity. The ideal warhead moieties should be stable under physiological conditions and eliminate the off-target reaction with undesired biological targets as far as possible. Undoubtedly, target-induced covalent inhibitors (a proximity-driven reactivity) are an ideal type.
Despite the huge information contributed by academia and industry in the past decades, a rational approach using the structure-based drug design with the aid of computational methods remains challenging. There are large flexible variations in the process of protein–ligand binding: there can be, beyond the protein and ligand, cofactors and solvent molecules that should be observed. Additionally, entropic contributions can be important because the protein and ligand often possess significant flexibility.(223) In an recent study, the role of protein conformational entropy and the response of water molecules located around the binding sites and ligand are highlighted in detail.(257)
In most cases, drugs are identified from the biological screening of compound collection, followed by hit to lead optimization toward functional end points. A large number of failures in the late stages of drug development underlines the point that drug discovery is a multiparameter optimization process, and multiple properties should be enhanced to reach the stage where a molecule could be considered for in vivo studies. However, if a lead compound is not considered to be efficient, it will never transform to a drug candidate, irrespective of other properties, which makes the structure–activity and structure–property relationships as a central task during early to midstages of lead optimization. Structural diversity within chemical libraries increases the probability of identifying a lead molecule. In phenotype-based drug discovery, molecular diversity is even more significant due to absence of target information. Consequently, the features of screening collections are often balanced between diversity, physicochemical desirability, intrinsic complexity, and synthetic feasibility. Even then, multiparameter optimization of the lead compound for efficacy and drug-like properties is challenging not only because of synthetic considerations but also because of the limited ability to predict how compounds will interact with complex biological systems. Given the complexity of lead optimization, this process is mainly driven by knowledge, intuition, and experience. In this stage, diversity-oriented synthesis-facilitated medicinal chemistry with combinations of many cheminformatics tools, as exemplified by hierarchical multiple-filter database screening (in silico ADMET prediction), is an attractive strategy.
Innovations in synthetic methodologies (exemplified by LSF), synthetic chemistry techniques (microwave chemistry, continuous flow synthesis, automated synthesis, and purification methods), and development of modular, convergent synthetic reactions (“build-couple-pair” approach, bioorthogonal reactions, cascade reactions, multicomponent reactions, and late-stage microsomal oxidation) have enabled the diversity-oriented, synthesis-facilitated medicinal chemistry, which can greatly facilitate the construction of diverse and drug-like compound libraries.(258−260) As exemplified by bioorthogonal chemistry and photoactivatable-inspired drug discovery, a strong communication between synthetic and medicinal chemists could allow greater impact of novel methodologies and expand the synthetic toolbox of medicinal chemistry in future drug discovery.
Drug repositioning has emerged as an alternative approach to the traditional drug discovery and development due to its efficiency in cost and time. Historically, this approach was accomplished by serendipitous discoveries and the exploitation of unintended side effects. Core concepts that support drug repurposing using network strategies include drug–target interactions, target–disease associations, and drug–indication associations. On the basis of medically inspired phenotypic screening and the modern mechanism-of-action methods, drug repositioning will continue to promote drug discovery.(261) Meanwhile, computational (network-based) repositioning strategies are becoming increasingly popular. However, it should also be noted that the potential of the drug repurposing strategy has not been as widely realized as had been hoped, in part owing to legal and regulatory barriers.
Similarly, “over-represented” features of “privileged structures” in drug-like molecules enable us to design isosteres with structural diversity by maintaining the core physicochemical properties. Focused libraries of privileged scaffolds can expand the molecular diversity of synthetic collections. The strategy of “privileged structure” repositioning has been extensively employed to exploit additional bioactivities by rapid derivatization of key intermediates with well-established synthetic protocols. We envision that fragment-based lead discovery methodology and computational chemistry will significantly facilitate the exploitation of privileged motifs.
The “precise” drug delivery is one of the pivotal aspects of contemporary drug development. Notably, drug delivery systems with high temporal and spatial precision using bioorthogonal uncaging strategies, photoactivatable chemistry, antibody-recruiting molecules, and human serum albumin-derived drug delivery have received significant attention during the past few years, which reflects the deep integration of medicinal chemistry and biology. Challenges such as nonspecific binding, accumulation, degradation, or renal clearance require the development of innovative drug delivery systems that are capable of selective targeting and real-time monitoring of drug release. Bringing the two disciplines chemistry and biology closer and diminishing the boundaries creates new opportunities to identify new drug delivery systems. What can not be ignored is the use of proteolysis-targeting chimeras (PROTACs), which induce selective degradation of specific target proteins through the ubiquitin–proteasome system, found as a novel, though well-known, drug discovery strategy with the capability to offer unique therapeutic advantages, compared with the present approaches.(262) Relevant research papers and reviews are abundant, so this is not covered in this Perspective.
All in all, the main goal of medicinal chemists is to change the drug discovery process to become more efficient by reducing the number and duration of design cycles required to optimize lead compounds into safe and efficacious drug candidates. No single strategy is likely to be a universal panacea.(263,264) The successful development of innovative drugs requires interdisciplinary teamwork at the interface between chemistry, biology, and informatics and multiple techniques working in concert (Figure 18).(265) For example, medicinal chemists are deploying artificial intelligence (machine learning) to discover drugs, which will accelerate the productivity of the drug discovery process via automated compound optimization.(266,267) We hope this Perspective will contribute to overcoming the problems associated with drug discovery campaigns by summarizing the many ideas and strategies that are available to researchers in the field.

Author Information

ARTICLE SECTIONS
Jump To

  • Corresponding Authors
    • Vasanthanathan Poongavanam - Department of Physics, Chemistry, and Pharmacy, University of Southern Denmark, DK-5230 Odense M, DenmarkPresent Address: Biomedicinskt Centrum (BMC), Department of Chemistry, Uppsala University, Husargatan 3, 75237 Uppsala, SwedenOrcidhttp://orcid.org/0000-0002-8880-9247 Email: [email protected]
    • Xinyong Liu - Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji’nan, Shandong, P. R. China Email: [email protected]
    • Peng Zhan - Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji’nan, Shandong, P. R. ChinaOrcidhttp://orcid.org/0000-0002-9675-6026 Email: [email protected]
  • Authors
    • Gaochan Wu - Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji’nan, Shandong, P. R. China
    • Tong Zhao - Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji’nan, Shandong, P. R. China
    • Dongwei Kang - Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji’nan, Shandong, P. R. ChinaOrcidhttp://orcid.org/0000-0001-9232-953X
    • Jian Zhang - Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji’nan, Shandong, P. R. ChinaOrcidhttp://orcid.org/0000-0002-5668-2974
    • Yuning Song - Department of Clinical Pharmacy, Qilu Hospital of Shandong University, 250012 Ji’nan, China
    • Vigneshwaran Namasivayam - Pharmaceutical Institute, Pharmaceutical Chemistry II, University of Bonn, 53121 Bonn, GermanyOrcidhttp://orcid.org/0000-0003-3031-3377
    • Jacob Kongsted - Department of Physics, Chemistry, and Pharmacy, University of Southern Denmark, DK-5230 Odense M, DenmarkOrcidhttp://orcid.org/0000-0002-7725-2164
    • Christophe Pannecouque - Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, K.U. Leuven, Herestraat 49 Postbus 1043 (09.A097), B-3000 Leuven, Belgium
    • Erik De Clercq - Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, K.U. Leuven, Herestraat 49 Postbus 1043 (09.A097), B-3000 Leuven, BelgiumOrcidhttp://orcid.org/0000-0002-2985-8890
  • Author Contributions

    These authors contributed equally. All authors contributed to writing the manuscript. All authors have given approval to the final version of the manuscript.

  • Notes
    The authors declare no competing financial interest.

Biographies

ARTICLE SECTIONS
Jump To

Gaochan Wu

Gaochan Wu received his bachelor’s degree in pharmacy from Hebei University, China, in 2016. Currently, he is a master graduate student in medicinal chemistry at the School of Pharmaceutical Sciences, Shandong University, working under the supervision of Professor Xinyong Liu and Associate Professor Peng Zhan. His work focuses on the discovery of novel anti-AIDS agents based on rational drug design and combinatorial chemistry approaches.

Tong Zhao

Tong Zhao graduated from Shandong University with his B.S. degree in 2015. Since September 2016, he has been working in the School of Pharmaceutical Sciences of Shandong University as a Ph.D. candidate, supervised by Professor Xinyong Liu. His research interests focus on rational design, synthesis, and biological evaluation of novel potent inhibitors of URAT1.

Dongwei Kang

Dongwei Kang graduated from the School of Hebei University of Technology with his BS degree in 2012. He earned his M.S. degree and Ph.D. in medicinal chemistry from Shandong University in 2015 and 2018, respectively. He is currently working as a postdoctoral researcher in the Department of Medicinal Chemistry of the School of Pharmaceutical Sciences at Shandong University.

Jian Zhang

Jian Zhang received his Master’s degree from Shandong Normal University in 2010 and then worked in a pharmaceutical company from 2010 to 2014. Since September 2014, he has been working in the School of Pharmaceutical Sciences of Shandong University as a Ph.D. candidate, supervised by Professor Xinyong Liu. His research interests focus on rational design, synthesis, and biological evaluation of novel potent inhibitors of influenza virus neuraminidase.

Yuning Song

Yu’ning Song graduated from China Pharmaceutical University in 2007. Then she earned her M.S. and Ph.D. in pharmacology from Shandong University in 2008 and 2010, respectively. She is currently working as a licensed pharmacist in the Department of Clinical Pharmacy, Qilu Hospital of Shandong University.

Vigneshwaran Namasivayam

Vigneshwaran Namasivayam is a senior research scientist at Pharmaceutical Institute, University of Bonn, Germany (since 2010) and involved in the field of cheminformatics, computational chemistry, data analysis, and molecular modeling. He gained his doctoral degree under the supervision of Prof. Dr. Hans-Jörg Hofmann from Leipzig University, Germany (2009). He carried out his postdoctoral research at the Technical University of Munich, Germany (2010). Prior to his doctoral studies in Germany, he worked as a Research Executive (2004–2006) at Orchid Chemical and Pharmaceutical Limited, Chennai, India.

Jacob Kongsted

Jacob Kongsted completed his Ph.D. in theoretical and computational chemistry at the University of Copenhagen in 2005, followed by postdoctoral training at Lund University (Sweden) and University of Aarhus (Denmark). In 2009, he moved to University of Southern Denmark as an Assistant Professor, and from 2015, he has been Full Professor of computational quantum chemistry at the University of Southern Denmark. Kongsted has a broad research interest in theoretical and computational chemistry and has especially contributed to this field by development of novel quantum chemistry embedding methods as well as the application of these computational models to systems of biophysical and biochemical interest. In recent research, he is using quantum chemistry methods for rational design of light-induced biological functional materials and advanced drug design.

Christophe Pannecouque

Christophe Pannecouque graduated in pharmaceutical sciences at the Rega Institute for Medical Research of the Katholieke Universiteit Leuven in 1990. He obtained his Ph.D. in medicinal chemistry at the same university in 1995 and joined the group of Professor Erik De Clercq as a postdoctoral fellow. In 2003, he became an associate professor. In the field of virological research, he has unravelled the modes of action of several classes of new products with anti-HIV activity. Recently, his research has been focused on cellular targets interfering with HIV replication and on regulation of the (cyto)pathogenicity of the virus.

Erik De Clercq

Erik De Clercq has MD and Ph.D. degrees and has taught at the Katholieke Universiteit Leuven (and Kortrijk) Medical School, Belgium, where he was Chairman of the Department of Microbiology and Immunology until September 2006. He is currently Emeritus Professor of K.U. Leuven University, Member of the Belgian (Flemish) Royal Academy of Medicine and the Academia Europaea, and Fellow of the American Association for the Advancement of Science. In 2008, he was elected European Inventor of the Year (Lifetime Achievement Award), and in 2010, he, together with Dr. A. S. Fauci, was Laureate of the Dr. Paul Janssen Award for Biomedical Research. He is the (co)inventor of a number of antiviral drugs (valaciclovir, brivudin, cidofovir, adefovir, and tenofovir).

Vasanthanathan Poongavanam

Vasanthanathan Poongavanam obtained his Ph.D. in Medicinal Chemistry at the Faculty of Pharmaceutical Sciences, University of Copenhagen on computational modeling of Cytochrome P450–ligand interactions (2007–2010), followed by postdoctoral training at University of Vienna, Austria (2011–2012) and Southern Denmark University, Denmark (2013–2015). Currently, he is working as a researcher at Uppsala University, Sweden. His research activities involve prediction of ADMET properties and drug design using the cheminformatics, biomolecular simulation, and computational chemistry approaches.

Xinyong Liu

Xinyong Liu received his B.S. and M.S. degrees from the School of Pharmaceutical Sciences, Shandong University, in 1984 and in 1991, respectively. From 1997 to 1999, he worked at the Instituto de Quimica Medica (CSIC) in Spain as a senior visiting scholar. He obtained his Ph.D. from Shandong University in 2004. He is currently a full Professor of the Institute of Medicinal Chemistry, Shandong University. His research interests include rational drug design, synthesis, and antiviral evaluation of a variety of molecules that interact with specific enzymes and receptors in the viral life cycle. Other ongoing programs include studies of the molecular modification and structure–activity relationships of some natural products used to treat cardiovascular diseases, and drug delivery research using PEGylated small-molecular agents.

Peng Zhan

Peng Zhan obtained his B.S. degree from Shandong University, China, in 2005. Then he earned his M.S. degree and Ph.D. in medicinal chemistry from Shandong University in 2008 and 2010, respectively. He subsequently joined the research group of Professor Xinyong Liu as a Lecturer (2010–2012). From 2012 to 2014, he worked as a Postdoctoral Fellow funded by JSPS (Japan Society for the Promotion of Science) in the Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan. He is currently an associate professor in the Institute of Medicinal Chemistry, Shandong University. His research interests involve the discovery of novel antiviral, anticancer, and neurodegenerative diseases-related agents based on rational drug design and combinatorial chemistry approaches.

Acknowledgments

ARTICLE SECTIONS
Jump To

We gratefully acknowledge financial support from the National Natural Science Foundation of China (NSFC Nos. 81573347, 81603028), Young Scholars Program of Shandong University (YSPSDU No. 2016WLJH32), the Fundamental Research Funds of Shandong University (No. 2017JC006), Key Project of NSFC for International Cooperation (No. 81420108027), the Natural Science Foundation of Shandong Province (No. ZR2016HB26), and the Key research and development project of Shandong Province (No. 2017CXGC1401). All figures showing binding modes were generated using PyMol (www.pymol.org).

Abbreviations Used
AChE

acetylcholinesterase

ARMs

antibody-recruiting molecules

BSAA

broad-spectrum antiviral agents

CNS

central nervous system

CuAAC

copper(I)-catalyzed azide–alkyne [3 + 2] dipolar cycloaddition

DCC

dynamic combinatorial chemistry

DEL

DNA-encoded chemical library

DOS

diversity-oriented synthesis

DPM

drug profile matching

EPIs

efflux pump inhibitors

FDA

Food and Drug Administration

FMS

(2-sulfo)-9-fluorenylmethoxycarbonyl

GAT1

γ-aminobutyric acid transporter 1

HAS

human serum albumin

HDAC

histone deacetylase

Hh

hedgehog

HTS

high-throughput screen(ing)

LOPAC

library of pharmacologically active compounds

LSF

late-stage functionalization

MD

molecular dynamics

MLSD

multiple ligand simultaneous docking

MPO

multiparameter optimization

MS

mass spectrometry

NNRTIs

non-nucleoside reverse transcriptase inhibitors

Pf

Plasmodium falciparum

PROTACs

proteolysis-targeting chimeras

RT

reverse transcriptase

PXR

pregnane X receptor

SAR

structure–activity relationship

SPR

surface plasmon resonance

SKR

structure–kinetic relationship

TGS

target-guided synthesis

TOS

target-oriented synthesis

TTR

transthyretin

VEGFR2

vascular endothelial growth receptor 2

References

ARTICLE SECTIONS
Jump To

This article references 267 other publications.

  1. 1
    Costantino, L.; Barlocco, D. Ten years of medicinal chemistry (2005–2014) in the Journal of Medicinal Chemistry: country of contributors, topics, and public-private partnerships. J. Med. Chem. 2016, 59, 73527359,  DOI: 10.1021/acs.jmedchem.5b01349
  2. 2
    Aliagas, I.; Berger, R.; Goldberg, K.; Nishimura, R. T.; Reilly, J.; Richardson, P.; Richter, D.; Sherer, E. C. Sustainable practices in medicinal chemistry part 2: green by design. J. Med. Chem. 2017, 60, 59555968,  DOI: 10.1021/acs.jmedchem.6b01837
  3. 3
    Bryan, M. C.; Dillon, B.; Hamann, L. G.; Hughes, G. J.; Kopach, M. E.; Peterson, E. A.; Pourashraf, M.; Raheem, I.; Richardson, P.; Richter, D.; Sneddon, H. F. Sustainable practices in medicinal chemistry: current state and future directions. J. Med. Chem. 2013, 56, 60076021,  DOI: 10.1021/jm400250p
  4. 4
    Zheng, M.; Zhao, J.; Cui, C.; Fu, Z.; Li, X.; Liu, X.; Ding, X.; Tan, X.; Li, F.; Luo, X.; Chen, K.; Jiang, H. Computational chemical biology and drug design: facilitating protein structure, function, and modulation studies. Med. Res. Rev. 2018, 38, 914950,  DOI: 10.1002/med.21483
  5. 5
    Zhan, P.; Itoh, Y.; Suzuki, T.; Liu, X. Strategies for the discovery of target-specific or isoform-selective modulators. J. Med. Chem. 2015, 58, 76117633,  DOI: 10.1021/acs.jmedchem.5b00229
  6. 6
    Zhan, P.; Pannecouque, C.; De Clercq, E.; Liu, X. Anti-HIV drug discovery and development: current innovations and future trends. J. Med. Chem. 2016, 59, 28492878,  DOI: 10.1021/acs.jmedchem.5b00497
  7. 7
    Young, R. J.; Leeson, P. D. Mapping the efficiency and physicochemical trajectories of successful optimizations. J. Med. Chem. 2018, 61, 64216467,  DOI: 10.1021/acs.jmedchem.8b00180
  8. 8
    Breckenridge, A.; Jacob, R. Overcoming the legal and regulatory barriers to drug repurposing. Nat. Rev. Drug Discovery 2018, 18, 12,  DOI: 10.1038/nrd.2018.92
  9. 9
    Pushpakom, S.; Iorio, F.; Eyers, P. A.; Escott, K. J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; Norris, A.; Sanseau, P.; Cavalla, D.; Pirmohamed, M. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discovery 2018, 18, 41,  DOI: 10.1038/nrd.2018.168
  10. 10
    Novac, N. Challenges and opportunities of drug repositioning. Trends Pharmacol. Sci. 2013, 34, 267272,  DOI: 10.1016/j.tips.2013.03.004
  11. 11
    Madrid, P. B.; Chopra, S.; Manger, I. D.; Gilfillan, L.; Keepers, T. R.; Shurtleff, A. C.; Green, C. E.; Iyer, L. V.; Dilks, H. H.; Davey, R. A.; Kolokoltsov, A. A.; Carrion, R., Jr.; Patterson, J. L.; Bavari, S.; Panchal, R. G.; Warren, T. K.; Wells, J. B.; Moos, W. H.; Burke, R. L.; Tanga, M. J. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 2013, 8, e60579,  DOI: 10.1371/journal.pone.0060579
  12. 12
    Ashburn, T. T.; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discovery 2004, 3, 673683,  DOI: 10.1038/nrd1468
  13. 13
    Nosengo, N. Can you teach old drugs new tricks?. Nature 2016, 534, 314316,  DOI: 10.1038/534314a
  14. 14
    Hayashi, T.; Jean, M.; Huang, H.; Simpson, S.; Santoso, N. G.; Zhu, J. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. Antiviral Res. 2017, 146, 7685,  DOI: 10.1016/j.antiviral.2017.08.013
  15. 15
    (a) Ren, J.; Zhao, Y.; Fry, E. E.; Stuart, D. I. Target identification and mode of action of four chemically divergent drugs against ebolavirus infection. J. Med. Chem. 2018, 61, 724733,  DOI: 10.1021/acs.jmedchem.7b01249 .
    (b) Zhao, Y.; Ren, J.; Harlos, K.; Jones, D. M.; Zeltina, A.; Bowden, T. A.; Padilla-Parra, S.; Fry, E. E.; Stuart, D. I. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 2016, 535, 169172,  DOI: 10.1038/nature18615 .
    (c) Zhao, Y.; Ren, J.; Fry, E. E.; Xiao, J.; Townsend, A. R.; Stuart, D. I. Structures of Ebola virus glycoprotein complexes with tricyclic antidepressant and antipsychotic drugs. J. Med. Chem. 2018, 61, 49384945,  DOI: 10.1021/acs.jmedchem.8b00350
  16. 16
    Zhang, L.; Wei, T. T.; Li, Y.; Li, J.; Fan, Y.; Huang, F. Q.; Cai, Y. Y.; Ma, G.; Liu, J. F.; Chen, Q. Q.; Wang, S. L.; Li, H.; Alolga, R. N.; Liu, B.; Zhao, D. S.; Shen, J. H.; Wang, X. M.; Zhu, W.; Li, P.; Qi, L. W. Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases. Circulation 2018, 137, 13741390,  DOI: 10.1161/CIRCULATIONAHA.117.031139
  17. 17
    Urquiza, P.; Laín, A.; Sanz-Parra, A.; Moreno, J.; Bernardo-Seisdedos, G.; Dubus, P.; González, E.; Gutiérrez-de-Juan, V.; García, S.; Eraña, H.; San Juan, I.; Macías, I.; Ben Bdira, F.; Pluta, P.; Ortega, G.; Oyarzábal, J.; González-Muñiz, R.; Rodríguez-Cuesta, J.; Anguita, J.; Díez, E.; Blouin, J. M.; de Verneuil, H.; Mato, J. M.; Richard, E.; Falcón-Pérez, J. M.; Castilla, J.; Millet, O. Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria. Sci. Transl. Med. 2018, 10, eaat7467,  DOI: 10.1126/scitranslmed.aat7467
  18. 18
    Gwag, T.; Meng, Z.; Sui, Y.; Helsley, R. N.; Park, S. H.; Wang, S.; Greenberg, R. N.; Zhou, C. Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis. J. Hepatol. 2019, 70, 930,  DOI: 10.1016/j.jhep.2018.12.038
  19. 19
    Gkountela, S.; Castro-Giner, F.; Szczerba, B. M.; Vetter, M.; Landin, J.; Scherrer, R.; Krol, I.; Scheidmann, M. C.; Beisel, C.; Stirnimann, C. U.; Kurzeder, C.; Heinzelmann-Schwarz, V.; Rochlitz, C.; Weber, W. P.; Aceto, N. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell 2019, 176, 98112,  DOI: 10.1016/j.cell.2018.11.046
  20. 20
    Marrugal-Lorenzo, J. A.; Serna-Gallego, A.; Berastegui-Cabrera, J.; Pachón, J.; Sánchez-Céspedes, J. Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections. Sci. Rep. 2019, 9, 17,  DOI: 10.1038/s41598-018-37290-3
  21. 21
    Liu, Z.; Fang, H.; Reagan, K.; Xu, X.; Mendrick, D. L.; Slikker, W., Jr.; Tong, W. In silico drug repositioning: what we need to know. Drug Discovery Today 2013, 18, 110115,  DOI: 10.1016/j.drudis.2012.08.005
  22. 22
    Haupt, V. J.; Schroeder, M. Old friends in new guise: repositioning of known drugs with structural bioinformatics. Briefings Bioinf. 2011, 12, 312326,  DOI: 10.1093/bib/bbr011
  23. 23
    McClure, R. A.; Williams, J. D. Impact of mass spectrometry-based technologies and strategies on chemoproteomics as a tool for drug discovery. ACS Med. Chem. Lett. 2018, 9, 785791,  DOI: 10.1021/acsmedchemlett.8b00181
  24. 24
    Lim, R. K.; Lin, Q. Photoinducible bioorthogonal chemistry: a spatiotemporally controllable tool to visualize and perturb proteins in live cells. Acc. Chem. Res. 2011, 44, 828839,  DOI: 10.1021/ar200021p
  25. 25
    Head, S. A.; Liu, J. O. Identification of small molecule-binding proteins in a native cellular environment by live-cell photoaffinity labeling. J. Vis. Exp. 2016, 115, e54529,  DOI: 10.3791/54529
  26. 26
    Hill, J. R.; Robertson, A. A. B. Fishing for drug targets: a focus on diazirine photoaffinity probe synthesis. J. Med. Chem. 2018, 61, 69456963,  DOI: 10.1021/acs.jmedchem.7b01561
  27. 27
    Hu, Y.; Wassermann, A. M.; Lounkine, E.; Bajorath, J. Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families. J. Med. Chem. 2010, 53, 752758,  DOI: 10.1021/jm9014229
  28. 28
    Ma, D. L.; Chan, D. S.; Leung, C. H. Drug repositioning by structure-based virtual screening. Chem. Soc. Rev. 2013, 42, 21302141,  DOI: 10.1039/c2cs35357a
  29. 29
    Giannopoulos, P. F.; Chiu, J.; Pratico, D. Learning impairments, memory deficits, and neuropathology in aged tau transgenic mice are dependent on leukotrienes biosynthesis: role of the cdk5 kinase pathway. Mol. Neurobiol. 2019, 56, 1211,  DOI: 10.1007/s12035-018-1124-7
  30. 30
    Lu, W.; Yao, X.; Ouyang, P.; Dong, N.; Wu, D.; Jiang, X.; Wu, Z.; Zhang, C.; Xu, Z.; Tang, Y. Drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis. J. Med. Chem. 2017, 60, 18171828,  DOI: 10.1021/acs.jmedchem.6b01507
  31. 31
    Iwata, M.; Hirose, L.; Kohara, H.; Liao, J.; Sawada, R.; Akiyoshi, S.; Tani, K.; Yamanishi, Y. Pathway-based drug repositioning for cancers: computational prediction and experimental validation. J. Med. Chem. 2018, 61, 95839595,  DOI: 10.1021/acs.jmedchem.8b01044
  32. 32
    Mejía-Pedroza, R. A.; Espinal-Enríquez, J.; Hernández-Lemus, E. Pathway-based drug repositioning for breast cancer molecular subtypes. Front Pharmacol. 2018, 9, 905,  DOI: 10.3389/fphar.2018.00905
  33. 33
    Huang, C. H.; Chang, P. M.; Lin, Y. J.; Wang, C. H.; Huang, C. Y.; Ng, K. L. Drug repositioning discovery for early- and late-stage non-small-cell lung cancer. Biomed Res. Int. 2014, 2014, 193817,  DOI: 10.1155/2014/193817
  34. 34
    Astolfi, A.; Felicetti, T.; Iraci, N.; Manfroni, G.; Massari, S.; Pietrella, D.; Tabarrini, O.; Kaatz, G. W.; Barreca, M. L.; Sabatini, S.; Cecchetti, V. Pharmacophore-based repositioning of approved drugs as novel staphylococcus aureus NorA efflux pump inhibitors. J. Med. Chem. 2017, 60, 15981604,  DOI: 10.1021/acs.jmedchem.6b01439
  35. 35
    Fako, V. E.; Wu, X.; Pflug, B.; Liu, J. Y.; Zhang, J. T. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase. J. Med. Chem. 2015, 58, 778784,  DOI: 10.1021/jm501543u
  36. 36
    (a) Li, H.; Liu, A.; Zhao, Z.; Xu, Y.; Lin, J.; Jou, D.; Li, C. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). J. Med. Chem. 2011, 54, 55925596,  DOI: 10.1021/jm101330h .
    (b) Li, H.; Xiao, H.; Lin, L.; Jou, D.; Kumari, V.; Lin, J.; Li, C. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J. Med. Chem. 2014, 57, 632641,  DOI: 10.1021/jm401144z
  37. 37
    Vegner, L.; Peragovics, A.; Tombor, L.; Jelinek, B.; Czobor, P.; Bender, A.; Simon, Z.; Malnasi-Csizmadia, A. Experimental confirmation of new drug-target interactions predicted by drug profile matching. J. Med. Chem. 2013, 56, 83778388,  DOI: 10.1021/jm400813y
  38. 38
    Huang, C. H.; Chang, P. M.; Hsu, C. W.; Huang, C. Y.; Ng, K. L. Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory. BMC Bioinformatics 2016, 17, S2,  DOI: 10.1186/s12859-015-0845-0
  39. 39
    Dakshanamurthy, S.; Issa, N. T.; Assefnia, S.; Seshasayee, A.; Peters, O. J.; Madhavan, S.; Uren, A.; Brown, M. L.; Byers, S. W. Predicting new indications for approved drugs using a proteochemometric method. J. Med. Chem. 2012, 55, 68326848,  DOI: 10.1021/jm300576q
  40. 40
    Coley, C. W.; Green, W. H.; Jensen, K. F. Machine learning in computer-aided synthesis planning. Acc. Chem. Res. 2018, 51, 12811289,  DOI: 10.1021/acs.accounts.8b00087
  41. 41
    Zhong, F.; Xing, J.; Li, X.; Liu, X.; Fu, Z.; Xiong, Z.; Lu, D.; Wu, X.; Zhao, J.; Tan, X.; Li, F.; Luo, X.; Li, Z.; Chen, K.; Zheng, M.; Jiang, H. Artificial intelligence in drug design. Sci. China: Life Sci. 2018, 61, 1191,  DOI: 10.1007/s11427-018-9342-2
  42. 42
    Polamreddy, P.; Gattu, N. The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. Drug Discovery Today 2019, 24, 789,  DOI: 10.1016/j.drudis.2018.11.022
  43. 43
    (a) Bartolini, S.; Mai, A.; Artico, M.; Paesano, N.; Rotili, D.; Spadafora, C.; Sbardella, G. 6-[1-(2,6-difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase. J. Med. Chem. 2005, 48, 67766778,  DOI: 10.1021/jm0507330 .
    (b) Sbardella, G.; Mai, A.; Bartolini, S.; Castellano, S.; Cirilli, R.; Rotili, D.; Milite, C.; Santoriello, M.; Orlando, S.; Sciamanna, I.; Serafino, A.; Lavia, P.; Spadafora, C. Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 2011, 54, 59275936,  DOI: 10.1021/jm200734j
  44. 44
    Shahinas, D.; Liang, M.; Datti, A.; Pillai, D. R. A repurposing strategy identifies novel synergistic inhibitors of plasmodium falciparum heat shock protein 90. J. Med. Chem. 2010, 53, 35523557,  DOI: 10.1021/jm901796s
  45. 45
    Deeks, E. D. Lesinurad: a review in hyperuricaemia of gout. Drugs Aging 2017, 34, 401410,  DOI: 10.1007/s40266-017-0461-y
  46. 46
    Hoy, S. M. Lesinurad: first global approval. Drugs 2016, 76, 509516,  DOI: 10.1007/s40265-016-0550-y
  47. 47
    Pace, J. R.; DeBerardinis, A. M.; Sail, V.; Tacheva-Grigorova, S. K.; Chan, K. A.; Tran, R.; Raccuia, D. S.; Wechsler-Reya, R. J.; Hadden, M. K. Repurposing the clinically efficacious antifungal agent itraconazole as an anticancer chemotherapeutic. J. Med. Chem. 2016, 59, 36353649,  DOI: 10.1021/acs.jmedchem.5b01718
  48. 48
    (a) Shi, W.; Nacev, B. A.; Aftab, B. T.; Head, S.; Rudin, C. M.; Liu, J. O. Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling. J. Med. Chem. 2011, 54, 73637674,  DOI: 10.1021/jm200944b .
    (b) Li, Y.; Pasunooti, K. K.; Li, R. J.; Liu, W.; Head, S. A.; Shi, W. Q.; Liu, J. O. Novel tetrazole-containing analogs of itraconazole as potent anti-angiogenic agents with reduced CYP3A4 inhibition. J. Med. Chem. 2018, 61, 11158,  DOI: 10.1021/acs.jmedchem.8b01252
  49. 49
    Thompson, A. M.; O’Connor, P. D.; Blaser, A.; Yardley, V.; Maes, L.; Gupta, S.; Launay, D.; Martin, D.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A. Repositioning antitubercular 6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for neglected tropical diseases: structure-activity studies on a preclinical candidate for visceral leishmaniasis. J. Med. Chem. 2016, 59, 25302550,  DOI: 10.1021/acs.jmedchem.5b01699
  50. 50
    Turk, S.; Merget, B.; Eid, S.; Fulle, S. From cancer to pain target by automated selectivity inversion of a clinical candidate. J. Med. Chem. 2018, 61, 48514859,  DOI: 10.1021/acs.jmedchem.8b00140
  51. 51
    Perlmutter, J. I.; Forbes, L. T.; Krysan, D. J.; Ebsworth-Mojica, K.; Colquhoun, J. M.; Wang, J. L.; Dunman, P. M.; Flaherty, D. P. Repurposing the antihistamine terfenadine for antimicrobial activity against staphylococcus aureus. J. Med. Chem. 2014, 57, 85408562,  DOI: 10.1021/jm5010682
  52. 52
    Dilly, S.; Fotso Fotso, A.; Lejal, N.; Zedda, G.; Chebbo, M.; Rahman, F.; Companys, S.; Bertrand, H. C.; Vidic, J.; Noiray, M.; Alessi, M. C.; Tarus, B.; Quideau, S.; Riteau, B.; Slama-Schwok, A. From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus. J. Med. Chem. 2018, 61, 72027217,  DOI: 10.1021/acs.jmedchem.8b00557
  53. 53
    Mohiuddin, G.; Khan, K. M.; Salar, U.; Kanwal; Wadood, A.; Riaz, M.; Perveen, S. Biology-oriented drug synthesis (BIODS), in vitro urease inhibitory activity, and in silico study of S-naproxen derivatives. Bioorg. Chem. 2019, 83, 2946,  DOI: 10.1016/j.bioorg.2018.10.021
  54. 54
    Mercorelli, B.; Palu, G.; Loregian, A. Drug repurposing for viral infectious diseases: how far are we?. Trends Microbiol. 2018, 26, 865876,  DOI: 10.1016/j.tim.2018.04.004
  55. 55
    Debing, Y.; Neyts, J.; Delang, L. The future of antivirals: broad-spectrum inhibitors. Curr. Opin. Infect. Dis. 2015, 28, 596602,  DOI: 10.1097/QCO.0000000000000212
  56. 56
    Sacramento, C. Q.; de Melo, G. R.; de Freitas, C. S.; Rocha, N.; Hoelz, L. V.; Miranda, M.; Fintelman-Rodrigues, N.; Marttorelli, A.; Ferreira, A. C.; Barbosa-Lima, G.; Abrantes, J. L.; Vieira, Y. R.; Bastos, M. M.; de Mello Volotao, E.; Nunes, E. P.; Tschoeke, D. A.; Leomil, L.; Loiola, E. C.; Trindade, P.; Rehen, S. K.; Bozza, F. A.; Bozza, P. T.; Boechat, N.; Thompson, F. L.; de Filippis, A. M.; Bruning, K.; Souza, T. M. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci. Rep. 2017, 7, 40920,  DOI: 10.1038/srep40920
  57. 57
    Abdelnabi, R.; Morais, A. T. S.; Leyssen, P.; Imbert, I.; Beaucourt, S.; Blanc, H.; Froeyen, M.; Vignuzzi, M.; Canard, B.; Neyts, J.; Delang, L. Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): key role of the F1 motif of the viral polymerase. J. Virol. 2017, 91, e00487,  DOI: 10.1128/JVI.00487-17
  58. 58
    Rossignol, J. F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014, 110, 94103,  DOI: 10.1016/j.antiviral.2014.07.014
  59. 59
    (a) Li, C. C.; Wang, X. J.; Wang, H. R. Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discov. Today 2019, 24, 726,  DOI: 10.1016/j.drudis.2019.01.018 .
    (b) Meng, W.; Wang, X. J.; Wang, H. R. Targeting nuclear proteins for control of viral replication. Crit. Rev. Microbiol. 2019, 119,  DOI: 10.1080/1040841X.2018.1553848
  60. 60
    Tong, X.; Smith, J.; Bukreyeva, N.; Koma, T.; Manning, J. T.; Kalkeri, R.; Kwong, A. D.; Paessler, S. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens. Antiviral Res. 2018, 149, 3440,  DOI: 10.1016/j.antiviral.2017.11.004
  61. 61
    Dang, W.; Yin, Y.; Wang, Y.; Wang, W.; Su, J.; Sprengers, D.; van der Laan, L. J. W.; Felczak, K.; Pankiewicz, K. W.; Chang, K. O.; Koopmans, M. P. G.; Metselaar, H. J.; Peppelenbosch, M. P.; Pan, Q. Inhibition of calcineurin or IMP dehydrogenase exerts moderate to potent antiviral activity against norovirus replication. Antimicrob. Agents Chemother. 2017, 61, e0109517,  DOI: 10.1128/AAC.01095-17
  62. 62
    Hu, J.; Ma, L.; Wang, H.; Yan, H.; Zhang, D.; Li, Z.; Jiang, J.; Li, Y. A novel benzo-heterocyclic amine derivative N30 inhibits influenza virus replication by depression of Inosine-5′-Monophospate dehydrogenase activity. Virol J. 2017, 14, 55,  DOI: 10.1186/s12985-017-0724-6
  63. 63
    Nair, V.; Chi, G.; Shu, Q.; Julander, J.; Smee, D. F. A heterocyclic molecule with significant activity against dengue virus. Bioorg. Med. Chem. Lett. 2009, 19, 14251427,  DOI: 10.1016/j.bmcl.2009.01.031
  64. 64
    Mejdrova, I.; Chalupska, D.; Plackova, P.; Muller, C.; Sala, M.; Klima, M.; Baumlova, A.; Hrebabecky, H.; Prochazkova, E.; Dejmek, M.; Strunin, D.; Weber, J.; Lee, G.; Matousova, M.; Mertlikova-Kaiserova, H.; Ziebuhr, J.; Birkus, G.; Boura, E.; Nencka, R. Rational design of novel highly potent and selective phosphatidylinositol 4-kinase IIIbeta (PI4KB) inhibitors as broad-spectrum antiviral agents and tools for chemical biology. J. Med. Chem. 2017, 60, 100118,  DOI: 10.1021/acs.jmedchem.6b01465
  65. 65
    Bauer, L.; Ferla, S.; Head, S. A.; Bhat, S.; Pasunooti, K. K.; Shi, W. Q.; Albulescu, L.; Liu, J. O.; Brancale, A.; van Kuppeveld, F. J. M.; Strating, J. R. P. M. Structure-activity relationship study of itraconazole, a broad-range inhibitor of picornavirus replication that targets oxysterol-binding protein (OSBP). Antiviral Res. 2018, 156, 5563,  DOI: 10.1016/j.antiviral.2018.05.010
  66. 66
    (a) Taylor, R. D.; MacCoss, M.; Lawson, A. D. Rings in drugs. J. Med. Chem. 2014, 57, 58455859,  DOI: 10.1021/jm4017625 .
    (b) Taylor, R. D.; MacCoss, M.; Lawson, A. D. Combining molecular scaffolds from FDA approved drugs: application to drug discovery. J. Med. Chem. 2017, 60, 16381647,  DOI: 10.1021/acs.jmedchem.6b01367
  67. 67
    (a) Song, Y.; Chen, W.; Kang, D.; Zhang, Q.; Zhan, P.; Liu, X. ″Old friends in new guise″: exploiting privileged structures for scaffold re-evolution/refining. Comb. Chem. High Throughput Screening 2014, 17, 536553,  DOI: 10.2174/1386207317666140122101631 .
    (b) Li, Z.; Zhan, P.; Liu, X. 1,3,4-oxadiazole: a privileged structure in antiviral agents. Mini-Rev. Med. Chem. 2011, 11, 11301142,  DOI: 10.2174/138955711797655407 .
    (c) Song, Y.; Zhan, P.; Zhang, Q.; Liu, X. Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. Curr. Pharm. Des. 2013, 19, 15281548,  DOI: 10.2174/138161213804805559 .
    (d) Song, Y.; Zhan, P.; Liu, X. Heterocycle-thioacetic acid motif: a privileged molecular scaffold with potent, broad-ranging pharmacological activities. Curr. Pharm. Des. 2013, 19, 71417154,  DOI: 10.2174/13816128113199990505 .
    (e) Zhao, F.; Liu, N.; Zhan, P.; Liu, X. Repurposing of HDAC inhibitors toward anti-hepatitis C virus drug discovery: teaching an old dog new tricks. Future Med. Chem. 2015, 7, 13671371,  DOI: 10.4155/fmc.15.76
  68. 68
    Zeng, L. F.; Wang, Y.; Kazemi, R.; Xu, S.; Xu, Z. L.; Sanchez, T. W.; Yang, L. M.; Debnath, B.; Odde, S.; Xie, H.; Zheng, Y. T.; Ding, J.; Neamati, N.; Long, Y. Q. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. J. Med. Chem. 2012, 55, 94929509,  DOI: 10.1021/jm300667v
  69. 69
    Schwehm, C.; Kellam, B.; Garces, A. E.; Hill, S. J.; Kindon, N. D.; Bradshaw, T. D.; Li, J.; Macdonald, S. J.; Rowedder, J. E.; Stoddart, L. A.; Stocks, M. J. Design and Elaboration of a tractable tricyclic scaffold to synthesize druglike inhibitors of dipeptidyl peptidase-4 (DPP-4), antagonists of the C-C chemokine receptor type 5 (CCR5), and highly potent and selective phosphoinositol-3 kinase delta (PI3Kdelta) inhibitors. J. Med. Chem. 2017, 60, 15341554,  DOI: 10.1021/acs.jmedchem.6b01801
  70. 70
    John, J.; Kim, Y.; Bennett, N.; Das, K.; Liekens, S.; Naesens, L.; Arnold, E.; Maguire, A. R.; Gotte, M.; Dehaen, W.; Balzarini, J. Pronounced inhibition shift from HIV reverse transcriptase to herpetic DNA polymerases by increasing the flexibility of alpha-carboxy nucleoside phosphonates. J. Med. Chem. 2015, 58, 81108127,  DOI: 10.1021/acs.jmedchem.5b01180
  71. 71
    (a) Nowotny, M. Retroviral integrase superfamily: the structural perspective. EMBO Rep. 2009, 10, 144151,  DOI: 10.1038/embor.2008.256 .
    (b) Majorek, K. A.; Dunin-Horkawicz, S.; Steczkiewicz, K.; Muszewska, A.; Nowotny, M.; Ginalski, K.; Bujnicki, J. M. The RNase H-like superfamily: new members, comparative structural analysis and evolutionary classification. Nucleic Acids Res. 2014, 42, 41604179,  DOI: 10.1093/nar/gkt1414
  72. 72
    (a) Xu, P.; Ganaie, S. S.; Wang, X.; Wang, Z.; Kleiboeker, S.; Horton, N. C.; Heier, R. F.; Meyers, M. J.; Tavis, J. E.; Qiu, J. Endonuclease activity inhibition of the NS1 protein of parvovirus B19 as a novel target for antiviral drug development. Antimicrob. Agents Chemother. 2019, 63, AAC.01879,  DOI: 10.1128/AAC.01879-18 .
    (b) Tavis, J. E.; Zoidis, G.; Meyers, M. J.; Murelli, R. P. Chemical approaches to inhibiting the hepatitis B virus ribonuclease H. ACS Infect. Dis. 2018,  DOI: 10.1021/acsinfecdis.8b00045 .
    (c) Lomonosova, E.; Daw, J.; Garimallaprabhakaran, A. K.; Agyemang, N. B.; Ashani, Y.; Murelli, R. P.; Tavis, J. E. Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H. Antiviral Res. 2017, 144, 164172,  DOI: 10.1016/j.antiviral.2017.06.014 .
    (d) Edwards, T. C.; Lomonosova, E.; Patel, J. A.; Li, Q.; Villa, J. A.; Gupta, A. K.; Morrison, L. A.; Bailly, F.; Cotelle, P.; Giannakopoulou, E.; Zoidis, G.; Tavis, J. E. Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles. Antiviral Res. 2017, 143, 205217,  DOI: 10.1016/j.antiviral.2017.04.012 .
    (e) Lu, G.; Lomonosova, E.; Cheng, X.; Moran, E. A.; Meyers, M. J.; Le Grice, S. F.; Thomas, C. J.; Jiang, J. K.; Meck, C.; Hirsch, D. R.; D’Erasmo, M. P.; Suyabatmaz, D. M.; Murelli, R. P.; Tavis, J. E. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Antimicrob. Agents Chemother. 2015, 59, 10701079,  DOI: 10.1128/AAC.04617-14 .
    (f) Cai, C. W.; Lomonosova, E.; Moran, E. A.; Cheng, X.; Patel, K. B.; Bailly, F.; Cotelle, P.; Meyers, M. J.; Tavis, J. E. Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Antiviral Res. 2014, 108, 4855,  DOI: 10.1016/j.antiviral.2014.05.007 .
    (g) Hu, Y.; Cheng, X.; Cao, F.; Huang, A.; Tavis, J. E. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res. 2013, 99, 221229,  DOI: 10.1016/j.antiviral.2013.06.007 .
    (h) Tavis, J. E.; Cheng, X.; Hu, Y.; Totten, M.; Cao, F.; Michailidis, E.; Aurora, R.; Meyers, M. J.; Jacobsen, E. J.; Parniak, M. A.; Sarafianos, S. G. The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog. 2013, 9, e1003125,  DOI: 10.1371/journal.ppat.1003125 .
    (i) Ireland, P. J.; Tavis, J. E.; D’Erasmo, M. P.; Hirsch, D. R.; Murelli, R. P.; Cadiz, M. M.; Patel, B. S.; Gupta, A. K.; Edwards, T. C.; Korom, M.; Moran, E. A.; Morrison, L. A. Synthetic α-hydroxytropolones inhibit replication of wild-type and acyclovir-resistant herpes simplex viruses. Antimicrob. Agents Chemother. 2016, 60, 21402149,  DOI: 10.1128/AAC.02675-15
  73. 73
    (a) Huber, A. D.; Michailidis, E.; Tang, J.; Puray-Chavez, M. N.; Boftsi, M.; Wolf, J. J.; Boschert, K. N.; Sheridan, M. A.; Leslie, M. D.; Kirby, K. A.; Singh, K.; Mitsuya, H.; Parniak, M. A.; Wang, Z.; Sarafianos, S. G. 3-Hydroxypyrimidine-2,4-diones as novel hepatitis B virus antivirals targeting the viral ribonuclease H. Antimicrob. Agents Chemother. 2017, 61, e00245,  DOI: 10.1128/AAC.00245-17 .
    (b) Wu, B.; Tang, J.; Wilson, D. J.; Huber, A. D.; Casey, M. C.; Ji, J.; Kankanala, J.; Xie, J.; Sarafianos, S. G.; Wang, Z. 3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides potently inhibit HIV-1 integrase and RNase H. J. Med. Chem. 2016, 59, 61366148,  DOI: 10.1021/acs.jmedchem.6b00040 .
    (c) Kankanala, J.; Kirby, K. A.; Liu, F.; Miller, L.; Nagy, E.; Wilson, D. J.; Parniak, M. A.; Sarafianos, S. G.; Wang, Z. Design, synthesis, and biological evaluations of hydroxypyridonecarboxylic acids as inhibitors of hiv reverse transcriptase associated RNase H. J. Med. Chem. 2016, 59, 50515062,  DOI: 10.1021/acs.jmedchem.6b00465 .
    (d) Tang, J.; Liu, F.; Nagy, E.; Miller, L.; Kirby, K. A.; Wilson, D. J.; Wu, B.; Sarafianos, S. G.; Parniak, M. A.; Wang, Z. 3-Hydroxypyrimidine-2,4-diones as selective active site inhibitors of hiv reverse transcriptase-associated RNase H: design, synthesis, and biochemical evaluations. J. Med. Chem. 2016, 59, 26482659,  DOI: 10.1021/acs.jmedchem.5b01879 .
    (e) Wang, Y.; Tang, J.; Wang, Z.; Geraghty, R. J. Metal-chelating 3-hydroxypyrimidine-2,4-diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication. Antiviral Res. 2018, 152, 1017,  DOI: 10.1016/j.antiviral.2018.01.015
  74. 74
    (a) Sun, L.; Gao, P.; Dong, G.; Zhang, X.; Cheng, X.; Ding, X.; Wang, X.; Daelemans, D.; De Clercq, E.; Pannecouque, C.; Menéndez-Arias, L.; Zhan, P.; Liu, X. 5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase. Eur. J. Med. Chem. 2018, 155, 714724,  DOI: 10.1016/j.ejmech.2018.06.036 .
    (b) Gao, P.; Zhang, L.; Sun, L.; Huang, T.; Tan, J.; Zhang, J.; Zhou, Z.; Zhao, T.; Menéndez-Arias, L.; Pannecouque, C.; Clercq, E.; Zhan, P.; Liu, X. 1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. Bioorg. Med. Chem. 2017, 25, 57795789,  DOI: 10.1016/j.bmc.2017.09.006 .
    (c) Wang, X.; Gao, P.; Menendez-Arias, L.; Liu, X.; Zhan, P. Update on recent developments in small molecular hiv-1 rnase h inhibitors (2013–2016): opportunities and challenges. Curr. Med. Chem. 2018, 25, 16821702,  DOI: 10.2174/0929867324666170113110839 .
    (d) Cao, L.; Song, W.; De Clercq, E.; Zhan, P.; Liu, X. Recent progress in the research of small molecule HIV-1 RNase H inhibitors. Curr. Med. Chem. 2014, 21, 19561967,  DOI: 10.2174/0929867321666140120121158 .
    (e) Ju, H.; Zhang, J.; Huang, B.; Kang, D.; Huang, B.; Liu, X.; Zhan, P. Inhibitors of influenza virus polymerase acidic (PA) endonuclease: contemporary developments and perspectives. J. Med. Chem. 2017, 60, 35333551,  DOI: 10.1021/acs.jmedchem.6b01227 .
    (f) Ju, H.; Zhan, P.; Liu, X. Designing influenza polymerase acidic endonuclease inhibitors via ’privileged scaffold’ re-evolution/refining strategy. Future Med. Chem. 2019, 11, 265,  DOI: 10.4155/fmc-2018-0489
  75. 75
    Yang, T. Baloxavir Marboxil: The first cap-dependent endonuclease inhibitor for the treatment of influenza. Ann. Pharmacother. 2019, 106002801982656,  DOI: 10.1177/1060028019826565
  76. 76
    Oh, S.; Park, Y.; Engelhart, C. A.; Wallach, J. B.; Schnappinger, D.; Arora, K.; Manikkam, M.; Gac, B.; Wang, H.; Murgolo, N.; Olsen, D. B.; Goodwin, M.; Sutphin, M.; Weiner, D. M.; Via, L. E.; Boshoff, H. I. M.; Barry, C. E., 3rd. Discovery and structure-activity-relationship study of n-alkyl-5-hydroxypyrimidinone carboxamides as novel antitubercular agents targeting decaprenylphosphoryl-β-d-ribose 2′-oxidase. J. Med. Chem. 2018, 61, 99529965,  DOI: 10.1021/acs.jmedchem.8b00883
  77. 77
    Ramil, C. P.; Lin, Q. Bioorthogonal chemistry: strategies and recent developments. Chem. Commun. (Cambridge, U. K.) 2013, 49, 1100711022,  DOI: 10.1039/c3cc44272a
  78. 78
    Kim, J.; Kim, H.; Park, S. B. Privileged structures: efficient chemical ″navigators″ toward unexplored biologically relevant chemical spaces. J. Am. Chem. Soc. 2014, 136, 1462914638,  DOI: 10.1021/ja508343a
  79. 79
    (a) Wang, X.; Huang, B.; Liu, X.; Zhan, P. Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. Drug Discovery Today 2016, 21, 118132,  DOI: 10.1016/j.drudis.2015.08.004 .
    (b) Huang, B.; Kang, D.; Zhan, P.; Liu, X. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. Expert Opin. Drug Discovery 2015, 10, 12711281,  DOI: 10.1517/17460441.2015.1083007 .
    (c) Gao, P.; Sun, L.; Zhou, J.; Li, X.; Zhan, P.; Liu, X. Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach. Expert Opin. Drug Discovery 2016, 11, 857871,  DOI: 10.1080/17460441.2016.1210125
  80. 80
    Whiting, M.; Tripp, J. C.; Lin, Y. C.; Lindstrom, W.; Olson, A. J.; Elder, J. H.; Sharpless, K. B.; Fokin, V. V. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization. J. Med. Chem. 2006, 49, 76977710,  DOI: 10.1021/jm060754+
  81. 81
    (a) Zhan, P.; Wang, X.; Liu, X.; Suzuki, T. Medicinal chemistry insights into novel HDAC inhibitors: an updated patent review (2012–2016). Recent Pat. Anti-Cancer Drug Discovery 2017, 12, 1634,  DOI: 10.2174/1574892811666161101102842 .
    (b) Suzuki, T.; Ota, Y.; Ri, M.; Bando, M.; Gotoh, A.; Itoh, Y.; Tsumoto, H.; Tatum, P. R.; Mizukami, T.; Nakagawa, H.; Iida, S.; Ueda, R.; Shirahige, K.; Miyata, N. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. J. Med. Chem. 2012, 55, 95629575,  DOI: 10.1021/jm300837y .
    (c) Suzuki, T.; Kasuya, Y.; Itoh, Y.; Ota, Y.; Zhan, P.; Asamitsu, K.; Nakagawa, H.; Okamoto, T.; Miyata, N. Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. PLoS One 2013, 8, e68669,  DOI: 10.1371/journal.pone.0068669 .
    (d) Tatum, P. R.; Sawada, H.; Ota, Y.; Itoh, Y.; Zhan, P.; Ieda, N.; Nakagawa, H.; Miyata, N.; Suzuki, T. Identification of novel SIRT2-selective inhibitors using a click chemistry approach. Bioorg. Med. Chem. Lett. 2014, 24, 18711874,  DOI: 10.1016/j.bmcl.2014.03.026
  82. 82
    Gehringer, M.; Forster, M.; Laufer, S. A. Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition. ACS Comb. Sci. 2015, 17, 510,  DOI: 10.1021/co500122h
  83. 83
    Diaz, L.; Casas, J.; Bujons, J.; Llebaria, A.; Delgado, A. New glucocerebrosidase inhibitors by exploration of chemical diversity of N-substituted aminocyclitols using click chemistry and in situ screening. J. Med. Chem. 2011, 54, 20692079,  DOI: 10.1021/jm101204u
  84. 84
    Coumar, M. S.; Chu, C. Y.; Lin, C. W.; Shiao, H. Y.; Ho, Y. L.; Reddy, R.; Lin, W. H.; Chen, C. H.; Peng, Y. H.; Leou, J. S.; Lien, T. W.; Huang, C. T.; Fang, M. Y.; Wu, S. H.; Wu, J. S.; Chittimalla, S. K.; Song, J. S.; Hsu, J. T.; Wu, S. Y.; Liao, C. C.; Chao, Y. S.; Hsieh, H. P. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J. Med. Chem. 2010, 53, 49804988,  DOI: 10.1021/jm1000198
  85. 85
    Ding, S.; Qiao, X.; Kucera, G. L.; Bierbach, U. Using a build-and-click approach for producing structural and functional diversity in DNA-targeted hybrid anticancer agents. J. Med. Chem. 2012, 55, 1019810203,  DOI: 10.1021/jm301278c
  86. 86
    Akgun, B.; Hall, D. G. Fast and tight boronate formation for click bioorthogonal conjugation. Angew. Chem., Int. Ed. 2016, 55, 39093913,  DOI: 10.1002/anie.201510321
  87. 87
    Oueis, E.; Sabot, C.; Renard, P. Y. New insights into the kinetic target-guided synthesis of protein ligands. Chem. Commun. (Cambridge, U. K.) 2015, 51, 1215812169,  DOI: 10.1039/C5CC04183J
  88. 88
    Frei, P.; Hevey, R.; Ernst, B. Dynamic combinatorial chemistry: A new methodology comes of age. Chemistry 2019, 25, 60,  DOI: 10.1002/chem.201803365
  89. 89
    Unver, M. Y.; Gierse, R. M.; Ritchie, H.; Hirsch, A. K. H. Druggability assessment of targets used in kinetic target-guided synthesis. J. Med. Chem. 2018, 61, 93959409,  DOI: 10.1021/acs.jmedchem.8b00266
  90. 90
    Hochgurtel, M.; Biesinger, R.; Kroth, H.; Piecha, D.; Hofmann, M. W.; Krause, S.; Schaaf, O.; Nicolau, C.; Eliseev, A. V. Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target. J. Med. Chem. 2003, 46, 356358,  DOI: 10.1021/jm025589m
  91. 91
    Nasr, G.; Petit, E.; Vullo, D.; Winum, J. Y.; Supuran, C. T.; Barboiu, M. Carbonic anhydrase-encoded dynamic constitutional libraries: toward the discovery of isozyme-specific inhibitors. J. Med. Chem. 2009, 52, 48534859,  DOI: 10.1021/jm900449v
  92. 92
    Bunyapaiboonsri, T.; Ramstrom, H.; Ramstrom, O.; Haiech, J.; Lehn, J. M. Generation of bis-cationic heterocyclic inhibitors of Bacillus subtilis HPr kinase/phosphatase from a ditopic dynamic combinatorial library. J. Med. Chem. 2003, 46, 58035811,  DOI: 10.1021/jm030917j
  93. 93
    Bhardwaj, A.; Kaur, J.; Wuest, M.; Wuest, F. In situ click chemistry generation of cyclooxygenase-2 inhibitors. Nat. Commun. 2017, 8, 1,  DOI: 10.1038/s41467-016-0009-6
  94. 94
    Wang, Y.; Zhu, J.; Zhang, L. Discovery of cell-permeable O-GlcNAc transferase inhibitors via tethering in situ click chemistry. J. Med. Chem. 2017, 60, 263272,  DOI: 10.1021/acs.jmedchem.6b01237
  95. 95
    Namelikonda, N. K.; Manetsch, R. Sulfo-click reaction via in situ generated thioacids and its application in kinetic target-guided synthesis. Chem. Commun. (Cambridge, U. K.) 2012, 48, 15261528,  DOI: 10.1039/C1CC14724B
  96. 96
    Kulkarni, S. S.; Hu, X.; Doi, K.; Wang, H. G.; Manetsch, R. Screening of protein-protein interaction modulators via sulfo-click kinetic target-guided synthesis. ACS Chem. Biol. 2011, 6, 724732,  DOI: 10.1021/cb200085q
  97. 97
    Antti, H.; Sellstedt, M. Cell-based kinetic target-guided synthesis of an enzyme Inhibitor. ACS Med. Chem. Lett. 2018, 9, 351353,  DOI: 10.1021/acsmedchemlett.7b00535
  98. 98
    Lebraud, H.; Wright, D. J.; Johnson, C. N.; Heightman, T. D. Protein degradation by in-cell self-assembly of proteolysis targeting chimeras. ACS Cent. Sci. 2016, 2, 927934,  DOI: 10.1021/acscentsci.6b00280
  99. 99
    (a) Sindelar, M.; Wanner, K. T. Library screening by means of mass spectrometry (MS) binding assays-exemplarily demonstrated for a pseudostatic library addressing γ-aminobutyric acid (GABA) transporter 1 (GAT1). ChemMedChem 2012, 7, 16781690,  DOI: 10.1002/cmdc.201200201 .
    (b) Sindelar, M.; Lutz, T. A.; Petrera, M.; Wanner, K. T. Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1. J. Med. Chem. 2013, 56, 13231340,  DOI: 10.1021/jm301800j .
    (c) Hauke, T. J.; Wein, T.; Höfner, G.; Wanner, K. T. Novel allosteric ligands of γ-aminobutyric acid transporter 1 (GAT1) by MS based screening of pseudostatic hydrazone libraries. J. Med. Chem. 2018, 61, 1031010332,  DOI: 10.1021/acs.jmedchem.8b01602 .
    (d) Huber, S. K.; Höfner, G.; Wanner, K. T. Identification of pyrrolidine-3-acetic acid derived oximes as potent inhibitors of γ-aminobutyric acid transporter 1 through library screening with MS binding assays. ChemMedChem 2018, 13, 24882503,  DOI: 10.1002/cmdc.201800556
  100. 100
    (a) Demetriades, M.; Leung, I. K. H.; Chowdhury, R.; Chan, M. C.; Yeoh, K. K.; Tian, Y.-M.; Claridge, T. D. W.; Rgatcliffe, P. J.; Woon, E. C. Y.; Schofield, C. J. Dynamic combinatorial chemistry employing boronic acids/boronate esters leads to potent oxygenase inhibitors. Angew. Chem., Int. Ed. 2012, 51, 66726675,  DOI: 10.1002/anie.201202000 .
    (b) Woon, E. C. Y.; Demetriades, M.; Bagg, E. A. L.; Aik, W. S.; Krylova, S. M.; Ma, J. H. Y.; Chan, M. C.; Walport, L. J.; Wegman, D. W.; Dack, K. N.; McDonough, M. A.; Krylov, S. N.; Schofield, C. J. Dynamic combinatorial mass spectrometry leads to inhibitors of a 2-oxoglutarate dependent nucleic acid demethylase. J. Med. Chem. 2012, 55, 21732184,  DOI: 10.1021/jm201417e .
    (c) Rose, N. R.; Woon, E. C. Y.; Kingham, G. L.; King, O. N. F.; Mecinovic, J.; Clifton, I. J.; Ng, S. S.; Talib-Hardy, J.; Oppermann, U.; McDonough, M. A.; Schofield, C. J. Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. J. Med. Chem. 2010, 53, 18101818,  DOI: 10.1021/jm901680b
  101. 101
    Das, M.; Tianming, Y.; Jinghua, D.; Prasetya, F.; Yiming, X.; Wong, K.; Cheong, A.; Woon, E. C. Y. Multi-protein dynamic combinatorial chemistry: a novel strategy that leads to simultaneous discovery of subfamily-selective inhibitors for nucleic acid demethylases FTO and ALKBH3. Chem. Asian J. 2018, 13, 2854,  DOI: 10.1002/asia.201800729
  102. 102
    Jana, S.; Panda, D.; Saha, P.; Pantos, D.; Dash, J. Dynamic generation of G-quadruplex DNA ligands by target-guided combinatorial chemistry on a magnetic nano-platform. J. Med. Chem. 2019, 62, 762,  DOI: 10.1021/acs.jmedchem.8b01459
  103. 103
    Tu, J.; Xu, M.; Franzini, R. Dissociative bioorthogonal reactions. ChemBioChem 2019,  DOI: 10.1002/cbic.201800810
  104. 104
    Li, J.; Chen, P. R. Development and application of bond cleavage reactions in bioorthogonal chemistry. Nat. Chem. Biol. 2016, 12, 129137,  DOI: 10.1038/nchembio.2024
  105. 105
    (a) Unciti-Broceta, A.; Johansson, E. M.; Yusop, R. M.; Sanchez-Martin, R. M.; Bradley, M. Synthesis of polystyrene microspheres and functionalization with Pd(0) nanoparticles to perform bioorthogonal organometallic chemistry in living cells. Nat. Protoc. 2012, 7, 12071218,  DOI: 10.1038/nprot.2012.052 .
    (b) Yusop, R. M.; Unciti-Broceta, A.; Johansson, E. M.; Sanchez-Martin, R. M.; Bradley, M. Palladium-mediated intracellular chemistry. Nat. Chem. 2011, 3, 239243,  DOI: 10.1038/nchem.981 .
    (c) Unciti-Broceta, A. Bioorthogonal catalysis: Rise of the nanobots. Nat. Chem. 2015, 7, 538539,  DOI: 10.1038/nchem.2291 .
    (d) Weiss, J. T.; Dawson, J. C.; Fraser, C.; Rybski, W.; Torres-Sanchez, C.; Bradley, M.; Patton, E. E.; Carragher, N. O.; Unciti-Broceta, A. Development and bioorthogonal activation of palladium-labile prodrugs of gemcitabine. J. Med. Chem. 2014, 57, 53955404,  DOI: 10.1021/jm500531z .
    (e) Weiss, J. T.; Dawson, J. C.; Macleod, K. G.; Rybski, W.; Fraser, C.; Torres-Sanchez, C.; Patton, E. E.; Bradley, M.; Carragher, N. O.; Unciti-Broceta, A. Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach. Nat. Commun. 2014, 5, 3277,  DOI: 10.1038/ncomms4277 .
    (f) Weiss, J. T.; Fraser, C.; Rubio-Ruiz, B.; Myers, S. H.; Crispin, R.; Dawson, J. C.; Brunton, V. G.; Patton, E. E.; Carragher, N. O.; Unciti-Broceta, A. N-alkynyl derivatives of 5-fluorouracil: susceptibility to palladium-mediated dealkylation and toxigenicity in cancer cell culture. Front Chem. 2014, 2, 56,  DOI: 10.3389/fchem.2014.00056 .
    (g) Weiss, J. T.; Carragher, N. O.; Unciti-Broceta, A. Palladium-mediated dealkylation of N-propargyl-floxuridine as a bioorthogonal oxygen-independent prodrug strategy. Sci. Rep. 2015, 5, 9329,  DOI: 10.1038/srep09329 .
    (h) Rubio-Ruiz, B.; Weiss, J. T.; Unciti-Broceta, A. Efficient palladium-triggered release of vorinostat from a bioorthogonal precursor. J. Med. Chem. 2016, 59, 99749980,  DOI: 10.1021/acs.jmedchem.6b01426
  106. 106
    Lv, T.; Wu, J.; Kang, F.; Wang, T.; Wan, B.; Lu, J. J.; Zhang, Y.; Huang, Z. Synthesis and evaluation of O(2)-derived diazeniumdiolates activatable via bioorthogonal chemistry reactions in living cells. Org. Lett. 2018, 20, 21642167,  DOI: 10.1021/acs.orglett.8b00423
  107. 107
    Li, J.; Jia, S.; Chen, P. R. Diels-Alder reaction-triggered bioorthogonal protein decaging in living cells. Nat. Chem. Biol. 2014, 10, 10031005,  DOI: 10.1038/nchembio.1656
  108. 108
    Perez-Lopez, A. M.; Rubio-Ruiz, B.; Sebastián, V.; Hamilton, L.; Adam, C.; Bray, T. L.; Irusta, S.; Brennan, P. M.; Lloyd-Jones, G. C.; Sieger, D.; Santamaría, J.; Unciti-Broceta, A. Gold-triggered uncaging chemistry in living systems. Angew. Chem., Int. Ed. 2017, 56, 1254812552,  DOI: 10.1002/anie.201705609
  109. 109
    Devaraj, N. K. The future of bioorthogonal chemistry. ACS Cent. Sci. 2018, 4, 952959,  DOI: 10.1021/acscentsci.8b00251
  110. 110
    (a) Zheng, Y.; Ji, X.; Yu, B.; Ji, K.; Gallo, D.; Csizmadia, E.; Zhu, M.; Choudhury, M. R.; De La Cruz, L. K. C.; Chittavong, V.; Pan, Z.; Yuan, Z.; Otterbein, L. E.; Wang, B. Enrichment-triggered prodrug activation demonstrated through mitochondria-targeted delivery of doxorubicin and carbon monoxide. Nat. Chem. 2018, 10, 787,  DOI: 10.1038/s41557-018-0055-2 .
    (b) Ji, X.; Pan, Z.; Yu, B.; De La Cruz, L. K.; Zheng, Y.; Ke, B.; Wang, B. Click and release: bioorthogonal approaches to ″on-demand″ activation of prodrugs. Chem. Soc. Rev. 2019, 48, 1077,  DOI: 10.1039/C8CS00395E
  111. 111
    Klán, P.; Šolomek, T.; Bochet, C. G.; Blanc, A.; Givens, R.; Rubina, M.; Popik, V.; Kostikov, A.; Wirz, J. Photoremovable protecting groups in chemistry and biology: reaction mechanisms and efficacy. Chem. Rev. 2013, 113, 119191,  DOI: 10.1021/cr300177k
  112. 112
    Horbert, R.; Pinchuk, B.; Davies, P.; Alessi, D.; Peifer, C. Photoactivatable prodrugs of anti-melanoma agent vemurafenib. ACS Chem. Biol. 2015, 10, 2099107,  DOI: 10.1021/acschembio.5b00174
  113. 113
    Bliman, D.; Nilsson, J. R.; Kettunen, P.; Andréasson, J.; Grøtli, M. A Caged ret kinase inhibitor and its effect on motoneuron development in zebrafish embryos. Sci. Rep. 2015, 5, 13109,  DOI: 10.1038/srep13109
  114. 114
    Zindler, M.; Pinchuk, B.; Renn, C.; Horbert, R.; Döbber, A.; Peifer, C. Design, synthesis, and characterization of a photoactivatable caged prodrug of imatinib. ChemMedChem 2015, 10, 13351338,  DOI: 10.1002/cmdc.201500163
  115. 115
    Ieda, N.; Yamada, S.; Kawaguchi, M.; Miyata, N.; Nakagawa, H. (7-Diethylaminocoumarin-4-yl)methyl ester of suberoylanilide hydroxamic acid as a caged inhibitor for photocontrol of histone deacetylase activity. Bioorg. Med. Chem. 2016, 24, 27892793,  DOI: 10.1016/j.bmc.2016.04.042
  116. 116
    Parasar, B.; Chang, P. V. Chemical optogenetic modulation of inflammation and immunity. Chem. Sci. 2017, 8, 14501453,  DOI: 10.1039/C6SC03702J
  117. 117
    Tamura, R.; Balabanova, A.; Frakes, S. A.; Bargmann, A.; Grimm, J.; Koch, T. H.; Yin, H. H. Photoactivatable prodrug of doxazolidine targeting exosomes. J. Med. Chem. 2019, 62, 1959,  DOI: 10.1021/acs.jmedchem.8b01508
  118. 118
    Döbber, A.; Phoa, A. F.; Abbassi, R. H.; Stringer, B. W.; Day, B. W.; Johns, T. G.; Abadleh, M.; Peifer, C.; Munoz, L. Development and biological evaluation of a photoactivatable small molecule microtubule-targeting agent. ACS Med. Chem. Lett. 2017, 8, 395400,  DOI: 10.1021/acsmedchemlett.6b00483
  119. 119
    Perdicakis, B.; Montgomery, H. J.; Abbott, G. L.; Fishlock, D.; Lajoie, G. A.; Guillemette, J. G.; Jervis, E. Photocontrol of nitric oxide production in cell culture using a caged isoform selective inhibitor. Bioorg. Med. Chem. 2005, 13, 4757,  DOI: 10.1016/j.bmc.2004.10.002
  120. 120
    Abrahamse, H.; Hamblin, M. R. New photosensitizers for photodynamic therapy. Biochem. J. 2016, 473, 347364,  DOI: 10.1042/BJ20150942
  121. 121
    Detty, M. R.; Gibson, S. L.; Wagner, S. J. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J. Med. Chem. 2004, 47, 38973915,  DOI: 10.1021/jm040074b
  122. 122
    Hirohara, S.; Oka, C.; Totani, M.; Obata, M.; Yuasa, J.; Ito, H.; Tamura, M.; Matsui, H.; Kakiuchi, K.; Kawai, T.; Kawaichi, M.; Tanihara, M. Synthesis, photophysical properties, and biological evaluation of trans-bisthioglycosylated tetrakis(fluorophenyl)chlorin for photodynamic therapy. J. Med. Chem. 2015, 58, 86588670,  DOI: 10.1021/acs.jmedchem.5b01262
  123. 123
    Monro, S.; Colón, K. L.; Yin, H.; Roque, J., 3rd.; Konda, P.; Gujar, S.; Thummel, R. P.; Lilge, L.; Cameron, C. G.; McFarland, S. A. Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433. Chem. Rev. 2019, 119, 797,  DOI: 10.1021/acs.chemrev.8b00211
  124. 124
    Xu, P.; Jia, Y.; Yang, Y.; Chen, J.; Hu, P.; Chen, Z.; Huang, M. Photodynamic oncotherapy mediated by gonadotropin-releasing hormone receptors. J. Med. Chem. 2017, 60, 86678672,  DOI: 10.1021/acs.jmedchem.7b01216
  125. 125
    Thapa, P.; Li, M.; Bio, M.; Rajaputra, P.; Nkepang, G.; Sun, Y.; Woo, S.; You, Y. Far-red light-activatable prodrug of paclitaxel for the combined effects of photodynamic therapy and site-specific paclitaxel chemotherapy. J. Med. Chem. 2016, 59, 32043214,  DOI: 10.1021/acs.jmedchem.5b01971
  126. 126
    Battah, S.; Hider, R. C.; MacRobert, A. J.; Dobbin, P. S.; Zhou, T. Hydroxypyridinone and 5-aminolaevulinic acid conjugates for photodynamic therapy. J. Med. Chem. 2017, 60, 34983510,  DOI: 10.1021/acs.jmedchem.7b00346
  127. 127
    Feng, X.; Shi, Y.; Xie, L.; Zhang, K.; Wang, X.; Liu, Q.; Wang, P. Synthesis, characterization, and biological evaluation of a porphyrin-based photosensitizer and its isomer for effective photodynamic therapy against breast cancer. J. Med. Chem. 2018, 61, 71897201,  DOI: 10.1021/acs.jmedchem.8b00547
  128. 128
    Zhou, Y.; Cheung, Y. K.; Ma, C.; Zhao, S.; Gao, D.; Lo, P. C.; Fong, W. P.; Wong, K. S.; Ng, D. K. P. Endoplasmic reticulum-localized two-photon-absorbing boron dipyrromethenes as advanced photosensitizers for photodynamic therapy. J. Med. Chem. 2018, 61, 39523961,  DOI: 10.1021/acs.jmedchem.7b01907
  129. 129
    Cheruku, R. R.; Cacaccio, J.; Durrani, F.; Tabaczynski, W. A.; Watson, R.; Marko, A. J.; Kumar, R.; El-Khouly, M. E.; Fukuzumi, S.; Missert, J. R.; Yao, R.; Sajjad, M.; Chandra, D.; Guru, K.; Pandey, R. K. Epidermal growth factor receptor targeted multifunctional photosensitizers for bladder cancer imaging and photodynamic therapy. J. Med. Chem. 2019, 62, 2598,  DOI: 10.1021/acs.jmedchem.8b01927
  130. 130
    Blacklock, K. M.; Yachnin, B. J.; Woolley, G. A.; Khare, S. D. Computational design of a photocontrolled cytosine deaminase. J. Am. Chem. Soc. 2018, 140, 1417,  DOI: 10.1021/jacs.7b08709
  131. 131
    Zhu, M.; Zhou, H. Azobenzene-based small molecular photoswitches for protein modulation. Org. Biomol. Chem. 2018, 16, 84348445,  DOI: 10.1039/C8OB02157K
  132. 132
    (a) Quandt, G.; Höfner, G.; Pabel, J.; Dine, J.; Eder, M.; Wanner, K. T. First photoswitchable neurotransmitter transporter inhibitor: light-induced control of γ-aminobutyric acid transporter 1 (GAT1) activity in mouse brain. J. Med. Chem. 2014, 57, 68096821,  DOI: 10.1021/jm5008566 .
    (b) Lutz, T.; Wein, T.; Höfner, G.; Pabel, J.; Eder, M.; Dine, J.; Wanner, K. T. Development of new photoswitchable azobenzene based γ-aminobutyric acid (GABA) uptake inhibitors with distinctly enhanced potency upon photoactivation. J. Med. Chem. 2018, 61, 62116235,  DOI: 10.1021/acs.jmedchem.8b00629
  133. 133
    Nørager, N. G.; Poulsen, M. H.; Strømgaard, K. Controlling Ca2+ permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors with photochromic ion channel blockers. J. Med. Chem. 2018, 61, 80488053,  DOI: 10.1021/acs.jmedchem.8b00756
  134. 134
    Matera, C.; Gomila, A. M. J.; Camarero, N.; Libergoli, M.; Soler, C.; Gorostiza, P. Photoswitchable antimetabolite for targeted photoactivated chemotherapy. J. Am. Chem. Soc. 2018, 140, 1576415773,  DOI: 10.1021/jacs.8b08249
  135. 135
    Li, J.; Kong, H.; Huang, L.; Cheng, B.; Qin, K.; Zheng, M.; Yan, Z.; Zhang, Y. Visible light-initiated bioorthogonal photoclick cycloaddition. J. Am. Chem. Soc. 2018, 140, 1454214546,  DOI: 10.1021/jacs.8b08175
  136. 136
    Comer, E.; Beaudoin, J. A.; Kato, N.; Fitzgerald, M. E.; Heidebrecht, R. W.; Lee, Md, 4th.; Masi, D.; Mercier, M.; Mulrooney, C.; Muncipinto, G.; Rowley, A.; Crespo-Llado, K.; Serrano, A. E.; Lukens, A. K.; Wiegand, R. C.; Wirth, D. F.; Palmer, M. A.; Foley, M. A.; Munoz, B.; Scherer, C. A.; Duvall, J. R.; Schreiber, S. L. Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agents. J. Med. Chem. 2014, 57, 84968502,  DOI: 10.1021/jm500994n
  137. 137
    Kuttruff, C. A.; Haile, M.; Kraml, J.; Tautermann, C. S. Late-stage functionalization of drug-like molecules using diversinates. ChemMedChem 2018, 13, 983987,  DOI: 10.1002/cmdc.201800151
  138. 138
    Caro-Diaz, E. J. E.; Urbano, M.; Buzard, D. J.; Jones, R. M. C-H activation reactions as useful tools for medicinal chemists. Bioorg. Med. Chem. Lett. 2016, 26, 53785383,  DOI: 10.1016/j.bmcl.2016.06.036
  139. 139
    Sekizawa, H.; Amaike, K.; Itoh, Y.; Suzuki, T.; Itami, K.; Yamaguchi, J. Late-stage C-H coupling enables rapid identification of HDAC inhibitors: synthesis and evaluation of NCH-31 analogues. ACS Med. Chem. Lett. 2014, 5, 582586,  DOI: 10.1021/ml500024s
  140. 140
    Miyamura, S.; Araki, M.; Suzuki, T.; Yamaguchi, J.; Itami, K. Stereodivergent synthesis of arylcyclopropylamines by sequential C-H borylation and Suzuki-Miyaura coupling. Angew. Chem., Int. Ed. 2015, 54, 846851,  DOI: 10.1002/anie.201409186
  141. 141
    El Marrouni, A.; Campbell, M.; Perkins, J. J.; Converso, A. Development of a sp(2)-sp(3) stille cross-coupling for rapid synthesis of HIV NNRTI doravirine analogues. Org. Lett. 2017, 19, 30713074,  DOI: 10.1021/acs.orglett.7b01142
  142. 142
    Naret, T.; Khelifi, I.; Provot, O.; Bignon, J.; Levaique, H.; Dubois, J.; Souce, M.; Kasselouri, A.; Deroussent, A.; Paci, A.; Varela, P. F.; Gigant, B.; Alami, M.; Hamze, A. 1,1-Diheterocyclic ethylenes derived from quinaldine and carbazole as new tubulin polymerization inhibitors: synthesis, metabolism, and biological evaluation. J. Med. Chem. 2019, 62, 1902,  DOI: 10.1021/acs.jmedchem.8b01386
  143. 143
    Brown, D. G.; Boström, J. Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone?. J. Med. Chem. 2016, 59, 44434458,  DOI: 10.1021/acs.jmedchem.5b01409
  144. 144
    Fier, P. S.; Maloney, K. M. NHC-Catalyzed deamination of primary sulfonamides: a platform for late-stage functionalization. J. Am. Chem. Soc. 2019, 141, 1441,  DOI: 10.1021/jacs.8b11800
  145. 145
    Uehling, M. R.; King, R. P.; Krska, S. W.; Cernak, T.; Buchwald, S. L. Pharmaceutical diversification via palladium oxidative addition complexes. Science 2019, 363, 405408,  DOI: 10.1126/science.aac6153
  146. 146
    Clark, J. R.; Feng, K.; Sookezian, A.; White, M. C. Manganese-catalysed benzylic C(sp(3))-H amination for late-stage functionalization. Nat. Chem. 2018, 10, 583591,  DOI: 10.1038/s41557-018-0020-0
  147. 147
    Margrey, K. A.; Czaplyski, W. L.; Nicewicz, D. A.; Alexanian, E. J. A general strategy for aliphatic C-H functionalization enabled by organic photoredox catalysis. J. Am. Chem. Soc. 2018, 140, 42134217,  DOI: 10.1021/jacs.8b00592
  148. 148
    Laudadio, G.; Govaerts, S.; Wang, Y.; Ravelli, D.; Koolman, H. F.; Fagnoni, M.; Djuric, S. W.; Noël, T. Selective C(sp3)-H aerobic oxidation enabled by decatungstate photocatalysis in flow. Angew. Chem., Int. Ed. 2018, 57, 40784082,  DOI: 10.1002/anie.201800818
  149. 149
    Liu, Z.; Li, J.; Li, S.; Li, G.; Sharpless, K. B.; Wu, P. SuFEx click chemistry enabled late-stage drug functionalization. J. Am. Chem. Soc. 2018, 140, 29192925,  DOI: 10.1021/jacs.7b12788
  150. 150
    Boström, J.; Brown, D. G.; Young, R. J.; Keserü, G. M. Expanding the medicinal chemistry synthetic toolbox. Nat. Rev. Drug Discovery 2018, 17, 709,  DOI: 10.1038/nrd.2018.116
  151. 151
    Roughley, S. D.; Jordan, A. M. The medicinal chemist’s toolbox: an analysis of reactions used in the pursuit of drug candidates. J. Med. Chem. 2011, 54, 34513479,  DOI: 10.1021/jm200187y
  152. 152
    Frédérich, M.; Pirotte, B.; Fillet, M.; de Tullio, P. Metabolomics as a challenging approach for medicinal chemistry and personalized medicine. J. Med. Chem. 2016, 59, 86498666,  DOI: 10.1021/acs.jmedchem.5b01335
  153. 153
    (a) Stepan, A. F.; Tran, T. P.; Helal, C. J.; Brown, M. S.; Chang, C.; O’Connor, R. E.; De Vivo, M.; Doran, S. D.; Fisher, E. L.; Jenkinson, S.; Karanian, D.; Kormos, B. L.; Sharma, R.; Walker, G. S.; Wright, A. S.; Yang, E. X.; Brodney, M. A.; Wager, T. T.; Verhoest, P. R.; Obach, R. S. Late-stage microsomal oxidation reduces drug-drug interaction and identifies phosphodiesterase 2A inhibitor PF-06815189. ACS Med. Chem. Lett. 2018, 9, 6872,  DOI: 10.1021/acsmedchemlett.7b00343 .
    (b) Obach, R. S.; Walker, G. S.; Sharma, R.; Jenkinson, S.; Tran, T. P.; Stepan, A. F. Lead diversification at the nanomole scale using liver microsomes and quantitative nuclear magnetic resonance spectroscopy: application to phosphodiesterase 2 inhibitors. J. Med. Chem. 2018, 61, 36263640,  DOI: 10.1021/acs.jmedchem.8b00116
  154. 154
    Clouthier, C. M.; Pelletier, J. N. Expanding the organic toolbox: a guide to integrating biocatalysis in synthesis. Chem. Soc. Rev. 2012, 41, 15851605,  DOI: 10.1039/c2cs15286j
  155. 155
    Segall, M. Advances in multiparameter optimization methods for de novo drug design. Expert Opin. Drug Discovery 2014, 9, 803817,  DOI: 10.1517/17460441.2014.913565
  156. 156
    Segall, M. D.; Yusof, I.; Champness, E. J. Avoiding missed opportunities by analyzing the sensitivity of our decisions. J. Med. Chem. 2016, 59, 42674277,  DOI: 10.1021/acs.jmedchem.5b01921
  157. 157
    Shultz, M. D. Two decades under the influence of the rule of five and the changing properties of approved oral drugs. J. Med. Chem. 2019, 62, 1701,  DOI: 10.1021/acs.jmedchem.8b00686
  158. 158
    Doak, B. C.; Zheng, J.; Dobritzsch, D.; Kihlberg, J. How beyond rule of 5 drugs and clinical candidates bind to their targets. J. Med. Chem. 2016, 59, 23122327,  DOI: 10.1021/acs.jmedchem.5b01286
  159. 159
    DeGoey, D. A.; Chen, H. J.; Cox, P. B.; Wendt, M. D. Beyond the rule of 5: lessons learned from AbbVie’s drugs and compound collection. J. Med. Chem. 2018, 61, 26362651,  DOI: 10.1021/acs.jmedchem.7b00717
  160. 160
    Raymer, B.; Bhattacharya, S. K. Lead-like drugs: A perspective. J. Med. Chem. 2018, 61, 10375,  DOI: 10.1021/acs.jmedchem.8b00407
  161. 161
    Johnson, T. W.; Gallego, R. A. Lipophilic efficiency as an important metric in drug design. J. Med. Chem. 2018, 61, 64016420,  DOI: 10.1021/acs.jmedchem.8b00077
  162. 162
    Wager, T. T.; Kormos, B. L.; Brady, J. T.; Will, Y.; Aleo, M. D.; Stedman, D. B.; Kuhn, M.; Chandrasekaran, R. Y. Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies. J. Med. Chem. 2013, 56, 97719779,  DOI: 10.1021/jm401485p
  163. 163
    (a) Shultz, M. D.; Majumdar, D.; Chin, D. N.; Fortin, P. D.; Feng, Y.; Gould, T.; Kirby, C. A.; Stams, T.; Waters, N. J.; Shao, W. Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. J. Med. Chem. 2013, 56, 70497059,  DOI: 10.1021/jm400826j .
    (b) Shultz, M. D.; Cheung, A. K.; Kirby, C. A.; Firestone, B.; Fan, J.; Chen, C. H.; Chen, Z.; Chin, D. N.; Dipietro, L.; Fazal, A.; Feng, Y.; Fortin, P. D.; Gould, T.; Lagu, B.; Lei, H.; Lenoir, F.; Majumdar, D.; Ochala, E.; Palermo, M. G.; Pham, L.; Pu, M.; Smith, T.; Stams, T.; Tomlinson, R. C.; Toure, B. B.; Visser, M.; Wang, R. M.; Waters, N. J.; Shao, W. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J. Med. Chem. 2013, 56, 64956511,  DOI: 10.1021/jm400807n
  164. 164
    Jiang, Z. Y.; Xu, L. L.; Lu, M. C.; Chen, Z. Y.; Yuan, Z. W.; Xu, X. L.; Guo, X. K.; Zhang, X. J.; Sun, H. P.; You, Q. D. Structure-activity and structure-property relationship and exploratory in vivo evaluation of the nanomolar Keap1-Nrf2 protein-protein interaction inhibitor. J. Med. Chem. 2015, 58, 64106421,  DOI: 10.1021/acs.jmedchem.5b00185
  165. 165
    (a) Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 2010, 1, 435449,  DOI: 10.1021/cn100008c .
    (b) Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Central nervous system multiparameter optimization desirability: application in drug discovery. ACS Chem. Neurosci. 2016, 7, 767775,  DOI: 10.1021/acschemneuro.6b00029 .
    (c) Wager, T. T.; Chappie, T.; Horton, D.; Chandrasekaran, R. Y.; Samas, B.; Dunn-Sims, E. R.; Hsu, C.; Nawreen, N.; Vanase-Frawley, M. A.; O’Connor, R. E.; Schmidt, C. J.; Dlugolenski, K.; Stratman, N. C.; Majchrzak, M. J.; Kormos, B. L.; Nguyen, D. P.; Sawant-Basak, A.; Mead, A. N. Dopamine D3/D2 receptor antagonist PF-4363467 attenuates opioid drug-seeking behavior without concomitant D2 side effects. ACS Chem. Neurosci. 2017, 8, 165177,  DOI: 10.1021/acschemneuro.6b00297
  166. 166
    Vilums, M.; Zweemer, A. J.; Yu, Z.; de Vries, H.; Hillger, J. M.; Wapenaar, H.; Bollen, I. A.; Barmare, F.; Gross, R.; Clemens, J.; Krenitsky, P.; Brussee, J.; Stamos, D.; Saunders, J.; Heitman, L. H.; Ijzerman, A. P. Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists. J. Med. Chem. 2013, 56, 77067714,  DOI: 10.1021/jm4011737
  167. 167
    Yu, Z.; van Veldhoven, J. P.; Louvel, J.; t Hart, I. M.; Rook, M. B.; van der Heyden, M. A.; Heitman, L. H.; IJzerman, A. P. Structure-affinity relationships (SARs) and Structure-kinetics relationships (SKRs) of Kv11.1 blockers. J. Med. Chem. 2015, 58, 59165929,  DOI: 10.1021/acs.jmedchem.5b00518
  168. 168
    Rai, G.; Brimacombe, K. R.; Mott, B. T.; Urban, D. J.; Hu, X.; Yang, S. M.; Lee, T. D.; Cheff, D. M.; Kouznetsova, J.; Benavides, G. A.; Pohida, K.; Kuenstner, E. J.; Luci, D. K.; Lukacs, C. M.; Davies, D. R.; Dranow, D. M.; Zhu, H.; Sulikowski, G.; Moore, W. J.; Stott, G. M.; Flint, A. J.; Hall, M. D.; Darley-Usmar, V. M.; Neckers, L. M.; Dang, C. V.; Waterson, A. G.; Simeonov, A.; Jadhav, A.; Maloney, D. J. Discovery and optimization of potent, cell-active pyrazole-based inhibitors of lactate dehydrogenase (LDH). J. Med. Chem. 2017, 60, 91849204,  DOI: 10.1021/acs.jmedchem.7b00941
  169. 169
    Brough, P. A.; Baker, L.; Bedford, S.; Brown, K.; Chavda, S.; Chell, V.; D’Alessandro, J.; Davies, N. G.; Davis, B.; Le Strat, L.; Macias, A. T.; Maddox, D.; Mahon, P. C.; Massey, A. J.; Matassova, N.; McKenna, S.; Meissner, J. W.; Moore, J. D.; Murray, J. B.; Northfield, C. J.; Parry, C.; Parsons, R.; Roughley, S. D.; Shaw, T.; Simmonite, H.; Stokes, S.; Surgenor, A.; Stefaniak, E.; Robertson, A.; Wang, Y.; Webb, P.; Whitehead, N.; Wood, M. Application of off-rate screening in the identification of novel pan-isoform inhibitors of pyruvate dehydrogenase kinase. J. Med. Chem. 2017, 60, 22712286,  DOI: 10.1021/acs.jmedchem.6b01478
  170. 170
    Klebe, G. Applying thermodynamic profiling in lead finding and optimization. Nat. Rev. Drug Discovery 2015, 14, 95110,  DOI: 10.1038/nrd4486
  171. 171
    Cusack, K. P.; Wang, Y.; Hoemann, M. Z.; Marjanovic, J.; Heym, R. G.; Vasudevan, A. Design strategies to address kinetics of drug binding and residence time. Bioorg. Med. Chem. Lett. 2015, 25, 20192027,  DOI: 10.1016/j.bmcl.2015.02.027
  172. 172
    Buch, I.; Giorgino, T.; De Fabritiis, G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 1018410189,  DOI: 10.1073/pnas.1103547108
  173. 173
    Perricone, U.; Gulotta, M. R.; Lombino, J.; Parrino, B.; Cascioferro, S.; Diana, P.; Cirrincione, G.; Padova, A. An overview of recent molecular dynamics applications as medicinal chemistry tools for the undruggable site challenge. MedChemComm 2018, 9, 920936,  DOI: 10.1039/C8MD00166A
  174. 174
    Mollica, L.; Theret, I.; Antoine, M.; Perron-Sierra, F.; Charton, Y.; Fourquez, J. M.; Wierzbicki, M.; Boutin, J. A.; Ferry, G.; Decherchi, S.; Bottegoni, G.; Ducrot, P.; Cavalli, A. Molecular dynamics simulations and kinetic measurements to estimate and predict protein-ligand residence times. J. Med. Chem. 2016, 59, 71677176,  DOI: 10.1021/acs.jmedchem.6b00632
  175. 175
    Krimmer, S. G.; Cramer, J.; Betz, M.; Fridh, V.; Karlsson, R.; Heine, A.; Klebe, G. Rational design of thermodynamic and kinetic binding profiles by optimizing surface water networks coating protein-bound ligands. J. Med. Chem. 2016, 59, 1053010548,  DOI: 10.1021/acs.jmedchem.6b00998
  176. 176
    Nasief, N. N.; Tan, H.; Kong, J.; Hangauer, D. Water mediated ligand functional group cooperativity: the contribution of a methyl group to binding affinity is enhanced by a COO(−) group through changes in the structure and thermodynamics of the hydration waters of ligand-thermolysin complexes. J. Med. Chem. 2012, 55, 82838302,  DOI: 10.1021/jm300472k
  177. 177
    Liu, L. Efficient hit and lead compound evaluation strategy based on off-rate screening by surface plasmon resonance. J. Med. Chem. 2014, 57, 28432844,  DOI: 10.1021/jm5003815
  178. 178
    Murray, J. B.; Roughley, S. D.; Matassova, N.; Brough, P. A. Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products. J. Med. Chem. 2014, 57, 28452850,  DOI: 10.1021/jm401848a
  179. 179
    Spagnuolo, L. A.; Eltschkner, S.; Yu, W.; Daryaee, F.; Davoodi, S.; Knudson, S. E.; Allen, E. K.; Merino, J.; Pschibul, A.; Moree, B.; Thivalapill, N.; Truglio, J. J.; Salafsky, J.; Slayden, R. A.; Kisker, C.; Tonge, P. J. Evaluating the contribution of transition-state destabilization to changes in the residence time of triazole-based InhA inhibitors. J. Am. Chem. Soc. 2017, 139, 34173429,  DOI: 10.1021/jacs.6b11148
  180. 180
    Kokh, D. B.; Amaral, M.; Bomke, J.; Grädler, U.; Musil, D.; Buchstaller, H. P.; Dreyer, M. K.; Frech, M.; Lowinski, M.; Vallee, F.; Bianciotto, M.; Rak, A.; Wade, R. C. Estimation of drug-target residence times by τ-random acceleration molecular dynamics simulations. J. Chem. Theory Comput. 2018, 14, 38593869,  DOI: 10.1021/acs.jctc.8b00230
  181. 181
    Cummins, D. J.; Bell, M. A. Integrating Everything: The molecule selection toolkit, a system for compound prioritization in drug discovery. J. Med. Chem. 2016, 59, 69997010,  DOI: 10.1021/acs.jmedchem.5b01338
  182. 182
    McEnaney, P. J.; Parker, C. G.; Zhang, A. X.; Spiegel, D. A. Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem. Biol. 2012, 7, 11391151,  DOI: 10.1021/cb300119g
  183. 183
    Casi, G.; Neri, D. Antibody-drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents. J. Med. Chem. 2015, 58, 87518761,  DOI: 10.1021/acs.jmedchem.5b00457
  184. 184
    Murelli, R. P.; Zhang, A. X.; Michel, J.; Jorgensen, W. L.; Spiegel, D. A. Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer. J. Am. Chem. Soc. 2009, 131, 1709017092,  DOI: 10.1021/ja906844e
  185. 185
    (a) Parker, C. G.; Domaoal, R. A.; Anderson, K. S.; Spiegel, D. A. An antibody-recruiting small molecule that targets HIV gp120. J. Am. Chem. Soc. 2009, 131, 1639216394,  DOI: 10.1021/ja9057647 .
    (b) Parker, C. G.; Dahlgren, M. K.; Tao, R. N.; Li, D. T.; Douglass, E. F., Jr.; Shoda, T.; Jawanda, N.; Spasov, K. A.; Lee, S.; Zhou, N.; Domaoal, R. A.; Sutton, R. E.; Anderson, K. S.; Jorgensen, W. L.; Krystal, M.; Spiegel, D. A. Illuminating HIV gp120-ligand recognition through computationally-driven optimization of antibody-recruiting molecules. Chem. Sci. 2014, 5, 23112317,  DOI: 10.1039/C4SC00484A
  186. 186
    Genady, A. R.; Janzen, N.; Banevicius, L.; El-Gamal, M.; El-Zaria, M. E.; Valliant, J. F. Preparation and evaluation of radiolabeled antibody recruiting small molecules that target prostate-specific membrane antigen for combined radiotherapy and immunotherapy. J. Med. Chem. 2016, 59, 26602673,  DOI: 10.1021/acs.jmedchem.5b01881
  187. 187
    Liu, Z.; Chen, X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem. Soc. Rev. 2016, 45, 14321456,  DOI: 10.1039/C5CS00158G
  188. 188
    Matos, M. J. Learning from nature: the role of albumin in drug delivery. Future Med. Chem. 2018, 10, 983985,  DOI: 10.4155/fmc-2018-0053
  189. 189
    Kratz, F.; Muller-Driver, R.; Hofmann, I.; Drevs, J.; Unger, C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem. 2000, 43, 12531256,  DOI: 10.1021/jm9905864
  190. 190
    Jafari, N.; Ahmed, R.; Gloyd, M.; Bloomfield, J.; Britz-McKibbin, P.; Melacini, G. Allosteric sensing of fatty acid binding by NMR: application to human serum albumin. J. Med. Chem. 2016, 59, 74577465,  DOI: 10.1021/acs.jmedchem.6b00410
  191. 191
    Shechter, Y.; Tsubery, H.; Fridkin, M. N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl](3)-gentamicin C(1) is a long-acting prodrug derivative. J. Med. Chem. 2002, 45, 42644270,  DOI: 10.1021/jm020042t
  192. 192
    Zheng, Y. R.; Suntharalingam, K.; Johnstone, T. C.; Yoo, H.; Lin, W.; Brooks, J. G.; Lippard, S. J. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J. Am. Chem. Soc. 2014, 136, 87908798,  DOI: 10.1021/ja5038269
  193. 193
    Bech, E. M.; Martos-Maldonado, M. C.; Wismann, P.; Sorensen, K. K.; van Witteloostuijn, S. B.; Thygesen, M. B.; Vrang, N.; Jelsing, J.; Pedersen, S. L.; Jensen, K. J. Peptide half-life extension: divalent, small-molecule albumin interactions direct the systemic properties of glucagon-like peptide 1 (GLP-1) analogues. J. Med. Chem. 2017, 60, 74347446,  DOI: 10.1021/acs.jmedchem.7b00787
  194. 194
    Kratz, F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin. Invest. Drugs 2007, 16, 855866,  DOI: 10.1517/13543784.16.6.855
  195. 195
    Zhang, H.; Wang, K.; Na, K.; Li, D.; Li, Z.; Zhao, D.; Zhong, L.; Wang, M.; Kou, L.; Luo, C.; Zhang, H.; Kan, Q.; Ding, H.; He, Z.; Sun, J. Striking a balance between carbonate/carbamate linkage bond- and reduction-sensitive disulfide bond-bearing linker for tailored controlled release: in situ covalent-albumin-binding gemcitabine prodrugs promote bioavailability and tumor accumulation. J. Med. Chem. 2018, 61, 49044917,  DOI: 10.1021/acs.jmedchem.8b00293
  196. 196
    http://www.thebodypro.com/content/81083/china-approves-albuvirtide-a-once-weekly-injectabl.html (accessed Apr 8, 2019).
  197. 197
    Chong, H.; Yao, X.; Zhang, C.; Cai, L.; Cui, S.; Wang, Y.; He, Y. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One 2012, 7, e32599,  DOI: 10.1371/journal.pone.0032599
  198. 198
    (a) Bohn, P.; Le Fur, N.; Hagues, G.; Costentin, J.; Torquet, N.; Papamicaël, C.; Marsais, F.; Levacher, V. Rational design of central selective acetylcholinesterase inhibitors by means of a ″bio-oxidisable prodrug″ strategy. Org. Biomol. Chem. 2009, 7, 26122618,  DOI: 10.1039/b903041g .
    (b) Bohn, P.; Gourand, F.; Papamicaël, C.; Ibazizène, M.; Dhilly, M.; Gembus, V.; Alix, F.; Ţînţaş, M. L.; Marsais, F.; Barré, L.; Levacher, V. Dihydroquinoline carbamate derivatives as ″bio-oxidizable″ prodrugs for brain delivery of acetylcholinesterase inhibitors: [11C] Radiosynthesis and biological evaluation. ACS Chem. Neurosci. 2015, 6, 737744,  DOI: 10.1021/cn5003539 .
    (c) Peauger, L.; Azzouz, R.; Gembus, V.; Ţînţaş, M. L.; Sopková-de Oliveira Santos, J.; Bohn, P.; Papamicaël, C.; Levacher, V. Donepezil-based central acetylcholinesterase inhibitors by means of a ″bio-oxidizable″ prodrug strategy: design, synthesis, and in vitro biological evaluation. J. Med. Chem. 2017, 60, 59095926,  DOI: 10.1021/acs.jmedchem.7b00702 .
    (d) Azzouz, R.; Peauger, L.; Gembus, V.; Ţînţaş, M. L.; Sopková-de Oliveira Santos, J.; Papamicaël, C.; Levacher, V. Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ″bio-oxidizable″ prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur. J. Med. Chem. 2018, 145, 165190,  DOI: 10.1016/j.ejmech.2017.12.084
  199. 199
    Childress, E. S.; Alexopoulos, S. J.; Hoehn, K. L.; Santos, W. L. Small molecule mitochondrial uncouplers and their therapeutic potential. J. Med. Chem. 2018, 61, 46414655,  DOI: 10.1021/acs.jmedchem.7b01182
  200. 200
    Millard, M.; Gallagher, J. D.; Olenyuk, B. Z.; Neamati, N. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. J. Med. Chem. 2013, 56, 91709179,  DOI: 10.1021/jm4012438
  201. 201
    (a) Ye, Y.; Zhang, T.; Yuan, H.; Li, D.; Lou, H.; Fan, P. Mitochondria-targeted lupane triterpenoid derivatives and their selective apoptosis-inducing anticancer mechanisms. J. Med. Chem. 2017, 60, 63536363,  DOI: 10.1021/acs.jmedchem.7b00679 .
    (b) Chang, W.; Liu, J.; Zhang, M.; Shi, H.; Zheng, S.; Jin, X.; Gao, Y.; Wang, S.; Ji, A.; Lou, H. Efflux pump-mediated resistance to antifungal compounds can be prevented by conjugation with triphenylphosphonium cation. Nat. Commun. 2018, 9, 5102,  DOI: 10.1038/s41467-018-07633-9
  202. 202
    Bauer, R. A. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discovery Today 2015, 20, 10611073,  DOI: 10.1016/j.drudis.2015.05.005
  203. 203
    Zhao, Z.; Liu, Q.; Bliven, S.; Xie, L.; Bourne, P. E. Determining cysteines available for covalent inhibition across the human kinome. J. Med. Chem. 2017, 60, 28792889,  DOI: 10.1021/acs.jmedchem.6b01815
  204. 204
    Akbar, A.; McNeil, N. M. R.; Albert, M. R.; Ta, V.; Adhikary, G.; Bourgeois, K.; Eckert, R. L.; Keillor, J. W. Structure-activity relationships of potent, targeted covalent inhibitors that abolish both the transamidation and GTP binding activities of human tissue transglutaminase. J. Med. Chem. 2017, 60, 79107927,  DOI: 10.1021/acs.jmedchem.7b01070
  205. 205
    Muth, F.; El-Gokha, A.; Ansideri, F.; Eitel, M.; Doring, E.; Sievers-Engler, A.; Lange, A.; Boeckler, F. M.; Lammerhofer, M.; Koch, P.; Laufer, S. A. Tri- and tetrasubstituted pyridinylimidazoles as covalent inhibitors of c-Jun N-terminal kinase 3. J. Med. Chem. 2017, 60, 594607,  DOI: 10.1021/acs.jmedchem.6b01180
  206. 206
    Shi, L.; Zhong, Z.; Li, X.; Zhou, Y.; Pan, Z. Discovery of an orally available janus kinase 3 selective covalent inhibitor. J. Med. Chem. 2019, 62, 1054,  DOI: 10.1021/acs.jmedchem.8b01823
  207. 207
    (a) Patricelli, M. P.; Janes, M. R.; Li, L. S.; Hansen, R.; Peters, U.; Kessler, L. V.; Chen, Y.; Kucharski, J. M.; Feng, J.; Ely, T.; Chen, J. H.; Firdaus, S. J.; Babbar, A.; Ren, P.; Liu, Y. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discovery 2016, 6, 316329,  DOI: 10.1158/2159-8290.CD-15-1105 .
    (b) Hansen, R.; Peters, U.; Babbar, A.; Chen, Y.; Feng, J.; Janes, M. R.; Li, L. S.; Ren, P.; Liu, Y.; Zarrinkar, P. P. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors. Nat. Struct. Mol. Biol. 2018, 25, 454,  DOI: 10.1038/s41594-018-0061-5
  208. 208
    Brameld, K. A.; Owens, T. D.; Verner, E.; Venetsanakos, E.; Bradshaw, J. M.; Phan, V. T.; Tam, D.; Leung, K.; Shu, J.; LaStant, J.; Loughhead, D. G.; Ton, T.; Karr, D. E.; Gerritsen, M. E.; Goldstein, D. M.; Funk, J. O. Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido [2,3-d]pyrimidin-7(8H)-one (PRN1371) for the treatment of solid tumors. J. Med. Chem. 2017, 60, 65166527,  DOI: 10.1021/acs.jmedchem.7b00360
  209. 209
    Wolle, P.; Hardick, J.; Cronin, S. J. F.; Engel, J.; Baumann, M.; Lategahn, J.; Penninger, J.; Rauh, D. Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c Jun N-Terminal Kinase) pathway with covalent inhibitors. J. Med. Chem. 2019, 62, 2843,  DOI: 10.1021/acs.jmedchem.9b00102
  210. 210
    Lelais, G.; Epple, R.; Marsilje, T. H.; Long, Y. O.; McNeill, M.; Chen, B.; Lu, W.; Anumolu, J.; Badiger, S.; Bursulaya, B.; DiDonato, M.; Fong, R.; Juarez, J.; Li, J.; Manuia, M.; Mason, D. E.; Gordon, P.; Groessl, T.; Johnson, K.; Jia, Y.; Kasibhatla, S.; Li, C.; Isbell, J.; Spraggon, G.; Bender, S.; Michellys, P. Y. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and wt sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR nutants for the treatment of EGFR mutant non-small-cell lung cancers. J. Med. Chem. 2016, 59, 66716689,  DOI: 10.1021/acs.jmedchem.5b01985
  211. 211
    Horton, J. R.; Woodcock, C. B.; Chen, Q.; Liu, X.; Zhang, X.; Shanks, J.; Rai, G.; Mott, B. T.; Jansen, D. J.; Kales, S. C.; Henderson, M. J.; Cyr, M.; Pohida, K.; Hu, X.; Shah, P.; Xu, X.; Jadhav, A.; Maloney, D. J.; Hall, M. D.; Simeonov, A.; Fu, H.; Vertino, P. M.; Cheng, X. Structure-based engineering of irreversible inhibitors against histone lysine demethylase KDM5A. J. Med. Chem. 2018, 61, 10588,  DOI: 10.1021/acs.jmedchem.8b01219
  212. 212
    Liu, Y.; Xie, Z.; Zhao, D.; Zhu, J.; Mao, F.; Tang, S.; Xu, H.; Luo, C.; Geng, M.; Huang, M.; Li, J. Development of the first generation of disulfide-based subtype-selective and potent covalent pyruvate dehydrogenase kinase 1 (PDK1) inhibitors. J. Med. Chem. 2017, 60, 22272244,  DOI: 10.1021/acs.jmedchem.6b01245
  213. 213
    (a) McAllister, L. A.; O’Neil, S. V.; Fonseca, K. R.; Piro, J. R.; Cianfrogna, J. A.; Foley, T. L.; Gilbert, A. M.; Harris, A. R.; Helal, C. J.; Johnson, D. S.; Montgomery, J. I.; Nason, D. M.; Noell, S.; Pandit, J.; Rogers, B. N.; Samad, T. A.; Shaffer, C. L.; da Silva, R. G.; Uccello, D. P.; Webb, D.; Brodney, M. A. Discovery of trifluoromethyl glycol carbamates as potent and selective covalent monoacylglycerol lipase (MAGL) inhibitors for treatment of neuroinflammation. J. Med. Chem. 2018, 61, 30083026,  DOI: 10.1021/acs.jmedchem.8b00070 .
    (b) Butler, C. R.; Beck, E. M.; Harris, A.; Huang, Z.; McAllister, L. A.; Am Ende, C. W.; Fennell, K.; Foley, T. L.; Fonseca, K.; Hawrylik, S. J.; Johnson, D. S.; Knafels, J. D.; Mente, S.; Noell, G. S.; Pandit, J.; Phillips, T. B.; Piro, J. R.; Rogers, B. N.; Samad, T. A.; Wang, J.; Wan, S.; Brodney, M. A. Azetidine and piperidine carbamates as efficient, covalent inhibitors of monoacylglycerol lipase. J. Med. Chem. 2017, 60, 98609873,  DOI: 10.1021/acs.jmedchem.7b01531
  214. 214
    Kulkarni, P. M.; Kulkarni, A. R.; Korde, A.; Tichkule, R. B.; Laprairie, R. B.; Denovan-Wright, E. M.; Zhou, H.; Janero, D. R.; Zvonok, N.; Makriyannis, A.; Cascio, M. G.; Pertwee, R. G.; Thakur, G. A. Novel electrophilic and photoaffinity covalent probes for mapping the cannabinoid 1 receptor allosteric site(s). J. Med. Chem. 2016, 59, 4460,  DOI: 10.1021/acs.jmedchem.5b01303
  215. 215
    Doornbos, M. L. J.; Wang, X.; Vermond, S. C.; Peeters, L.; Pérez-Benito, L.; Trabanco, A. A.; Lavreysen, H.; Cid, J. M.; Heitman, L. H.; Tresadern, G.; IJzerman, A. P. Covalent allosteric probe for the metabotropic glutamate receptor 2: Design, synthesis, and pharmacological characterization. J. Med. Chem. 2019, 62, 223,  DOI: 10.1021/acs.jmedchem.8b00051
  216. 216
    Casimiro-Garcia, A.; Trujillo, J. I.; Vajdos, F.; Juba, B.; Banker, M. E.; Aulabaugh, A.; Balbo, P.; Bauman, J.; Chrencik, J.; Coe, J. W.; Czerwinski, R.; Dowty, M.; Knafels, J. D.; Kwon, S.; Leung, L.; Liang, S.; Robinson, R. P.; Telliez, J. B.; Unwalla, R.; Yang, X.; Thorarensen, A. Identification of cyanamide-based Janus kinase 3 (JAK3) covalent inhibitors. J. Med. Chem. 2018, 61, 10665,  DOI: 10.1021/acs.jmedchem.8b01308
  217. 217
    Chan, A. H.; Lee, W. G.; Spasov, K. A.; Cisneros, J. A.; Kudalkar, S. N.; Petrova, Z. O.; Buckingham, A. B.; Anderson, K. S.; Jorgensen, W. Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: from design to protein crystallography. Proc. Natl. Acad. Sci. U. S. A. 2017, 114, 97259730,  DOI: 10.1073/pnas.1711463114
  218. 218
    Shindo, N.; Fuchida, H.; Sato, M.; Watari, K.; Shibata, T.; Kuwata, K.; Miura, C.; Okamoto, K.; Hatsuyama, Y.; Tokunaga, K.; Sakamoto, S.; Morimoto, S.; Abe, Y.; Shiroishi, M.; Caaveiro, J. M. M.; Ueda, T.; Tamura, T.; Matsunaga, N.; Nakao, T.; Koyanagi, S.; Ohdo, S.; Yamaguchi, Y.; Hamachi, I.; Ono, M.; Ojida, A. Selective and reversible modification of kinase cysteines with chlorofluoroacetamides. Nat. Chem. Biol. 2019, 15, 250,  DOI: 10.1038/s41589-018-0204-3
  219. 219
    (a) Brouwer, A. J.; Jonker, A.; Werkhoven, P.; Kuo, E.; Li, N.; Gallastegui, N.; Kemmink, J.; Florea, B. I.; Groll, M.; Overkleeft, H. S.; Liskamp, R. M. Peptido sulfonyl fluorides as new powerful proteasome inhibitors. J. Med. Chem. 2012, 55, 109951003,  DOI: 10.1021/jm301443r .
    (b) Artschwager, R.; Ward, D.; Gannon, S.; Brouwer, A. J.; van de Langemheen, H.; Kowalski, H.; Liskamp, R. Potent and highly selective inhibitors of the proteasome trypsin-like site by incorporation of basic side chain containing amino acid derived sulfonyl fluorides. J. Med. Chem. 2018, 61, 53955411,  DOI: 10.1021/acs.jmedchem.8b00685
  220. 220
    Yang, F.; Zhu, M.; Zhang, J.; Zhou, H. Synthesis of biologically active boron-containing compounds. MedChemComm 2018, 9, 201211,  DOI: 10.1039/C7MD00552K
  221. 221
    (a) Smith, T. P.; Windsor, I. W.; Forest, K. T.; Raines, R. T. Stilbene boronic acids form a covalent bond with human transthyretin and inhibit its aggregation. J. Med. Chem. 2017, 60, 78207834,  DOI: 10.1021/acs.jmedchem.7b00952 .
    (b) Windsor, I. W.; Palte, M. J.; Lukesh, J. C., 3rd.; Gold, B.; Forest, K. T.; Raines, R. T. Sub-picomolar inhibition of hiv-1 protease with a boronic acid. J. Am. Chem. Soc. 2018, 140, 1401514018,  DOI: 10.1021/jacs.8b07366
  222. 222
    Nitsche, C.; Zhang, L.; Weigel, L. F.; Schilz, J.; Graf, D.; Bartenschlager, R.; Hilgenfeld, R.; Klein, C. D. Peptide-boronic acid inhibitors of flaviviral proteases: medicinal chemistry and structural biology. J. Med. Chem. 2017, 60, 511516,  DOI: 10.1021/acs.jmedchem.6b01021
  223. 223
    Zervosen, A.; Herman, R.; Kerff, F.; Herman, A.; Bouillez, A.; Prati, F.; Pratt, R. F.; Frère, J. M.; Joris, B.; Luxen, A.; Charlier, P.; Sauvage, E. Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin-binding protein. J. Am. Chem. Soc. 2011, 133, 1083910848,  DOI: 10.1021/ja200696y
  224. 224
    (a) Powers, R. A.; Swanson, H. C.; Taracila, M. A.; Florek, N. W.; Romagnoli, C.; Caselli, E.; Prati, F.; Bonomo, R. A.; Wallar, B. J. Biochemical and structural analysis of inhibitors targeting the ADC-7 cephalosporinase of Acinetobacter baumannii. Biochemistry 2014, 53, 76707679,  DOI: 10.1021/bi500887n .
    (b) Caselli, E.; Romagnoli, C.; Vahabi, R.; Taracila, M. A.; Bonomo, R. A.; Prati, F. Click chemistry in lead optimization of boronic acids as β-lactamase inhibitors. J. Med. Chem. 2015, 58, 54455458,  DOI: 10.1021/acs.jmedchem.5b00341 .
    (c) Bouza, A. A.; Swanson, H. C.; Smolen, K. A.; VanDine, A. L.; Taracila, M. A.; Romagnoli, C.; Caselli, E.; Prati, F.; Bonomo, R. A.; Powers, R. A.; Wallar, B. J. Structure-based analysis of boronic acids as inhibitors of acinetobacter-derived cephalosporinase-7, a unique class C β-lactamase. ACS Infect. Dis. 2018, 4, 325336,  DOI: 10.1021/acsinfecdis.7b00152 .
    (d) Caselli, E.; Romagnoli, C.; Powers, R. A.; Taracila, M. A.; Bouza, A. A.; Swanson, H. C.; Smolen, K. A.; Fini, F.; Wallar, B. J.; Bonomo, R. A.; Prati, F. Inhibition of acinetobacter-derived cephalosporinase: exploring the carboxylate recognition site using novel β-lactamase inhibitors. ACS Infect. Dis. 2018, 4, 337348,  DOI: 10.1021/acsinfecdis.7b00153
  225. 225
    Mons, E.; Jansen, I. D. C.; Loboda, J.; van Doodewaerd, B. R.; Hermans, J.; Verdoes, M.; van Boeckel, C. A. A.; van Veelen, P. A.; Turk, B.; Turk, D.; Ovaa, H. The alkyne moiety as a latent electrophile in irreversible covalent small molecule inhibitors of Cathepsin K. J. Am. Chem. Soc. 2019, 141, 3507,  DOI: 10.1021/jacs.8b11027
  226. 226
    Palermo, G.; Branduardi, D.; Masetti, M.; Lodola, A.; Mor, M.; Piomelli, D.; Cavalli, A.; De Vivo, M. Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas. J. Med. Chem. 2011, 54, 66126623,  DOI: 10.1021/jm2004283
  227. 227
    Chatterjee, P.; Botello-Smith, W. M.; Zhang, H.; Qian, L.; Alsamarah, A.; Kent, D.; Lacroix, J. J.; Baudry, M.; Luo, Y. Can relative binding free energy predict selectivity of reversible covalent inhibitors?. J. Am. Chem. Soc. 2017, 139, 1794517952,  DOI: 10.1021/jacs.7b08938
  228. 228
    Scarpino, A.; Ferenczy, G. G.; Keseru, G. M. Comparative evaluation of covalent docking tools. J. Chem. Inf. Model. 2018, 58, 14411458,  DOI: 10.1021/acs.jcim.8b00228
  229. 229
    (a) Kathman, S. G.; Xu, Z.; Statsyuk, A. V. A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases. J. Med. Chem. 2014, 57, 49694974,  DOI: 10.1021/jm500345q .
    (b) Kathman, S. G.; Span, I.; Smith, A. T.; Xu, Z.; Zhan, J.; Rosenzweig, A. C.; Statsyuk, A. V. A small molecule that switches a ubiquitin ligase from a processive to a distributive enzymatic mechanism. J. Am. Chem. Soc. 2015, 137, 1244212445,  DOI: 10.1021/jacs.5b06839
  230. 230
    Johansson, H.; Tsai, Y. I.; Fantom, K.; Chung, C. W.; Kümper, S.; Martino, L.; Thomas, D. A.; Eberl, H. C.; Muelbaier, M.; House, D.; Rittinger, K. Fragment-based covalent ligand screening enables rapid discovery of inhibitors for the RBR E3 ubiquitin ligase HOIP. J. Am. Chem. Soc. 2019, 141, 2703,  DOI: 10.1021/jacs.8b13193
  231. 231
    Lavogina, D.; Lust, M.; Viil, I.; König, N.; Raidaru, G.; Rogozina, J.; Enkvist, E.; Uri, A.; Bossemeyer, D. Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. J. Med. Chem. 2009, 52, 308321,  DOI: 10.1021/jm800797n
  232. 232
    Gao, F.; Yan, X.; Shakya, T.; Baettig, O. M.; Ait-Mohand-Brunet, S.; Berghuis, A. M.; Wright, G. D.; Auclair, K. Synthesis and structure-activity relationships of truncated bisubstrate inhibitors of aminoglycoside 6′-N-acetyltransferases. J. Med. Chem. 2006, 49, 52735281,  DOI: 10.1021/jm060732n
  233. 233
    Bockman, M. R.; Kalinda, A. S.; Petrelli, R.; De la Mora-Rey, T.; Tiwari, D.; Liu, F.; Dawadi, S.; Nandakumar, M.; Rhee, K. Y.; Schnappinger, D.; Finzel, B. C.; Aldrich, C. C. Targeting mycobacterium tuberculosis biotin protein ligase (MtBPL) with nucleoside-based bisubstrate adenylation inhibitors. J. Med. Chem. 2015, 58, 73497369,  DOI: 10.1021/acs.jmedchem.5b00719
  234. 234
    Halby, L.; Menon, Y.; Rilova, E.; Pechalrieu, D.; Masson, V.; Faux, C.; Bouhlel, M. A.; David-Cordonnier, M. H.; Novosad, N.; Aussagues, Y.; Samson, A.; Lacroix, L.; Ausseil, F.; Fleury, L.; Guianvarc’h, D.; Ferroud, C.; Arimondo, P. B. Rational design of bisubstrate-type analogues as inhibitors of DNA methyltransferases in cancer cells. J. Med. Chem. 2017, 60, 46654679,  DOI: 10.1021/acs.jmedchem.7b00176
  235. 235
    Babault, N.; Allali-Hassani, A.; Li, F.; Fan, J.; Yue, A.; Ju, K.; Liu, F.; Vedadi, M.; Liu, J.; Jin, J. Discovery of bisubstrate inhibitors of nicotinamide N-methyltransferase (NNMT). J. Med. Chem. 2018, 61, 15411551,  DOI: 10.1021/acs.jmedchem.7b01422
  236. 236
    Cinelli, M. A.; Li, H.; Chreifi, G.; Poulos, T. L.; Silverman, R. B. Nitrile in the hole: Discovery of a small auxiliary pocket in neuronal nitric oxide synthase leading to the development of potent and selective 2-aminoquinoline Inhibitors. J. Med. Chem. 2017, 60, 39583978,  DOI: 10.1021/acs.jmedchem.7b00259
  237. 237
    Ye, S.; Loll, B.; Berger, A. A.; Mülow, U.; Alings, C.; Wahl, M. C.; Koksch, B. Fluorine teams up with water to restore inhibitor activity to mutant BPTI. Chem. Sci. 2015, 6, 52465254,  DOI: 10.1039/C4SC03227F
  238. 238
    Seo, J.; Igarashi, J.; Li, H.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Structure-based design and synthesis of N(omega)-nitro-L-arginine-containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water. J. Med. Chem. 2007, 50, 20892099,  DOI: 10.1021/jm061305c
  239. 239
    Fornabaio, M.; Spyrakis, F.; Mozzarelli, A.; Cozzini, P.; Abraham, D. J.; Kellogg, G. E. Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 3. The free energy contribution of structural water molecules in HIV-1 protease complexes. J. Med. Chem. 2004, 47, 45074516,  DOI: 10.1021/jm030596b
  240. 240
    (a) Chong, P. Y.; Shotwell, J. B.; Miller, J. F.; Price, D. J.; Maynard, A.; Voitenleitner, C.; Mathis, A.; Williams, S.; Pouliot, J.; Creech, K.; Wang, F.; Fang, J. M.; Zhang, H.; Tai, V.; Turner, E.; Kahler, K. M.; Crosby, R.; Peat, A. J. Design of N-benzoxaborole benzofuran GSK8175 - Optimization of human PK inspired by metabolites of a failed clinical HCV inhibitor. J. Med. Chem. 2019, 62, 3254,  DOI: 10.1021/acs.jmedchem.8b01719 .
    (b) Zhan, P.; Kang, D.; Liu, X. Resurrecting the condemned: Identification of N-benzoxaborole benzofuran GSK8175 as a clinical candidate with reduced metabolic liability. J. Med. Chem. 2019, 62, 3251,  DOI: 10.1021/acs.jmedchem.9b00415
  241. 241
    Spyrakis, F.; Ahmed, M. H.; Bayden, A. S.; Cozzini, P.; Mozzarelli, A.; Kellogg, G. E. The roles of water in the protein matrix: a largely untapped resource for drug discovery. J. Med. Chem. 2017, 60, 67816827,  DOI: 10.1021/acs.jmedchem.7b00057
  242. 242
    Gerstenberger, B. S.; Trzupek, J. D.; Tallant, C.; Fedorov, O.; Filippakopoulos, P.; Brennan, P. E.; Fedele, V.; Martin, S.; Picaud, S.; Rogers, C.; Parikh, M.; Taylor, A.; Samas, B.; O’Mahony, A.; Berg, E.; Pallares, G.; Torrey, A. D.; Treiber, D. K.; Samardjiev, I. J.; Nasipak, B. T.; Padilla-Benavides, T.; Wu, Q.; Imbalzano, A. N.; Nickerson, J. A.; Bunnage, M. E.; Muller, S.; Knapp, S.; Owen, D. R. Identification of a chemical probe for family VIII bromodomains through optimization of a fragment hit. J. Med. Chem. 2016, 59, 48004811,  DOI: 10.1021/acs.jmedchem.6b00012
  243. 243
    Kuhne, S.; Kooistra, A. J.; Bosma, R.; Bortolato, A.; Wijtmans, M.; Vischer, H. F.; Mason, J. S.; de Graaf, C.; de Esch, I. J.; Leurs, R. Identification of ligand binding hot spots of the histamine H1 receptor following structure-based fragment optimization. J. Med. Chem. 2016, 59, 90479061,  DOI: 10.1021/acs.jmedchem.6b00981
  244. 244
    Blanco, B.; Sedes, A.; Peon, A.; Otero, J. M.; van Raaij, M. J.; Thompson, P.; Hawkins, A. R.; Gonzalez-Bello, C. Exploring the water-binding pocket of the type II dehydroquinase enzyme in the structure-based design of inhibitors. J. Med. Chem. 2014, 57, 34943510,  DOI: 10.1021/jm500175z
  245. 245
    Wright, Z. V. F.; Wu, N. C.; Kadam, R. U.; Wilson, I. A.; Wolan, D. W. Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin. Bioorg. Med. Chem. Lett. 2017, 27, 37443748,  DOI: 10.1016/j.bmcl.2017.06.074
  246. 246
    Mosure, S.; Shang, J.; Eberhardt, J.; Brust, R.; Zheng, J.; Griffin, P. R.; Forli, S.; Kojetin, D. J. Structural basis of altered potency and efficacy displayed by a major in vivo metabolite of the anti-diabetic PPARγ drug pioglitazone. J. Med. Chem. 2019, 62, 2008,  DOI: 10.1021/acs.jmedchem.8b01573
  247. 247
    Thomaston, J. L.; Polizzi, N. F.; Konstantinidi, A.; Wang, J.; Kolocouris, A.; DeGrado, W. F. Inhibitors of the M2 proton channel engage and disrupt transmembrane networks of hydrogen-bonded waters. J. Am. Chem. Soc. 2018, 140, 15219,  DOI: 10.1021/jacs.8b06741
  248. 248
    Geist, L.; Mayer, M.; Cockcroft, X.-L.; Wolkerstorfer, B.; Kessler, D.; Engelhardt, H.; McConnell, D. B.; Konrat, R. Direct NMR probing of hydration shells of protein ligand interfaces and its application to drug design. J. Med. Chem. 2017, 60, 87088715,  DOI: 10.1021/acs.jmedchem.7b00845
  249. 249
    Murphy, R. B.; Repasky, M. P.; Greenwood, J. R.; Tubert-Brohman, I.; Jerome, S.; Annabhimoju, R.; Boyles, N. A.; Schmitz, C. D.; Abel, R.; Farid, R.; Friesner, R. A. WScore: A flexible and accurate treatment of explicit water molecules in ligand-receptor docking. J. Med. Chem. 2016, 59, 43644384,  DOI: 10.1021/acs.jmedchem.6b00131
  250. 250
    Peach, M. L.; Tan, N.; Choyke, S. J.; Giubellino, A.; Athauda, G.; Burke, T. R., Jr.; Nicklaus, M. C.; Bottaro, D. P. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. J. Med. Chem. 2009, 52, 943951,  DOI: 10.1021/jm800791f
  251. 251
    Klüter, S.; Grutter, C.; Naqvi, T.; Rabiller, M.; Simard, J. R.; Pawar, V.; Getlik, M.; Rauh, D. Displacement assay for the detection of stabilizers of inactive kinase conformations. J. Med. Chem. 2010, 53, 357367,  DOI: 10.1021/jm901297e
  252. 252
    (a) Whelligan, D. K.; Solanki, S.; Taylor, D.; Thomson, D. W.; Cheung, K. M.; Boxall, K.; Mas-Droux, C.; Barillari, C.; Burns, S.; Grummitt, C. G.; Collins, I.; van Montfort, R. L.; Aherne, G. W.; Bayliss, R.; Hoelder, S. Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J. Med. Chem. 2010, 53, 76827698,  DOI: 10.1021/jm1008727 .
    (b) Colombano, G.; Caldwell, J. J.; Matthews, T. P.; Bhatia, C.; Joshi, A.; McHardy, T.; Mok, N. Y.; Newbatt, Y.; Pickard, L.; Strover, J.; Hedayat, S.; Walton, M. I.; Myers, S.; Jones, A. M.; Saville, H.; McAndrew, C.; Burke, R.; Eccles, S.; Davies, F.; Bayliss, R.; Collins, I. Binding to an unusual inactive kinase conformation by highly selective inhibitors of inositol-requiring enzyme 1α kinase-endoribonuclease. J. Med. Chem. 2019, 62, 2447,  DOI: 10.1021/acs.jmedchem.8b01721
  253. 253
    Prado, V.; Lence, E.; Maneiro, M.; Vazquez-Ucha, J. C.; Beceiro, A.; Thompson, P.; Hawkins, A. R.; Gonzalez-Bello, C. Targeting the motion of shikimate kinase: development of competitive inhibitors that stabilize an inactive open conformation of the enzyme. J. Med. Chem. 2016, 59, 54715487,  DOI: 10.1021/acs.jmedchem.6b00483
  254. 254
    Weisner, J.; Gontla, R.; van der Westhuizen, L.; Oeck, S.; Ketzer, J.; Janning, P.; Richters, A.; Mühlenberg, T.; Fang, Z.; Taher, A.; Jendrossek, V.; Pelly, S. C.; Bauer, S.; van Otterlo, W. A.; Rauh, D. Covalent-allosteric kinase inhibitors. Angew. Chem., Int. Ed. 2015, 54, 1031310316,  DOI: 10.1002/anie.201502142
  255. 255
    (a) Milroy, L. G.; Bartel, M.; Henen, M. A.; Leysen, S.; Adriaans, J. M.; Brunsveld, L.; Landrieu, I.; Ottmann, C. Stabilizer-guided inhibition of protein-protein interactions. Angew. Chem., Int. Ed. 2015, 54, 1572015724,  DOI: 10.1002/anie.201507976 .
    (b) Sijbesma, E.; Hallenbeck, K. K.; Leysen, S.; de Vink, P.; Skora, L.; Jahnke, W.; Brunsveld, L.; Arkin, M. R.; Ottmann, C. Site-directed fragment-based screening for the discovery of protein-protein interaction stabilizers. J. Am. Chem. Soc. 2019, 141, 3524,  DOI: 10.1021/jacs.8b11658 .
    (c) Andrei, S. A.; de Vink, P.; Sijbesma, E.; Han, L.; Brunsveld, L.; Kato, N.; Ottmann, C.; Higuchi, Y. Rationally designed semisynthetic natural product analogues for stabilization of 14–3-3 protein-protein interactions. Angew. Chem., Int. Ed. 2018, 57, 1347013474,  DOI: 10.1002/anie.201806584
  256. 256
    (a) Andrei, S. A.; Sijbesma, E.; Hann, M.; Davis, J.; O’Mahony, G.; Perry, M. W. D.; Karawajczyk, A.; Eickhoff, J.; Brunsveld, L.; Doveston, R. G.; Milroy, L. G.; Ottmann, C. Stabilization of protein-protein interactions in drug discovery. Expert Opin. Drug Discovery 2017, 12, 925940,  DOI: 10.1080/17460441.2017.1346608 .
    (b) Bier, D.; Thiel, P.; Briels, J.; Ottmann, C. Stabilization of protein-protein interactions in chemical biology and drug discovery. Prog. Biophys. Mol. Biol. 2015, 119, 1019,  DOI: 10.1016/j.pbiomolbio.2015.05.002 .
    (c) Giordanetto, F.; Schäfer, A.; Ottmann, C. Stabilization of protein-protein interactions by small molecules. Drug Discovery Today 2014, 19, 18121821,  DOI: 10.1016/j.drudis.2014.08.005 .
    (d) Thiel, P.; Kaiser, M.; Ottmann, C. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?. Angew. Chem., Int. Ed. 2012, 51, 20122018,  DOI: 10.1002/anie.201107616
  257. 257
    Verteramo, M. L.; Stenström, O.; Ignjatović, M. M.; Caldararu, O.; Olsson, M. A.; Manzoni, F.; Leffler, H.; Oksanen, E.; Logan, D. T.; Nilsson, U. J.; Ryde, U.; Akke, M. Interplay between Conformational Entropy and Solvation Entropy in Protein-Ligand Binding. J. Am. Chem. Soc. 2019, 141, 20122026,  DOI: 10.1021/jacs.8b11099
  258. 258
    Campos, K. R.; Coleman, P. J.; Alvarez, J. C.; Dreher, S. D.; Garbaccio, R. M.; Terrett, N. K.; Tillyer, R. D.; Truppo, M. D.; Parmee, E. R. The importance of synthetic chemistry in the pharmaceutical industry. Science 2019, 363, eaat0805,  DOI: 10.1126/science.aat0805
  259. 259
    (a) Nielsen, T. E.; Schreiber, S. L. Towards the optimal screening collection: a synthesis strategy. Angew. Chem., Int. Ed. 2008, 47, 4856,  DOI: 10.1002/anie.200703073 .
    (b) Gerry, C. J.; Schreiber, S. L. Chemical probes and drug leads from advances in synthetic planning and methodology. Nat. Rev. Drug Discovery 2018, 17, 333352,  DOI: 10.1038/nrd.2018.53
  260. 260
    Dömling, A.; Wang, W.; Wang, K. Chemistry and biology of multicomponent reactions. Chem. Rev. 2012, 112, 3083135,  DOI: 10.1021/cr100233r
  261. 261
    Wagner, B. K.; Schreiber, S. L. The power of sophisticated phenotypic screening and modern mechanism-of-action methods. Cell Chem. Biol. 2016, 23, 39,  DOI: 10.1016/j.chembiol.2015.11.008
  262. 262
    Churcher, I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?. J. Med. Chem. 2018, 61, 444452,  DOI: 10.1021/acs.jmedchem.7b01272
  263. 263
    (a) Murcko, M. A. What makes a great medicinal chemist? A personal perspective. J. Med. Chem. 2018, 61, 74197424,  DOI: 10.1021/acs.jmedchem.7b01445 .
    (b) Walters, W. P.; Green, J.; Weiss, J. R.; Murcko, M. A. What do medicinal chemists actually make? A 50-year retrospective. J. Med. Chem. 2011, 54, 64056416,  DOI: 10.1021/jm200504p
  264. 264
    Zhang, P.; Huang, H.; Banerjee, S.; Clarkson, G. J.; Ge, C.; Imberti, C.; Sadler, P. J. Nucleus-targeted organoiridium-albumin conjugate for photodynamic cancer therapy. Angew. Chem., Int. Ed. Engl. 2019, 58, 2350,  DOI: 10.1002/anie.201813002
  265. 265
    Hoffer, L.; Voitovich, Y. V.; Raux, B.; Carrasco, K.; Muller, C.; Fedorov, A. Y.; Derviaux, C.; Amouric, A.; Betzi, S.; Horvath, D.; Varnex, A.; Collette, Y.; Combes, S.; Roche, P.; Morelli, X. Integrated strategy for lead optimization based on fragment growing: The diversity-oriented-target-focused-synthesis approach. J. Med. Chem. 2018, 61, 57195732,  DOI: 10.1021/acs.jmedchem.8b00653
  266. 266
    Fleming, N. How artificial intelligence is changing drug discovery. Nature 2018, 557, S55S57,  DOI: 10.1038/d41586-018-05267-x
  267. 267
    Schneider, G. Automating drug discovery. Nat. Rev. Drug Discovery 2017, 17, 97113,  DOI: 10.1038/nrd.2017.232

Cited By


This article is cited by 39 publications.

  1. Siyu Xiu, Alexej Dick, Han Ju, Sako Mirzaie, Fatemeh Abdi, Simon Cocklin, Peng Zhan, Xinyong Liu. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. Journal of Medicinal Chemistry 2020, 63 (21) , 12256-12274. https://doi.org/10.1021/acs.jmedchem.0c00502OpenURL HONG KONG UNIV SCIENCE TECHLGY
  2. Lewis D. Pennington, Brian M. Aquila, Younggi Choi, Roman A. Valiulin, Ingo Muegge. Positional Analogue Scanning: An Effective Strategy for Multiparameter Optimization in Drug Design. Journal of Medicinal Chemistry 2020, 63 (17) , 8956-8976. https://doi.org/10.1021/acs.jmedchem.9b02092OpenURL HONG KONG UNIV SCIENCE TECHLGY
  3. Damien Bosc, Virgyl Camberlein, Ronan Gealageas, Omar Castillo-Aguilera, Benoit Deprez, Rebecca Deprez-Poulain. Kinetic Target-Guided Synthesis: Reaching the Age of Maturity. Journal of Medicinal Chemistry 2020, 63 (8) , 3817-3833. https://doi.org/10.1021/acs.jmedchem.9b01183OpenURL HONG KONG UNIV SCIENCE TECHLGY
  4. Siamak Javanbakht, Ahmad Shaabani. Multicomponent Reactions-Based Modified/Functionalized Materials in the Biomedical Platforms. ACS Applied Bio Materials 2020, 3 (1) , 156-174. https://doi.org/10.1021/acsabm.9b00799OpenURL HONG KONG UNIV SCIENCE TECHLGY
  5. Yali Sang, Sheng Han, Christophe Pannecouque, Erik De Clercq, Chunlin Zhuang, Fener Chen. Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles. Journal of Medicinal Chemistry 2019, 62 (24) , 11430-11436. https://doi.org/10.1021/acs.jmedchem.9b01446OpenURL HONG KONG UNIV SCIENCE TECHLGY
  6. Bruce E. Maryanoff, Peter Wipf. Medicinal Chemistry: From Targets to Therapies. ACS Medicinal Chemistry Letters 2019, 10 (7) , 1014-1014. https://doi.org/10.1021/acsmedchemlett.9b00244OpenURL HONG KONG UNIV SCIENCE TECHLGY
  7. Lei Wang, Tiffany C. Edwards, Rajkumar Lalji Sahani, Jiashu Xie, Hideki Aihara, Robert J. Geraghty, Zhengqiang Wang. Metal binding 6-arylthio-3-hydroxypyrimidine-2,4-diones inhibited human cytomegalovirus by targeting the pUL89 endonuclease of the terminase complex. European Journal of Medicinal Chemistry 2021, 222 , 113640. https://doi.org/10.1016/j.ejmech.2021.113640OpenURL HONG KONG UNIV SCIENCE TECHLGY
  8. Lucas Guillemard, Nikolaos Kaplaneris, Lutz Ackermann, Magnus J. Johansson. Late-stage C–H functionalization offers new opportunities in drug discovery. Nature Reviews Chemistry 2021, 446 https://doi.org/10.1038/s41570-021-00300-6OpenURL HONG KONG UNIV SCIENCE TECHLGY
  9. Athanasios Zarkadoulas, Ioanna Zgouleta, Nikolaos V. Tzouras, Georgios C. Vougioukalakis. Traceless Directing Groups in Sustainable Metal-Catalyzed C–H Activation. Catalysts 2021, 11 (5) , 554. https://doi.org/10.3390/catal11050554OpenURL HONG KONG UNIV SCIENCE TECHLGY
  10. Ke Cao, Jianwei Yan, Fulin Yan, Tiantian Yin. Synthesis and evaluation of antitumor activity of dibenzodiazepine derivatives. Molecular Diversity 2021, 25 (2) , 1111-1122. https://doi.org/10.1007/s11030-020-10051-zOpenURL HONG KONG UNIV SCIENCE TECHLGY
  11. Sravani Sana, Velma Ganga Reddy, T. Srinivasa Reddy, Ramya Tokala, Rahul Kumar, Suresh K. Bhargava, Nagula Shankaraiah. Cinnamide derived pyrimidine-benzimidazole hybrids as tubulin inhibitors: Synthesis, in silico and cell growth inhibition studies. Bioorganic Chemistry 2021, 110 , 104765. https://doi.org/10.1016/j.bioorg.2021.104765OpenURL HONG KONG UNIV SCIENCE TECHLGY
  12. Miroslav Smola, Ondrej Gutten, Milan Dejmek, Milan Kožíšek, Thomas Evangelidis, Zahra Aliakbar Tehrani, Barbora Novotná, Radim Nencka, Gabriel Birkuš, Lubomír Rulíšek, Evzen Boura. Ligand Strain and Its Conformational Complexity Is a Major Factor in the Binding of Cyclic Dinucleotides to STING Protein. Angewandte Chemie 2021, 133 (18) , 10260-10266. https://doi.org/10.1002/ange.202016805OpenURL HONG KONG UNIV SCIENCE TECHLGY
  13. Miroslav Smola, Ondrej Gutten, Milan Dejmek, Milan Kožíšek, Thomas Evangelidis, Zahra Aliakbar Tehrani, Barbora Novotná, Radim Nencka, Gabriel Birkuš, Lubomír Rulíšek, Evzen Boura. Ligand Strain and Its Conformational Complexity Is a Major Factor in the Binding of Cyclic Dinucleotides to STING Protein. Angewandte Chemie International Edition 2021, 60 (18) , 10172-10178. https://doi.org/10.1002/anie.202016805OpenURL HONG KONG UNIV SCIENCE TECHLGY
  14. Yue Ma, Estrella Frutos-Beltrán, Dongwei Kang, Christophe Pannecouque, Erik De Clercq, Luis Menéndez-Arias, Xinyong Liu, Peng Zhan. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chemical Society Reviews 2021, 50 (7) , 4514-4540. https://doi.org/10.1039/D0CS01084GOpenURL HONG KONG UNIV SCIENCE TECHLGY
  15. Shuo Yuan, Yong-Qiang Luo, Jia-Hui Zuo, Hui Liu, Fang Li, Bin Yu. New drug approvals for 2020: Synthesis and clinical applications. European Journal of Medicinal Chemistry 2021, 215 , 113284. https://doi.org/10.1016/j.ejmech.2021.113284OpenURL HONG KONG UNIV SCIENCE TECHLGY
  16. Abdulilah Dawoud Bani-Yaseen. Computational Study on the Mechanism of the Photouncaging Reaction of Vemurafenib: Toward an Enhanced Photoprotection Approach for Photosensitive Drugs. Molecules 2021, 26 (7) , 1846. https://doi.org/10.3390/molecules26071846OpenURL HONG KONG UNIV SCIENCE TECHLGY
  17. Lewis D. Pennington, Ingo Muegge. Holistic Drug Design for Multiparameter Optimization in Modern Small Molecule Drug Discovery. Bioorganic & Medicinal Chemistry Letters 2021, 10 , 128003. https://doi.org/10.1016/j.bmcl.2021.128003OpenURL HONG KONG UNIV SCIENCE TECHLGY
  18. Shenghan Teng, Yonggui Robin Chi, Jianrong Steve Zhou. Enantioselective Three‐Component Coupling of Heteroarenes, Cycloalkenes and Propargylic Acetates. Angewandte Chemie 2021, 133 (9) , 4541-4545. https://doi.org/10.1002/ange.202014781OpenURL HONG KONG UNIV SCIENCE TECHLGY
  19. Shenghan Teng, Yonggui Robin Chi, Jianrong Steve Zhou. Enantioselective Three‐Component Coupling of Heteroarenes, Cycloalkenes and Propargylic Acetates. Angewandte Chemie International Edition 2021, 60 (9) , 4491-4495. https://doi.org/10.1002/anie.202014781OpenURL HONG KONG UNIV SCIENCE TECHLGY
  20. Pedro Brandão, Carolina Marques, Anthony J. Burke, Marta Pineiro. The application of isatin-based multicomponent-reactions in the quest for new bioactive and druglike molecules. European Journal of Medicinal Chemistry 2021, 211 , 113102. https://doi.org/10.1016/j.ejmech.2020.113102OpenURL HONG KONG UNIV SCIENCE TECHLGY
  21. Mohammad Heiat, Mohammad-Reza Hashemi-Aghdam, Fatemeh Heiat, Mona Rastegar Shariat Panahi, Hossein Aghamollaei, Mehrdad Moosazadeh Moghaddam, Thozhukat Sathyapalan, Reza Ranjbar, Amirhossein Sahebkar. Integrative role of traditional and modern technologies to combat COVID-19. Expert Review of Anti-infective Therapy 2021, 19 (1) , 23-33. https://doi.org/10.1080/14787210.2020.1799784OpenURL HONG KONG UNIV SCIENCE TECHLGY
  22. Neena Goyal, Manveer Patel, Sanjay Batra. Modern Drug Discovery and Development in the Area of Leishmaniasis. 2021,,, 123-158. https://doi.org/10.1007/978-981-15-8002-4_5OpenURL HONG KONG UNIV SCIENCE TECHLGY
  23. Fenju Wei, Edeildo Ferreira da Silva-Júnior, Xinyong Liu, Peng Zhan. HIV-1 and HBV RNase H as Metal-Chelating Inhibitors: Discovery and Medicinal Chemistry Strategies. 2021,,, 585-602. https://doi.org/10.1007/978-3-030-71165-8_28OpenURL HONG KONG UNIV SCIENCE TECHLGY
  24. Dorota Wieczorek, Ewa Kaczorowska, Marta Wiśniewska, Izabela D. Madura, Magdalena Leśniak, Jacek Lipok, Agnieszka Adamczyk-Woźniak. Synthesis and Influence of 3-Amino Benzoxaboroles Structure on Their Activity against Candida albicans. Molecules 2020, 25 (24) , 5999. https://doi.org/10.3390/molecules25245999OpenURL HONG KONG UNIV SCIENCE TECHLGY
  25. Shuo Yuan, Bin Yu, Hong-Min Liu. New drug approvals for 2019: Synthesis and clinical applications. European Journal of Medicinal Chemistry 2020, 205 , 112667. https://doi.org/10.1016/j.ejmech.2020.112667OpenURL HONG KONG UNIV SCIENCE TECHLGY
  26. Yujie Ren, Yue Ma, Srinivasulu Cherukupalli, John E. Tavis, Luis Menéndez-Arias, Xinyong Liu, Peng Zhan. Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies. European Journal of Medicinal Chemistry 2020, 206 , 112714. https://doi.org/10.1016/j.ejmech.2020.112714OpenURL HONG KONG UNIV SCIENCE TECHLGY
  27. Wei Luo, Cherukupalli Srinivasulu, Xia Hao, Xinyong Liu, Peng Zhan. The increasing impact of Chinese innovative drug research on the global stage with a focus on drug discovery. Expert Opinion on Drug Discovery 2020, 15 (10) , 1115-1120. https://doi.org/10.1080/17460441.2020.1775577OpenURL HONG KONG UNIV SCIENCE TECHLGY
  28. Shuang-Xi Gu, Yuan-Yuan Zhu, Chao Wang, Hai-Feng Wang, Gen-Yan Liu, Shuang Cao, Lu Huang. Recent discoveries in HIV-1 reverse transcriptase inhibitors. Current Opinion in Pharmacology 2020, 54 , 166-172. https://doi.org/10.1016/j.coph.2020.09.017OpenURL HONG KONG UNIV SCIENCE TECHLGY
  29. Wenxiu Wei, Srinivasulu Cherukupalli, Lanlan Jing, Xinyong Liu, Peng Zhan. Fsp3: A new parameter for drug-likeness. Drug Discovery Today 2020, 25 (10) , 1839-1845. https://doi.org/10.1016/j.drudis.2020.07.017OpenURL HONG KONG UNIV SCIENCE TECHLGY
  30. Afaf Zekri, Dalal Harkati, Samir Kenouche, Basil A. Saleh. QSAR modeling, docking, ADME and reactivity of indazole derivatives as antagonizes of estrogen receptor alpha (ER-α) positive in breast cancer. Journal of Molecular Structure 2020, 1217 , 128442. https://doi.org/10.1016/j.molstruc.2020.128442OpenURL HONG KONG UNIV SCIENCE TECHLGY
  31. Diana I. S. P. Resende, Fernando Durães, Miguel Maia, Emília Sousa, Madalena M. M. Pinto. Recent advances in the synthesis of xanthones and azaxanthones. Organic Chemistry Frontiers 2020, 7 (19) , 3027-3066. https://doi.org/10.1039/D0QO00659AOpenURL HONG KONG UNIV SCIENCE TECHLGY
  32. Jintong Du, Jing Guo, Dongwei Kang, Zhihong Li, Guan Wang, Jianbing Wu, Zhen Zhang, Hao Fang, Xuben Hou, Zhangjian Huang, Guobo Li, Xiaoyun Lu, Xinyong Liu, Liang Ouyang, Li Rao, Peng Zhan, Xiaojin Zhang, Yihua Zhang. New techniques and strategies in drug discovery. Chinese Chemical Letters 2020, 31 (7) , 1695-1708. https://doi.org/10.1016/j.cclet.2020.03.028OpenURL HONG KONG UNIV SCIENCE TECHLGY
  33. Fenju Wei, Dongwei Kang, Luis Menéndez‐Arias, Xinyong Liu, Peng Zhan. Recent Developments in Small Molecular HIV‐1 and Hepatitis B Virus RNase H Inhibitors. 2020,,, 273-292. https://doi.org/10.1002/9781119640868.ch9OpenURL HONG KONG UNIV SCIENCE TECHLGY
  34. Andrea Mammoli, Alice Coletti, Marco Ballarotto, Alessandra Riccio, Andrea Carotti, Ursula Grohmann, Emidio Camaioni, Antonio Macchiarulo. New Insights from Crystallographic Data: Diversity of Structural Motifs and Molecular Recognition Properties between Groups of IDO1 Structures. ChemMedChem 2020, 15 (10) , 891-899. https://doi.org/10.1002/cmdc.202000116OpenURL HONG KONG UNIV SCIENCE TECHLGY
  35. Qiwen Zhu, Madiha Saeed, Rundi Song, Tao Sun, Chen Jiang, Haijun Yu. Dynamic covalent chemistry-regulated stimuli-activatable drug delivery systems for improved cancer therapy. Chinese Chemical Letters 2020, 31 (5) , 1051-1059. https://doi.org/10.1016/j.cclet.2019.12.002OpenURL HONG KONG UNIV SCIENCE TECHLGY
  36. Blanca Angelica Vega Alanis, Maria Teresa Iorio, Luca L. Silva, Konstantina Bampali, Margot Ernst, Michael Schnürch, Marko D. Mihovilovic. Allosteric GABAA Receptor Modulators—A Review on the Most Recent Heterocyclic Chemotypes and Their Synthetic Accessibility. Molecules 2020, 25 (4) , 999. https://doi.org/10.3390/molecules25040999OpenURL HONG KONG UNIV SCIENCE TECHLGY
  37. Bruna Machado Araújo Sanches, Elizabeth Igne Ferreira. Prodrug Design to Enhance Bioavailability and Systemic Delivery. 2020,,, 123-154. https://doi.org/10.1007/978-3-030-54490-4_5OpenURL HONG KONG UNIV SCIENCE TECHLGY
  38. Jean Jacques Vanden Eynde, Arduino A. Mangoni, Jarkko Rautio, Jérôme Leprince, Yasu-Taka Azuma, Alfonso T. García-Sosa, Christopher Hulme, Josef Jampilek, Rafik Karaman, Wei Li, Paula A. C. Gomes, Dimitra Hadjipavlou-Litina, Raffaele Capasso, Athina Geronikaki, Laura Cerchia, Jean-Marc Sabatier, Rino Ragno, Tiziano Tuccinardi, Andrea Trabocchi, Jean-Yves Winum, F. Javier Luque, Katalin Prokai-Tatrai, Mariana Spetea, Michael Gütschow, Ivan Kosalec, Catherine Guillou, M. Helena Vasconcelos, George Kokotos, Giulio Rastelli, Maria Emília de Sousa, Clementina Manera, Sandra Gemma, Stefano Mangani, Carlo Siciliano, Stefania Galdiero, Hong Liu, Peter J. H. Scott, Cristóbal de los Ríos, Luigi A. Agrofoglio, Simona Collina, Rita C. Guedes, Diego Muñoz-Torrero. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6. Molecules 2020, 25 (1) , 119. https://doi.org/10.3390/molecules25010119OpenURL HONG KONG UNIV SCIENCE TECHLGY
  39. Xiangyi Jiang, Gaochan Wu, Waleed A. Zalloum, Megan E. Meuser, Alexej Dick, Lin Sun, Chin-Ho Chen, Dongwei Kang, Lanlan Jing, Ruifang Jia, Simon Cocklin, Kuo-Hsiung Lee, Xinyong Liu, Peng Zhan. Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors. RSC Advances 2019, 9 (50) , 28961-28986. https://doi.org/10.1039/C9RA05869AOpenURL HONG KONG UNIV SCIENCE TECHLGY
  • Abstract

    Figure 1

    Figure 1. Overview of recent strategic advances in medicinal chemistry.

    Figure 2

    Figure 2. Examples of drugs that have been repositioned: finding and developing new uses for the approved drugs.

    Figure 3

    Figure 3. Identifying and developing new uses from existing (investigational) drugs via new approaches or further optimization.

    Figure 4

    Figure 4. Representative broad-spectrum antiviral drugs.

    Figure 5

    Figure 5. Discovery of bioactive molecules via diversity-oriented “privileged structure” repositioning approach.

    Figure 6

    Figure 6. Discovery of bioactive molecules via target similarity-inspired “privileged structure” repositioning.

    Figure 7

    Figure 7. Discovery of highly potent and selective inhibitors through click chemistry-based combinatorial fragment assembly. CuAAC: copper(I)-catalyzed azide–alkyne [3 + 2] dipolar cycloaddition.

    Figure 8

    Figure 8. (A) KTGS principle. Best building blocks from each binding pocket of the biomolecule would preferentially react together because of their spatial proximity and afford the corresponding dimeric binder displaying synergistic bioactivity. (B) Thermodynamically controlled TGS or DCC principle. From appropriate fragments under equilibrium conditions, suitable dynamic combinatorial libraries (DCLs) are built up, allowing the generation of all possible library members in a thermodynamically controlled distribution (via selection pressure of the biotarget).

    Figure 9

    Figure 9. Kinetic target-guided synthesis of (A) cell-permeable O-GlcNAc transferase inhibitors and (B) Bcl-X(L)/BH3 protein–protein interaction modulators.

    Figure 10

    Figure 10. Tetrazine bioorthogonal reaction was used to form drug-like heterobifunctional molecule 87 inside cells, as the BRD4 degrader via the ubiquitin pathway.(98)

    Figure 11

    Figure 11. GAT1 inhibitor hits 88 and 89 were obtained by means of library screening and further optimization.

    Figure 12

    Figure 12. Bioorthogonally activated palladium-labile prodrug strategy and toxigenic mode of action (Prototype drugs were highlighted in blue).

    Figure 13

    Figure 13. Schematic illustration of the application of the highly strained alkene transcyclooctene and ene ether to mask an amine or alcohol.(109)

    Figure 14

    Figure 14. Photoactivatable caged kinase inhibitors, HDAC inhibitors, and photoactivatable prodrug of doxazolidine targeting exosomes. Essentially, the photo prodrug concept is based on the mask of a pharmacophoric moiety. The PPG (pink) is therefore attached to the bioactive compound by a covalent bond. The parent bioactive molecules can be released by irradiation with ultraviolet light. Therefore, this method might improve higher drug concentrations in the area of interest sparing other compartments (such as cancer-afflicted tissues) in a rapid and efficient manner with lower side effects.

    Figure 15

    Figure 15. Photosensitizers 107 and 108 mediated by GnRH receptors, and 109, the far-red light-activatable prodrug of PTX.

    Figure 16

    Figure 16. Chemical structures of phototrexate in the trans (in the dark and under blue/white light illumination) and cis (under UVA illumination) configurations.

    Figure 17

    Figure 17. Late-stage functionalization using C–H diversification reactions and cytochrome P450 enabled rapid identification of HDAC inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, and phosphodiesterase 2 inhibitors.

    Figure 18

    Figure 18. Antibody-recruiting small molecules 128 and 130 that target HIV gp120 and 131 that targets prostate-specific membrane antigen.

    Figure 19

    Figure 19. Examples of the in vivo noncovalent endogenous HSA targeting approach.

    Figure 20

    Figure 20. (A) X-ray structure of human serum albumin (bound with diflunisal, PDB ID 2BXE): the position of cysteine-34 is highlighted. (B) Schematic illustration of in vivo thiol–maleimide conjugation. (C) Chemical structure of doxorubicin-maleimide derivative 138, gemcitabine-maleimide derivatives 139 and 140, and albuvirtide.

    Figure 21

    Figure 21. (A) Approved AChE inhibitors for the symptomatic treatment of AD and schematic representation of the ligand binding site of AChE; the “anionic” and “esterase” sites are highlighted. (B) Rational design of central selective AChE inhibitors via a “bio-oxidizable” prodrug approach.

    Figure 22

    Figure 22. Mitochondria-targeted anticancer agents.

    Figure 23

    Figure 23. Covalent inhibitors in drug discovery: typical examples. The warheads for covalent binding are highlighted in red.

    Figure 24

    Figure 24. Discovery of covalent inhibitors via (A) optimization of noncovalent reversible interactions and (B) diversity-oriented modification of warheads.

    Figure 25

    Figure 25. Structures of boron-containing drugs.

    Figure 26

    Figure 26. Structure of stilbene boronic acid 175 and its binding mode with TTR (PDB code 5u4f).

    Figure 27

    Figure 27. Discovery of boronic acid-bearing subpicomolar inhibitors of HIV-1 protease.

    Figure 28

    Figure 28. Discovery of 179 as a capped peptide–boronic acid inhibitor of flaviviral proteases and its binding mode with West Nile virus NS2B-NS3 protease (PDB code 5IDK).

    Figure 29

    Figure 29. Cocrystal structure of 180 in complex with ADC-7 β-Lactamase (PDB code 4U0X).

    Figure 30

    Figure 30. Covalent small molecule inhibitors with a latent electrophile or via a proximity-driven mode.

    Figure 31

    Figure 31. (A) Targeting MtBPL with nucleoside-based bisubstrate adenylation inhibitors. (B) Schematic representation of the transition state of DNMT (DNMT1 and DNMT3A) catalytic site and the chemical modulation strategy. In red is depicted the methyl-donor AdoMet and its mimic 4-aminoquinazoline, in blue the deoxycytidine in the DNA and its analogues, and in pink the linker between the two moieties. Besides, the amino moiety in C4 position of the quinazoline was substituted by phenylpropylamine as a hydrophobic group on the amine at C4 position of the adenosine in AdoMet analogues, which was probably favorable for DNMT inhibition potency. (C) Discovery of a bisubstrate inhibitor of NNMT.

    Figure 32

    Figure 32. Structure-based optimization based on the X-ray structure of Arbidol bound to influenza virus hemagglutinin (H3-HK68: A/Hong Kong/1/1968; PDB code 5T6N).

    Figure 33

    Figure 33. Schematic diagram of interdisciplinary teamwork at the interface between the field of chemistry and biology with the aid of informatics.

  • References

    ARTICLE SECTIONS
    Jump To

    This article references 267 other publications.

    1. 1
      Costantino, L.; Barlocco, D. Ten years of medicinal chemistry (2005–2014) in the Journal of Medicinal Chemistry: country of contributors, topics, and public-private partnerships. J. Med. Chem. 2016, 59, 73527359,  DOI: 10.1021/acs.jmedchem.5b01349
    2. 2
      Aliagas, I.; Berger, R.; Goldberg, K.; Nishimura, R. T.; Reilly, J.; Richardson, P.; Richter, D.; Sherer, E. C. Sustainable practices in medicinal chemistry part 2: green by design. J. Med. Chem. 2017, 60, 59555968,  DOI: 10.1021/acs.jmedchem.6b01837
    3. 3
      Bryan, M. C.; Dillon, B.; Hamann, L. G.; Hughes, G. J.; Kopach, M. E.; Peterson, E. A.; Pourashraf, M.; Raheem, I.; Richardson, P.; Richter, D.; Sneddon, H. F. Sustainable practices in medicinal chemistry: current state and future directions. J. Med. Chem. 2013, 56, 60076021,  DOI: 10.1021/jm400250p
    4. 4
      Zheng, M.; Zhao, J.; Cui, C.; Fu, Z.; Li, X.; Liu, X.; Ding, X.; Tan, X.; Li, F.; Luo, X.; Chen, K.; Jiang, H. Computational chemical biology and drug design: facilitating protein structure, function, and modulation studies. Med. Res. Rev. 2018, 38, 914950,  DOI: 10.1002/med.21483
    5. 5
      Zhan, P.; Itoh, Y.; Suzuki, T.; Liu, X. Strategies for the discovery of target-specific or isoform-selective modulators. J. Med. Chem. 2015, 58, 76117633,  DOI: 10.1021/acs.jmedchem.5b00229
    6. 6
      Zhan, P.; Pannecouque, C.; De Clercq, E.; Liu, X. Anti-HIV drug discovery and development: current innovations and future trends. J. Med. Chem. 2016, 59, 28492878,  DOI: 10.1021/acs.jmedchem.5b00497
    7. 7
      Young, R. J.; Leeson, P. D. Mapping the efficiency and physicochemical trajectories of successful optimizations. J. Med. Chem. 2018, 61, 64216467,  DOI: 10.1021/acs.jmedchem.8b00180
    8. 8
      Breckenridge, A.; Jacob, R. Overcoming the legal and regulatory barriers to drug repurposing. Nat. Rev. Drug Discovery 2018, 18, 12,  DOI: 10.1038/nrd.2018.92
    9. 9
      Pushpakom, S.; Iorio, F.; Eyers, P. A.; Escott, K. J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; Norris, A.; Sanseau, P.; Cavalla, D.; Pirmohamed, M. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discovery 2018, 18, 41,  DOI: 10.1038/nrd.2018.168
    10. 10
      Novac, N. Challenges and opportunities of drug repositioning. Trends Pharmacol. Sci. 2013, 34, 267272,  DOI: 10.1016/j.tips.2013.03.004
    11. 11
      Madrid, P. B.; Chopra, S.; Manger, I. D.; Gilfillan, L.; Keepers, T. R.; Shurtleff, A. C.; Green, C. E.; Iyer, L. V.; Dilks, H. H.; Davey, R. A.; Kolokoltsov, A. A.; Carrion, R., Jr.; Patterson, J. L.; Bavari, S.; Panchal, R. G.; Warren, T. K.; Wells, J. B.; Moos, W. H.; Burke, R. L.; Tanga, M. J. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One 2013, 8, e60579,  DOI: 10.1371/journal.pone.0060579
    12. 12
      Ashburn, T. T.; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discovery 2004, 3, 673683,  DOI: 10.1038/nrd1468
    13. 13
      Nosengo, N. Can you teach old drugs new tricks?. Nature 2016, 534, 314316,  DOI: 10.1038/534314a
    14. 14
      Hayashi, T.; Jean, M.; Huang, H.; Simpson, S.; Santoso, N. G.; Zhu, J. Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. Antiviral Res. 2017, 146, 7685,  DOI: 10.1016/j.antiviral.2017.08.013
    15. 15
      (a) Ren, J.; Zhao, Y.; Fry, E. E.; Stuart, D. I. Target identification and mode of action of four chemically divergent drugs against ebolavirus infection. J. Med. Chem. 2018, 61, 724733,  DOI: 10.1021/acs.jmedchem.7b01249 .
      (b) Zhao, Y.; Ren, J.; Harlos, K.; Jones, D. M.; Zeltina, A.; Bowden, T. A.; Padilla-Parra, S.; Fry, E. E.; Stuart, D. I. Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 2016, 535, 169172,  DOI: 10.1038/nature18615 .
      (c) Zhao, Y.; Ren, J.; Fry, E. E.; Xiao, J.; Townsend, A. R.; Stuart, D. I. Structures of Ebola virus glycoprotein complexes with tricyclic antidepressant and antipsychotic drugs. J. Med. Chem. 2018, 61, 49384945,  DOI: 10.1021/acs.jmedchem.8b00350
    16. 16
      Zhang, L.; Wei, T. T.; Li, Y.; Li, J.; Fan, Y.; Huang, F. Q.; Cai, Y. Y.; Ma, G.; Liu, J. F.; Chen, Q. Q.; Wang, S. L.; Li, H.; Alolga, R. N.; Liu, B.; Zhao, D. S.; Shen, J. H.; Wang, X. M.; Zhu, W.; Li, P.; Qi, L. W. Functional metabolomics characterizes a key role for N-acetylneuraminic acid in coronary artery diseases. Circulation 2018, 137, 13741390,  DOI: 10.1161/CIRCULATIONAHA.117.031139
    17. 17
      Urquiza, P.; Laín, A.; Sanz-Parra, A.; Moreno, J.; Bernardo-Seisdedos, G.; Dubus, P.; González, E.; Gutiérrez-de-Juan, V.; García, S.; Eraña, H.; San Juan, I.; Macías, I.; Ben Bdira, F.; Pluta, P.; Ortega, G.; Oyarzábal, J.; González-Muñiz, R.; Rodríguez-Cuesta, J.; Anguita, J.; Díez, E.; Blouin, J. M.; de Verneuil, H.; Mato, J. M.; Richard, E.; Falcón-Pérez, J. M.; Castilla, J.; Millet, O. Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria. Sci. Transl. Med. 2018, 10, eaat7467,  DOI: 10.1126/scitranslmed.aat7467
    18. 18
      Gwag, T.; Meng, Z.; Sui, Y.; Helsley, R. N.; Park, S. H.; Wang, S.; Greenberg, R. N.; Zhou, C. Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis. J. Hepatol. 2019, 70, 930,  DOI: 10.1016/j.jhep.2018.12.038
    19. 19
      Gkountela, S.; Castro-Giner, F.; Szczerba, B. M.; Vetter, M.; Landin, J.; Scherrer, R.; Krol, I.; Scheidmann, M. C.; Beisel, C.; Stirnimann, C. U.; Kurzeder, C.; Heinzelmann-Schwarz, V.; Rochlitz, C.; Weber, W. P.; Aceto, N. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell 2019, 176, 98112,  DOI: 10.1016/j.cell.2018.11.046
    20. 20
      Marrugal-Lorenzo, J. A.; Serna-Gallego, A.; Berastegui-Cabrera, J.; Pachón, J.; Sánchez-Céspedes, J. Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections. Sci. Rep. 2019, 9, 17,  DOI: 10.1038/s41598-018-37290-3
    21. 21
      Liu, Z.; Fang, H.; Reagan, K.; Xu, X.; Mendrick, D. L.; Slikker, W., Jr.; Tong, W. In silico drug repositioning: what we need to know. Drug Discovery Today 2013, 18, 110115,  DOI: 10.1016/j.drudis.2012.08.005
    22. 22
      Haupt, V. J.; Schroeder, M. Old friends in new guise: repositioning of known drugs with structural bioinformatics. Briefings Bioinf. 2011, 12, 312326,  DOI: 10.1093/bib/bbr011
    23. 23
      McClure, R. A.; Williams, J. D. Impact of mass spectrometry-based technologies and strategies on chemoproteomics as a tool for drug discovery. ACS Med. Chem. Lett. 2018, 9, 785791,  DOI: 10.1021/acsmedchemlett.8b00181
    24. 24
      Lim, R. K.; Lin, Q. Photoinducible bioorthogonal chemistry: a spatiotemporally controllable tool to visualize and perturb proteins in live cells. Acc. Chem. Res. 2011, 44, 828839,  DOI: 10.1021/ar200021p
    25. 25
      Head, S. A.; Liu, J. O. Identification of small molecule-binding proteins in a native cellular environment by live-cell photoaffinity labeling. J. Vis. Exp. 2016, 115, e54529,  DOI: 10.3791/54529
    26. 26
      Hill, J. R.; Robertson, A. A. B. Fishing for drug targets: a focus on diazirine photoaffinity probe synthesis. J. Med. Chem. 2018, 61, 69456963,  DOI: 10.1021/acs.jmedchem.7b01561
    27. 27
      Hu, Y.; Wassermann, A. M.; Lounkine, E.; Bajorath, J. Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families. J. Med. Chem. 2010, 53, 752758,  DOI: 10.1021/jm9014229
    28. 28
      Ma, D. L.; Chan, D. S.; Leung, C. H. Drug repositioning by structure-based virtual screening. Chem. Soc. Rev. 2013, 42, 21302141,  DOI: 10.1039/c2cs35357a
    29. 29
      Giannopoulos, P. F.; Chiu, J.; Pratico, D. Learning impairments, memory deficits, and neuropathology in aged tau transgenic mice are dependent on leukotrienes biosynthesis: role of the cdk5 kinase pathway. Mol. Neurobiol. 2019, 56, 1211,  DOI: 10.1007/s12035-018-1124-7
    30. 30
      Lu, W.; Yao, X.; Ouyang, P.; Dong, N.; Wu, D.; Jiang, X.; Wu, Z.; Zhang, C.; Xu, Z.; Tang, Y. Drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis. J. Med. Chem. 2017, 60, 18171828,  DOI: 10.1021/acs.jmedchem.6b01507
    31. 31
      Iwata, M.; Hirose, L.; Kohara, H.; Liao, J.; Sawada, R.; Akiyoshi, S.; Tani, K.; Yamanishi, Y. Pathway-based drug repositioning for cancers: computational prediction and experimental validation. J. Med. Chem. 2018, 61, 95839595,  DOI: 10.1021/acs.jmedchem.8b01044
    32. 32
      Mejía-Pedroza, R. A.; Espinal-Enríquez, J.; Hernández-Lemus, E. Pathway-based drug repositioning for breast cancer molecular subtypes. Front Pharmacol. 2018, 9, 905,  DOI: 10.3389/fphar.2018.00905
    33. 33
      Huang, C. H.; Chang, P. M.; Lin, Y. J.; Wang, C. H.; Huang, C. Y.; Ng, K. L. Drug repositioning discovery for early- and late-stage non-small-cell lung cancer. Biomed Res. Int. 2014, 2014, 193817,  DOI: 10.1155/2014/193817
    34. 34
      Astolfi, A.; Felicetti, T.; Iraci, N.; Manfroni, G.; Massari, S.; Pietrella, D.; Tabarrini, O.; Kaatz, G. W.; Barreca, M. L.; Sabatini, S.; Cecchetti, V. Pharmacophore-based repositioning of approved drugs as novel staphylococcus aureus NorA efflux pump inhibitors. J. Med. Chem. 2017, 60, 15981604,  DOI: 10.1021/acs.jmedchem.6b01439
    35. 35
      Fako, V. E.; Wu, X.; Pflug, B.; Liu, J. Y.; Zhang, J. T. Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase. J. Med. Chem. 2015, 58, 778784,  DOI: 10.1021/jm501543u
    36. 36
      (a) Li, H.; Liu, A.; Zhao, Z.; Xu, Y.; Lin, J.; Jou, D.; Li, C. Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). J. Med. Chem. 2011, 54, 55925596,  DOI: 10.1021/jm101330h .
      (b) Li, H.; Xiao, H.; Lin, L.; Jou, D.; Kumari, V.; Lin, J.; Li, C. Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. J. Med. Chem. 2014, 57, 632641,  DOI: 10.1021/jm401144z
    37. 37
      Vegner, L.; Peragovics, A.; Tombor, L.; Jelinek, B.; Czobor, P.; Bender, A.; Simon, Z.; Malnasi-Csizmadia, A. Experimental confirmation of new drug-target interactions predicted by drug profile matching. J. Med. Chem. 2013, 56, 83778388,  DOI: 10.1021/jm400813y
    38. 38
      Huang, C. H.; Chang, P. M.; Hsu, C. W.; Huang, C. Y.; Ng, K. L. Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory. BMC Bioinformatics 2016, 17, S2,  DOI: 10.1186/s12859-015-0845-0
    39. 39
      Dakshanamurthy, S.; Issa, N. T.; Assefnia, S.; Seshasayee, A.; Peters, O. J.; Madhavan, S.; Uren, A.; Brown, M. L.; Byers, S. W. Predicting new indications for approved drugs using a proteochemometric method. J. Med. Chem. 2012, 55, 68326848,  DOI: 10.1021/jm300576q
    40. 40
      Coley, C. W.; Green, W. H.; Jensen, K. F. Machine learning in computer-aided synthesis planning. Acc. Chem. Res. 2018, 51, 12811289,  DOI: 10.1021/acs.accounts.8b00087
    41. 41
      Zhong, F.; Xing, J.; Li, X.; Liu, X.; Fu, Z.; Xiong, Z.; Lu, D.; Wu, X.; Zhao, J.; Tan, X.; Li, F.; Luo, X.; Li, Z.; Chen, K.; Zheng, M.; Jiang, H. Artificial intelligence in drug design. Sci. China: Life Sci. 2018, 61, 1191,  DOI: 10.1007/s11427-018-9342-2
    42. 42
      Polamreddy, P.; Gattu, N. The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. Drug Discovery Today 2019, 24, 789,  DOI: 10.1016/j.drudis.2018.11.022
    43. 43
      (a) Bartolini, S.; Mai, A.; Artico, M.; Paesano, N.; Rotili, D.; Spadafora, C.; Sbardella, G. 6-[1-(2,6-difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase. J. Med. Chem. 2005, 48, 67766778,  DOI: 10.1021/jm0507330 .
      (b) Sbardella, G.; Mai, A.; Bartolini, S.; Castellano, S.; Cirilli, R.; Rotili, D.; Milite, C.; Santoriello, M.; Orlando, S.; Sciamanna, I.; Serafino, A.; Lavia, P.; Spadafora, C. Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors. J. Med. Chem. 2011, 54, 59275936,  DOI: 10.1021/jm200734j
    44. 44
      Shahinas, D.; Liang, M.; Datti, A.; Pillai, D. R. A repurposing strategy identifies novel synergistic inhibitors of plasmodium falciparum heat shock protein 90. J. Med. Chem. 2010, 53, 35523557,  DOI: 10.1021/jm901796s
    45. 45
      Deeks, E. D. Lesinurad: a review in hyperuricaemia of gout. Drugs Aging 2017, 34, 401410,  DOI: 10.1007/s40266-017-0461-y
    46. 46
      Hoy, S. M. Lesinurad: first global approval. Drugs 2016, 76, 509516,  DOI: 10.1007/s40265-016-0550-y
    47. 47
      Pace, J. R.; DeBerardinis, A. M.; Sail, V.; Tacheva-Grigorova, S. K.; Chan, K. A.; Tran, R.; Raccuia, D. S.; Wechsler-Reya, R. J.; Hadden, M. K. Repurposing the clinically efficacious antifungal agent itraconazole as an anticancer chemotherapeutic. J. Med. Chem. 2016, 59, 36353649,  DOI: 10.1021/acs.jmedchem.5b01718
    48. 48
      (a) Shi, W.; Nacev, B. A.; Aftab, B. T.; Head, S.; Rudin, C. M.; Liu, J. O. Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling. J. Med. Chem. 2011, 54, 73637674,  DOI: 10.1021/jm200944b .
      (b) Li, Y.; Pasunooti, K. K.; Li, R. J.; Liu, W.; Head, S. A.; Shi, W. Q.; Liu, J. O. Novel tetrazole-containing analogs of itraconazole as potent anti-angiogenic agents with reduced CYP3A4 inhibition. J. Med. Chem. 2018, 61, 11158,  DOI: 10.1021/acs.jmedchem.8b01252
    49. 49
      Thompson, A. M.; O’Connor, P. D.; Blaser, A.; Yardley, V.; Maes, L.; Gupta, S.; Launay, D.; Martin, D.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.; Denny, W. A. Repositioning antitubercular 6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for neglected tropical diseases: structure-activity studies on a preclinical candidate for visceral leishmaniasis. J. Med. Chem. 2016, 59, 25302550,  DOI: 10.1021/acs.jmedchem.5b01699
    50. 50
      Turk, S.; Merget, B.; Eid, S.; Fulle, S. From cancer to pain target by automated selectivity inversion of a clinical candidate. J. Med. Chem. 2018, 61, 48514859,  DOI: 10.1021/acs.jmedchem.8b00140
    51. 51
      Perlmutter, J. I.; Forbes, L. T.; Krysan, D. J.; Ebsworth-Mojica, K.; Colquhoun, J. M.; Wang, J. L.; Dunman, P. M.; Flaherty, D. P. Repurposing the antihistamine terfenadine for antimicrobial activity against staphylococcus aureus. J. Med. Chem. 2014, 57, 85408562,  DOI: 10.1021/jm5010682
    52. 52
      Dilly, S.; Fotso Fotso, A.; Lejal, N.; Zedda, G.; Chebbo, M.; Rahman, F.; Companys, S.; Bertrand, H. C.; Vidic, J.; Noiray, M.; Alessi, M. C.; Tarus, B.; Quideau, S.; Riteau, B.; Slama-Schwok, A. From naproxen repurposing to naproxen analogues and their antiviral activity against influenza A virus. J. Med. Chem. 2018, 61, 72027217,  DOI: 10.1021/acs.jmedchem.8b00557
    53. 53
      Mohiuddin, G.; Khan, K. M.; Salar, U.; Kanwal; Wadood, A.; Riaz, M.; Perveen, S. Biology-oriented drug synthesis (BIODS), in vitro urease inhibitory activity, and in silico study of S-naproxen derivatives. Bioorg. Chem. 2019, 83, 2946,  DOI: 10.1016/j.bioorg.2018.10.021
    54. 54
      Mercorelli, B.; Palu, G.; Loregian, A. Drug repurposing for viral infectious diseases: how far are we?. Trends Microbiol. 2018, 26, 865876,  DOI: 10.1016/j.tim.2018.04.004
    55. 55
      Debing, Y.; Neyts, J.; Delang, L. The future of antivirals: broad-spectrum inhibitors. Curr. Opin. Infect. Dis. 2015, 28, 596602,  DOI: 10.1097/QCO.0000000000000212
    56. 56
      Sacramento, C. Q.; de Melo, G. R.; de Freitas, C. S.; Rocha, N.; Hoelz, L. V.; Miranda, M.; Fintelman-Rodrigues, N.; Marttorelli, A.; Ferreira, A. C.; Barbosa-Lima, G.; Abrantes, J. L.; Vieira, Y. R.; Bastos, M. M.; de Mello Volotao, E.; Nunes, E. P.; Tschoeke, D. A.; Leomil, L.; Loiola, E. C.; Trindade, P.; Rehen, S. K.; Bozza, F. A.; Bozza, P. T.; Boechat, N.; Thompson, F. L.; de Filippis, A. M.; Bruning, K.; Souza, T. M. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci. Rep. 2017, 7, 40920,  DOI: 10.1038/srep40920
    57. 57
      Abdelnabi, R.; Morais, A. T. S.; Leyssen, P.; Imbert, I.; Beaucourt, S.; Blanc, H.; Froeyen, M.; Vignuzzi, M.; Canard, B.; Neyts, J.; Delang, L. Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): key role of the F1 motif of the viral polymerase. J. Virol. 2017, 91, e00487,  DOI: 10.1128/JVI.00487-17
    58. 58
      Rossignol, J. F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014, 110, 94103,  DOI: 10.1016/j.antiviral.2014.07.014
    59. 59
      (a) Li, C. C.; Wang, X. J.; Wang, H. R. Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discov. Today 2019, 24, 726,  DOI: 10.1016/j.drudis.2019.01.018 .
      (b) Meng, W.; Wang, X. J.; Wang, H. R. Targeting nuclear proteins for control of viral replication. Crit. Rev. Microbiol. 2019, 119,  DOI: 10.1080/1040841X.2018.1553848
    60. 60
      Tong, X.; Smith, J.; Bukreyeva, N.; Koma, T.; Manning, J. T.; Kalkeri, R.; Kwong, A. D.; Paessler, S. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens. Antiviral Res. 2018, 149, 3440,  DOI: 10.1016/j.antiviral.2017.11.004
    61. 61
      Dang, W.; Yin, Y.; Wang, Y.; Wang, W.; Su, J.; Sprengers, D.; van der Laan, L. J. W.; Felczak, K.; Pankiewicz, K. W.; Chang, K. O.; Koopmans, M. P. G.; Metselaar, H. J.; Peppelenbosch, M. P.; Pan, Q. Inhibition of calcineurin or IMP dehydrogenase exerts moderate to potent antiviral activity against norovirus replication. Antimicrob. Agents Chemother. 2017, 61, e0109517,  DOI: 10.1128/AAC.01095-17
    62. 62
      Hu, J.; Ma, L.; Wang, H.; Yan, H.; Zhang, D.; Li, Z.; Jiang, J.; Li, Y. A novel benzo-heterocyclic amine derivative N30 inhibits influenza virus replication by depression of Inosine-5′-Monophospate dehydrogenase activity. Virol J. 2017, 14, 55,  DOI: 10.1186/s12985-017-0724-6
    63. 63
      Nair, V.; Chi, G.; Shu, Q.; Julander, J.; Smee, D. F. A heterocyclic molecule with significant activity against dengue virus. Bioorg. Med. Chem. Lett. 2009, 19, 14251427,  DOI: 10.1016/j.bmcl.2009.01.031
    64. 64
      Mejdrova, I.; Chalupska, D.; Plackova, P.; Muller, C.; Sala, M.; Klima, M.; Baumlova, A.; Hrebabecky, H.; Prochazkova, E.; Dejmek, M.; Strunin, D.; Weber, J.; Lee, G.; Matousova, M.; Mertlikova-Kaiserova, H.; Ziebuhr, J.; Birkus, G.; Boura, E.; Nencka, R. Rational design of novel highly potent and selective phosphatidylinositol 4-kinase IIIbeta (PI4KB) inhibitors as broad-spectrum antiviral agents and tools for chemical biology. J. Med. Chem. 2017, 60, 100118,  DOI: 10.1021/acs.jmedchem.6b01465
    65. 65
      Bauer, L.; Ferla, S.; Head, S. A.; Bhat, S.; Pasunooti, K. K.; Shi, W. Q.; Albulescu, L.; Liu, J. O.; Brancale, A.; van Kuppeveld, F. J. M.; Strating, J. R. P. M. Structure-activity relationship study of itraconazole, a broad-range inhibitor of picornavirus replication that targets oxysterol-binding protein (OSBP). Antiviral Res. 2018, 156, 5563,  DOI: 10.1016/j.antiviral.2018.05.010
    66. 66
      (a) Taylor, R. D.; MacCoss, M.; Lawson, A. D. Rings in drugs. J. Med. Chem. 2014, 57, 58455859,  DOI: 10.1021/jm4017625 .
      (b) Taylor, R. D.; MacCoss, M.; Lawson, A. D. Combining molecular scaffolds from FDA approved drugs: application to drug discovery. J. Med. Chem. 2017, 60, 16381647,  DOI: 10.1021/acs.jmedchem.6b01367
    67. 67
      (a) Song, Y.; Chen, W.; Kang, D.; Zhang, Q.; Zhan, P.; Liu, X. ″Old friends in new guise″: exploiting privileged structures for scaffold re-evolution/refining. Comb. Chem. High Throughput Screening 2014, 17, 536553,  DOI: 10.2174/1386207317666140122101631 .
      (b) Li, Z.; Zhan, P.; Liu, X. 1,3,4-oxadiazole: a privileged structure in antiviral agents. Mini-Rev. Med. Chem. 2011, 11, 11301142,  DOI: 10.2174/138955711797655407 .
      (c) Song, Y.; Zhan, P.; Zhang, Q.; Liu, X. Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry. Curr. Pharm. Des. 2013, 19, 15281548,  DOI: 10.2174/138161213804805559 .
      (d) Song, Y.; Zhan, P.; Liu, X. Heterocycle-thioacetic acid motif: a privileged molecular scaffold with potent, broad-ranging pharmacological activities. Curr. Pharm. Des. 2013, 19, 71417154,  DOI: 10.2174/13816128113199990505 .
      (e) Zhao, F.; Liu, N.; Zhan, P.; Liu, X. Repurposing of HDAC inhibitors toward anti-hepatitis C virus drug discovery: teaching an old dog new tricks. Future Med. Chem. 2015, 7, 13671371,  DOI: 10.4155/fmc.15.76
    68. 68
      Zeng, L. F.; Wang, Y.; Kazemi, R.; Xu, S.; Xu, Z. L.; Sanchez, T. W.; Yang, L. M.; Debnath, B.; Odde, S.; Xie, H.; Zheng, Y. T.; Ding, J.; Neamati, N.; Long, Y. Q. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. J. Med. Chem. 2012, 55, 94929509,  DOI: 10.1021/jm300667v
    69. 69
      Schwehm, C.; Kellam, B.; Garces, A. E.; Hill, S. J.; Kindon, N. D.; Bradshaw, T. D.; Li, J.; Macdonald, S. J.; Rowedder, J. E.; Stoddart, L. A.; Stocks, M. J. Design and Elaboration of a tractable tricyclic scaffold to synthesize druglike inhibitors of dipeptidyl peptidase-4 (DPP-4), antagonists of the C-C chemokine receptor type 5 (CCR5), and highly potent and selective phosphoinositol-3 kinase delta (PI3Kdelta) inhibitors. J. Med. Chem. 2017, 60, 15341554,  DOI: 10.1021/acs.jmedchem.6b01801
    70. 70
      John, J.; Kim, Y.; Bennett, N.; Das, K.; Liekens, S.; Naesens, L.; Arnold, E.; Maguire, A. R.; Gotte, M.; Dehaen, W.; Balzarini, J. Pronounced inhibition shift from HIV reverse transcriptase to herpetic DNA polymerases by increasing the flexibility of alpha-carboxy nucleoside phosphonates. J. Med. Chem. 2015, 58, 81108127,  DOI: 10.1021/acs.jmedchem.5b01180
    71. 71
      (a) Nowotny, M. Retroviral integrase superfamily: the structural perspective. EMBO Rep. 2009, 10, 144151,  DOI: 10.1038/embor.2008.256 .
      (b) Majorek, K. A.; Dunin-Horkawicz, S.; Steczkiewicz, K.; Muszewska, A.; Nowotny, M.; Ginalski, K.; Bujnicki, J. M. The RNase H-like superfamily: new members, comparative structural analysis and evolutionary classification. Nucleic Acids Res. 2014, 42, 41604179,  DOI: 10.1093/nar/gkt1414
    72. 72
      (a) Xu, P.; Ganaie, S. S.; Wang, X.; Wang, Z.; Kleiboeker, S.; Horton, N. C.; Heier, R. F.; Meyers, M. J.; Tavis, J. E.; Qiu, J. Endonuclease activity inhibition of the NS1 protein of parvovirus B19 as a novel target for antiviral drug development. Antimicrob. Agents Chemother. 2019, 63, AAC.01879,  DOI: 10.1128/AAC.01879-18 .
      (b) Tavis, J. E.; Zoidis, G.; Meyers, M. J.; Murelli, R. P. Chemical approaches to inhibiting the hepatitis B virus ribonuclease H. ACS Infect. Dis. 2018,  DOI: 10.1021/acsinfecdis.8b00045 .
      (c) Lomonosova, E.; Daw, J.; Garimallaprabhakaran, A. K.; Agyemang, N. B.; Ashani, Y.; Murelli, R. P.; Tavis, J. E. Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H. Antiviral Res. 2017, 144, 164172,  DOI: 10.1016/j.antiviral.2017.06.014 .
      (d) Edwards, T. C.; Lomonosova, E.; Patel, J. A.; Li, Q.; Villa, J. A.; Gupta, A. K.; Morrison, L. A.; Bailly, F.; Cotelle, P.; Giannakopoulou, E.; Zoidis, G.; Tavis, J. E. Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles. Antiviral Res. 2017, 143, 205217,  DOI: 10.1016/j.antiviral.2017.04.012 .
      (e) Lu, G.; Lomonosova, E.; Cheng, X.; Moran, E. A.; Meyers, M. J.; Le Grice, S. F.; Thomas, C. J.; Jiang, J. K.; Meck, C.; Hirsch, D. R.; D’Erasmo, M. P.; Suyabatmaz, D. M.; Murelli, R. P.; Tavis, J. E. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Antimicrob. Agents Chemother. 2015, 59, 10701079,  DOI: 10.1128/AAC.04617-14 .
      (f) Cai, C. W.; Lomonosova, E.; Moran, E. A.; Cheng, X.; Patel, K. B.; Bailly, F.; Cotelle, P.; Meyers, M. J.; Tavis, J. E. Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Antiviral Res. 2014, 108, 4855,  DOI: 10.1016/j.antiviral.2014.05.007 .
      (g) Hu, Y.; Cheng, X.; Cao, F.; Huang, A.; Tavis, J. E. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res. 2013, 99, 221229,  DOI: 10.1016/j.antiviral.2013.06.007 .
      (h) Tavis, J. E.; Cheng, X.; Hu, Y.; Totten, M.; Cao, F.; Michailidis, E.; Aurora, R.; Meyers, M. J.; Jacobsen, E. J.; Parniak, M. A.; Sarafianos, S. G. The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. PLoS Pathog. 2013, 9, e1003125,  DOI: 10.1371/journal.ppat.1003125 .
      (i) Ireland, P. J.; Tavis, J. E.; D’Erasmo, M. P.; Hirsch, D. R.; Murelli, R. P.; Cadiz, M. M.; Patel, B. S.; Gupta, A. K.; Edwards, T. C.; Korom, M.; Moran, E. A.; Morrison, L. A. Synthetic α-hydroxytropolones inhibit replication of wild-type and acyclovir-resistant herpes simplex viruses. Antimicrob. Agents Chemother. 2016, 60, 21402149,  DOI: 10.1128/AAC.02675-15
    73. 73
      (a) Huber, A. D.; Michailidis, E.; Tang, J.; Puray-Chavez, M. N.; Boftsi, M.; Wolf, J. J.; Boschert, K. N.; Sheridan, M. A.; Leslie, M. D.; Kirby, K. A.; Singh, K.; Mitsuya, H.; Parniak, M. A.; Wang, Z.; Sarafianos, S. G. 3-Hydroxypyrimidine-2,4-diones as novel hepatitis B virus antivirals targeting the viral ribonuclease H. Antimicrob. Agents Chemother. 2017, 61, e00245,  DOI: 10.1128/AAC.00245-17 .
      (b) Wu, B.; Tang, J.; Wilson, D. J.; Huber, A. D.; Casey, M. C.; Ji, J.; Kankanala, J.; Xie, J.; Sarafianos, S. G.; Wang, Z. 3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides potently inhibit HIV-1 integrase and RNase H. J. Med. Chem. 2016, 59, 61366148,  DOI: 10.1021/acs.jmedchem.6b00040 .
      (c) Kankanala, J.; Kirby, K. A.; Liu, F.; Miller, L.; Nagy, E.; Wilson, D. J.; Parniak, M. A.; Sarafianos, S. G.; Wang, Z. Design, synthesis, and biological evaluations of hydroxypyridonecarboxylic acids as inhibitors of hiv reverse transcriptase associated RNase H. J. Med. Chem. 2016, 59, 50515062,  DOI: 10.1021/acs.jmedchem.6b00465 .
      (d) Tang, J.; Liu, F.; Nagy, E.; Miller, L.; Kirby, K. A.; Wilson, D. J.; Wu, B.; Sarafianos, S. G.; Parniak, M. A.; Wang, Z. 3-Hydroxypyrimidine-2,4-diones as selective active site inhibitors of hiv reverse transcriptase-associated RNase H: design, synthesis, and biochemical evaluations. J. Med. Chem. 2016, 59, 26482659,  DOI: 10.1021/acs.jmedchem.5b01879 .
      (e) Wang, Y.; Tang, J.; Wang, Z.; Geraghty, R. J. Metal-chelating 3-hydroxypyrimidine-2,4-diones inhibit human cytomegalovirus pUL89 endonuclease activity and virus replication. Antiviral Res. 2018, 152, 1017,  DOI: 10.1016/j.antiviral.2018.01.015
    74. 74
      (a) Sun, L.; Gao, P.; Dong, G.; Zhang, X.; Cheng, X.; Ding, X.; Wang, X.; Daelemans, D.; De Clercq, E.; Pannecouque, C.; Menéndez-Arias, L.; Zhan, P.; Liu, X. 5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase. Eur. J. Med. Chem. 2018, 155, 714724,  DOI: 10.1016/j.ejmech.2018.06.036 .
      (b) Gao, P.; Zhang, L.; Sun, L.; Huang, T.; Tan, J.; Zhang, J.; Zhou, Z.; Zhao, T.; Menéndez-Arias, L.; Pannecouque, C.; Clercq, E.; Zhan, P.; Liu, X. 1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. Bioorg. Med. Chem. 2017, 25, 57795789,  DOI: 10.1016/j.bmc.2017.09.006 .
      (c) Wang, X.; Gao, P.; Menendez-Arias, L.; Liu, X.; Zhan, P. Update on recent developments in small molecular hiv-1 rnase h inhibitors (2013–2016): opportunities and challenges. Curr. Med. Chem. 2018, 25, 16821702,  DOI: 10.2174/0929867324666170113110839 .
      (d) Cao, L.; Song, W.; De Clercq, E.; Zhan, P.; Liu, X. Recent progress in the research of small molecule HIV-1 RNase H inhibitors. Curr. Med. Chem. 2014, 21, 19561967,  DOI: 10.2174/0929867321666140120121158 .
      (e) Ju, H.; Zhang, J.; Huang, B.; Kang, D.; Huang, B.; Liu, X.; Zhan, P. Inhibitors of influenza virus polymerase acidic (PA) endonuclease: contemporary developments and perspectives. J. Med. Chem. 2017, 60, 35333551,  DOI: 10.1021/acs.jmedchem.6b01227 .
      (f) Ju, H.; Zhan, P.; Liu, X. Designing influenza polymerase acidic endonuclease inhibitors via ’privileged scaffold’ re-evolution/refining strategy. Future Med. Chem. 2019, 11, 265,  DOI: 10.4155/fmc-2018-0489
    75. 75
      Yang, T. Baloxavir Marboxil: The first cap-dependent endonuclease inhibitor for the treatment of influenza. Ann. Pharmacother. 2019, 106002801982656,  DOI: 10.1177/1060028019826565
    76. 76
      Oh, S.; Park, Y.; Engelhart, C. A.; Wallach, J. B.; Schnappinger, D.; Arora, K.; Manikkam, M.; Gac, B.; Wang, H.; Murgolo, N.; Olsen, D. B.; Goodwin, M.; Sutphin, M.; Weiner, D. M.; Via, L. E.; Boshoff, H. I. M.; Barry, C. E., 3rd. Discovery and structure-activity-relationship study of n-alkyl-5-hydroxypyrimidinone carboxamides as novel antitubercular agents targeting decaprenylphosphoryl-β-d-ribose 2′-oxidase. J. Med. Chem. 2018, 61, 99529965,  DOI: 10.1021/acs.jmedchem.8b00883
    77. 77
      Ramil, C. P.; Lin, Q. Bioorthogonal chemistry: strategies and recent developments. Chem. Commun. (Cambridge, U. K.) 2013, 49, 1100711022,  DOI: 10.1039/c3cc44272a
    78. 78
      Kim, J.; Kim, H.; Park, S. B. Privileged structures: efficient chemical ″navigators″ toward unexplored biologically relevant chemical spaces. J. Am. Chem. Soc. 2014, 136, 1462914638,  DOI: 10.1021/ja508343a
    79. 79
      (a) Wang, X.; Huang, B.; Liu, X.; Zhan, P. Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. Drug Discovery Today 2016, 21, 118132,  DOI: 10.1016/j.drudis.2015.08.004 .
      (b) Huang, B.; Kang, D.; Zhan, P.; Liu, X. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. Expert Opin. Drug Discovery 2015, 10, 12711281,  DOI: 10.1517/17460441.2015.1083007 .
      (c) Gao, P.; Sun, L.; Zhou, J.; Li, X.; Zhan, P.; Liu, X. Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach. Expert Opin. Drug Discovery 2016, 11, 857871,  DOI: 10.1080/17460441.2016.1210125
    80. 80
      Whiting, M.; Tripp, J. C.; Lin, Y. C.; Lindstrom, W.; Olson, A. J.; Elder, J. H.; Sharpless, K. B.; Fokin, V. V. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization. J. Med. Chem. 2006, 49, 76977710,  DOI: 10.1021/jm060754+
    81. 81
      (a) Zhan, P.; Wang, X.; Liu, X.; Suzuki, T. Medicinal chemistry insights into novel HDAC inhibitors: an updated patent review (2012–2016). Recent Pat. Anti-Cancer Drug Discovery 2017, 12, 1634,  DOI: 10.2174/1574892811666161101102842 .
      (b) Suzuki, T.; Ota, Y.; Ri, M.; Bando, M.; Gotoh, A.; Itoh, Y.; Tsumoto, H.; Tatum, P. R.; Mizukami, T.; Nakagawa, H.; Iida, S.; Ueda, R.; Shirahige, K.; Miyata, N. Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries. J. Med. Chem. 2012, 55, 95629575,  DOI: 10.1021/jm300837y .
      (c) Suzuki, T.; Kasuya, Y.; Itoh, Y.; Ota, Y.; Zhan, P.; Asamitsu, K.; Nakagawa, H.; Okamoto, T.; Miyata, N. Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. PLoS One 2013, 8, e68669,  DOI: 10.1371/journal.pone.0068669 .
      (d) Tatum, P. R.; Sawada, H.; Ota, Y.; Itoh, Y.; Zhan, P.; Ieda, N.; Nakagawa, H.; Miyata, N.; Suzuki, T. Identification of novel SIRT2-selective inhibitors using a click chemistry approach. Bioorg. Med. Chem. Lett. 2014, 24, 18711874,  DOI: 10.1016/j.bmcl.2014.03.026
    82. 82
      Gehringer, M.; Forster, M.; Laufer, S. A. Solution-phase parallel synthesis of ruxolitinib-derived Janus kinase inhibitors via copper-catalyzed azide-alkyne cycloaddition. ACS Comb. Sci. 2015, 17, 510,  DOI: 10.1021/co500122h
    83. 83
      Diaz, L.; Casas, J.; Bujons, J.; Llebaria, A.; Delgado, A. New glucocerebrosidase inhibitors by exploration of chemical diversity of N-substituted aminocyclitols using click chemistry and in situ screening. J. Med. Chem. 2011, 54, 20692079,  DOI: 10.1021/jm101204u
    84. 84
      Coumar, M. S.; Chu, C. Y.; Lin, C. W.; Shiao, H. Y.; Ho, Y. L.; Reddy, R.; Lin, W. H.; Chen, C. H.; Peng, Y. H.; Leou, J. S.; Lien, T. W.; Huang, C. T.; Fang, M. Y.; Wu, S. H.; Wu, J. S.; Chittimalla, S. K.; Song, J. S.; Hsu, J. T.; Wu, S. Y.; Liao, C. C.; Chao, Y. S.; Hsieh, H. P. Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J. Med. Chem. 2010, 53, 49804988,  DOI: 10.1021/jm1000198
    85. 85
      Ding, S.; Qiao, X.; Kucera, G. L.; Bierbach, U. Using a build-and-click approach for producing structural and functional diversity in DNA-targeted hybrid anticancer agents. J. Med. Chem. 2012, 55, 1019810203,  DOI: 10.1021/jm301278c
    86. 86
      Akgun, B.; Hall, D. G. Fast and tight boronate formation for click bioorthogonal conjugation. Angew. Chem., Int. Ed. 2016, 55, 39093913,  DOI: 10.1002/anie.201510321
    87. 87
      Oueis, E.; Sabot, C.; Renard, P. Y. New insights into the kinetic target-guided synthesis of protein ligands. Chem. Commun. (Cambridge, U. K.) 2015, 51, 1215812169,  DOI: 10.1039/C5CC04183J
    88. 88
      Frei, P.; Hevey, R.; Ernst, B. Dynamic combinatorial chemistry: A new methodology comes of age. Chemistry 2019, 25, 60,  DOI: 10.1002/chem.201803365
    89. 89
      Unver, M. Y.; Gierse, R. M.; Ritchie, H.; Hirsch, A. K. H. Druggability assessment of targets used in kinetic target-guided synthesis. J. Med. Chem. 2018, 61, 93959409,  DOI: 10.1021/acs.jmedchem.8b00266
    90. 90
      Hochgurtel, M.; Biesinger, R.; Kroth, H.; Piecha, D.; Hofmann, M. W.; Krause, S.; Schaaf, O.; Nicolau, C.; Eliseev, A. V. Ketones as building blocks for dynamic combinatorial libraries: highly active neuraminidase inhibitors generated via selection pressure of the biological target. J. Med. Chem. 2003, 46, 356358,  DOI: 10.1021/jm025589m
    91. 91
      Nasr, G.; Petit, E.; Vullo, D.; Winum, J. Y.; Supuran, C. T.; Barboiu, M. Carbonic anhydrase-encoded dynamic constitutional libraries: toward the discovery of isozyme-specific inhibitors. J. Med. Chem. 2009, 52, 48534859,  DOI: 10.1021/jm900449v
    92. 92
      Bunyapaiboonsri, T.; Ramstrom, H.; Ramstrom, O.; Haiech, J.; Lehn, J. M. Generation of bis-cationic heterocyclic inhibitors of Bacillus subtilis HPr kinase/phosphatase from a ditopic dynamic combinatorial library. J. Med. Chem. 2003, 46, 58035811,  DOI: 10.1021/jm030917j
    93. 93
      Bhardwaj, A.; Kaur, J.; Wuest, M.; Wuest, F. In situ click chemistry generation of cyclooxygenase-2 inhibitors. Nat. Commun. 2017, 8, 1,  DOI: 10.1038/s41467-016-0009-6
    94. 94
      Wang, Y.; Zhu, J.; Zhang, L. Discovery of cell-permeable O-GlcNAc transferase inhibitors via tethering in situ click chemistry. J. Med. Chem. 2017, 60, 263272,  DOI: 10.1021/acs.jmedchem.6b01237
    95. 95
      Namelikonda, N. K.; Manetsch, R. Sulfo-click reaction via in situ generated thioacids and its application in kinetic target-guided synthesis. Chem. Commun. (Cambridge, U. K.) 2012, 48, 15261528,  DOI: 10.1039/C1CC14724B
    96. 96
      Kulkarni, S. S.; Hu, X.; Doi, K.; Wang, H. G.; Manetsch, R. Screening of protein-protein interaction modulators via sulfo-click kinetic target-guided synthesis. ACS Chem. Biol. 2011, 6, 724732,  DOI: 10.1021/cb200085q
    97. 97
      Antti, H.; Sellstedt, M. Cell-based kinetic target-guided synthesis of an enzyme Inhibitor. ACS Med. Chem. Lett. 2018, 9, 351353,  DOI: 10.1021/acsmedchemlett.7b00535
    98. 98
      Lebraud, H.; Wright, D. J.; Johnson, C. N.; Heightman, T. D. Protein degradation by in-cell self-assembly of proteolysis targeting chimeras. ACS Cent. Sci. 2016, 2, 927934,  DOI: 10.1021/acscentsci.6b00280
    99. 99
      (a) Sindelar, M.; Wanner, K. T. Library screening by means of mass spectrometry (MS) binding assays-exemplarily demonstrated for a pseudostatic library addressing γ-aminobutyric acid (GABA) transporter 1 (GAT1). ChemMedChem 2012, 7, 16781690,  DOI: 10.1002/cmdc.201200201 .
      (b) Sindelar, M.; Lutz, T. A.; Petrera, M.; Wanner, K. T. Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1. J. Med. Chem. 2013, 56, 13231340,  DOI: 10.1021/jm301800j .
      (c) Hauke, T. J.; Wein, T.; Höfner, G.; Wanner, K. T. Novel allosteric ligands of γ-aminobutyric acid transporter 1 (GAT1) by MS based screening of pseudostatic hydrazone libraries. J. Med. Chem. 2018, 61, 1031010332,  DOI: 10.1021/acs.jmedchem.8b01602 .
      (d) Huber, S. K.; Höfner, G.; Wanner, K. T. Identification of pyrrolidine-3-acetic acid derived oximes as potent inhibitors of γ-aminobutyric acid transporter 1 through library screening with MS binding assays. ChemMedChem 2018, 13, 24882503,  DOI: 10.1002/cmdc.201800556
    100. 100
      (a) Demetriades, M.; Leung, I. K. H.; Chowdhury, R.; Chan, M. C.; Yeoh, K. K.; Tian, Y.-M.; Claridge, T. D. W.; Rgatcliffe, P. J.; Woon, E. C. Y.; Schofield, C. J. Dynamic combinatorial chemistry employing boronic acids/boronate esters leads to potent oxygenase inhibitors. Angew. Chem., Int. Ed. 2012, 51, 66726675,  DOI: 10.1002/anie.201202000 .
      (b) Woon, E. C. Y.; Demetriades, M.; Bagg, E. A. L.; Aik, W. S.; Krylova, S. M.; Ma, J. H. Y.; Chan, M. C.; Walport, L. J.; Wegman, D. W.; Dack, K. N.; McDonough, M. A.; Krylov, S. N.; Schofield, C. J. Dynamic combinatorial mass spectrometry leads to inhibitors of a 2-oxoglutarate dependent nucleic acid demethylase. J. Med. Chem. 2012, 55, 21732184,  DOI: 10.1021/jm201417e .
      (c) Rose, N. R.; Woon, E. C. Y.; Kingham, G. L.; King, O. N. F.; Mecinovic, J.; Clifton, I. J.; Ng, S. S.; Talib-Hardy, J.; Oppermann, U.; McDonough, M. A.; Schofield, C. J. Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. J. Med. Chem. 2010, 53, 18101818,  DOI: 10.1021/jm901680b
    101. 101
      Das, M.; Tianming, Y.; Jinghua, D.; Prasetya, F.; Yiming, X.; Wong, K.; Cheong, A.; Woon, E. C. Y. Multi-protein dynamic combinatorial chemistry: a novel strategy that leads to simultaneous discovery of subfamily-selective inhibitors for nucleic acid demethylases FTO and ALKBH3. Chem. Asian J. 2018, 13, 2854,  DOI: 10.1002/asia.201800729
    102. 102
      Jana, S.; Panda, D.; Saha, P.; Pantos, D.; Dash, J. Dynamic generation of G-quadruplex DNA ligands by target-guided combinatorial chemistry on a magnetic nano-platform. J. Med. Chem. 2019, 62, 762,  DOI: 10.1021/acs.jmedchem.8b01459
    103. 103
      Tu, J.; Xu, M.; Franzini, R. Dissociative bioorthogonal reactions. ChemBioChem 2019,  DOI: 10.1002/cbic.201800810
    104. 104
      Li, J.; Chen, P. R. Development and application of bond cleavage reactions in bioorthogonal chemistry. Nat. Chem. Biol. 2016, 12, 129137,  DOI: 10.1038/nchembio.2024
    105. 105
      (a) Unciti-Broceta, A.; Johansson, E. M.; Yusop, R. M.; Sanchez-Martin, R. M.; Bradley, M. Synthesis of polystyrene microspheres and functionalization with Pd(0) nanoparticles to perform bioorthogonal organometallic chemistry in living cells. Nat. Protoc. 2012, 7, 12071218,  DOI: 10.1038/nprot.2012.052 .
      (b) Yusop, R. M.; Unciti-Broceta, A.; Johansson, E. M.; Sanchez-Martin, R. M.; Bradley, M. Palladium-mediated intracellular chemistry. Nat. Chem. 2011, 3, 239243,  DOI: 10.1038/nchem.981 .
      (c) Unciti-Broceta, A. Bioorthogonal catalysis: Rise of the nanobots. Nat. Chem. 2015, 7, 538539,  DOI: 10.1038/nchem.2291 .
      (d) Weiss, J. T.; Dawson, J. C.; Fraser, C.; Rybski, W.; Torres-Sanchez, C.; Bradley, M.; Patton, E. E.; Carragher, N. O.; Unciti-Broceta, A. Development and bioorthogonal activation of palladium-labile prodrugs of gemcitabine. J. Med. Chem. 2014, 57, 53955404,  DOI: 10.1021/jm500531z .
      (e) Weiss, J. T.; Dawson, J. C.; Macleod, K. G.; Rybski, W.; Fraser, C.; Torres-Sanchez, C.; Patton, E. E.; Bradley, M.; Carragher, N. O.; Unciti-Broceta, A. Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach. Nat. Commun. 2014, 5, 3277,  DOI: 10.1038/ncomms4277 .
      (f) Weiss, J. T.; Fraser, C.; Rubio-Ruiz, B.; Myers, S. H.; Crispin, R.; Dawson, J. C.; Brunton, V. G.; Patton, E. E.; Carragher, N. O.; Unciti-Broceta, A. N-alkynyl derivatives of 5-fluorouracil: susceptibility to palladium-mediated dealkylation and toxigenicity in cancer cell culture. Front Chem. 2014, 2, 56,  DOI: 10.3389/fchem.2014.00056 .
      (g) Weiss, J. T.; Carragher, N. O.; Unciti-Broceta, A. Palladium-mediated dealkylation of N-propargyl-floxuridine as a bioorthogonal oxygen-independent prodrug strategy. Sci. Rep. 2015, 5, 9329,  DOI: 10.1038/srep09329 .
      (h) Rubio-Ruiz, B.; Weiss, J. T.; Unciti-Broceta, A. Efficient palladium-triggered release of vorinostat from a bioorthogonal precursor. J. Med. Chem. 2016, 59, 99749980,  DOI: 10.1021/acs.jmedchem.6b01426
    106. 106
      Lv, T.; Wu, J.; Kang, F.; Wang, T.; Wan, B.; Lu, J. J.; Zhang, Y.; Huang, Z. Synthesis and evaluation of O(2)-derived diazeniumdiolates activatable via bioorthogonal chemistry reactions in living cells. Org. Lett. 2018, 20, 21642167,  DOI: 10.1021/acs.orglett.8b00423
    107. 107
      Li, J.; Jia, S.; Chen, P. R. Diels-Alder reaction-triggered bioorthogonal protein decaging in living cells. Nat. Chem. Biol. 2014, 10, 10031005,  DOI: 10.1038/nchembio.1656
    108. 108
      Perez-Lopez, A. M.; Rubio-Ruiz, B.; Sebastián, V.; Hamilton, L.; Adam, C.; Bray, T. L.; Irusta, S.; Brennan, P. M.; Lloyd-Jones, G. C.; Sieger, D.; Santamaría, J.; Unciti-Broceta, A. Gold-triggered uncaging chemistry in living systems. Angew. Chem., Int. Ed. 2017, 56, 1254812552,  DOI: 10.1002/anie.201705609
    109. 109
      Devaraj, N. K. The future of bioorthogonal chemistry. ACS Cent. Sci. 2018, 4, 952959,  DOI: 10.1021/acscentsci.8b00251
    110. 110
      (a) Zheng, Y.; Ji, X.; Yu, B.; Ji, K.; Gallo, D.; Csizmadia, E.; Zhu, M.; Choudhury, M. R.; De La Cruz, L. K. C.; Chittavong, V.; Pan, Z.; Yuan, Z.; Otterbein, L. E.; Wang, B. Enrichment-triggered prodrug activation demonstrated through mitochondria-targeted delivery of doxorubicin and carbon monoxide. Nat. Chem. 2018, 10, 787,  DOI: 10.1038/s41557-018-0055-2 .
      (b) Ji, X.; Pan, Z.; Yu, B.; De La Cruz, L. K.; Zheng, Y.; Ke, B.; Wang, B. Click and release: bioorthogonal approaches to ″on-demand″ activation of prodrugs. Chem. Soc. Rev. 2019, 48, 1077,  DOI: 10.1039/C8CS00395E
    111. 111
      Klán, P.; Šolomek, T.; Bochet, C. G.; Blanc, A.; Givens, R.; Rubina, M.; Popik, V.; Kostikov, A.; Wirz, J. Photoremovable protecting groups in chemistry and biology: reaction mechanisms and efficacy. Chem. Rev. 2013, 113, 119191,  DOI: 10.1021/cr300177k
    112. 112
      Horbert, R.; Pinchuk, B.; Davies, P.; Alessi, D.; Peifer, C. Photoactivatable prodrugs of anti-melanoma agent vemurafenib. ACS Chem. Biol. 2015, 10, 2099107,  DOI: 10.1021/acschembio.5b00174
    113. 113
      Bliman, D.; Nilsson, J. R.; Kettunen, P.; Andréasson, J.; Grøtli, M. A Caged ret kinase inhibitor and its effect on motoneuron development in zebrafish embryos. Sci. Rep. 2015, 5, 13109,  DOI: 10.1038/srep13109
    114. 114
      Zindler, M.; Pinchuk, B.; Renn, C.; Horbert, R.; Döbber, A.; Peifer, C. Design, synthesis, and characterization of a photoactivatable caged prodrug of imatinib. ChemMedChem 2015, 10, 13351338,  DOI: 10.1002/cmdc.201500163
    115. 115
      Ieda, N.; Yamada, S.; Kawaguchi, M.; Miyata, N.; Nakagawa, H. (7-Diethylaminocoumarin-4-yl)methyl ester of suberoylanilide hydroxamic acid as a caged inhibitor for photocontrol of histone deacetylase activity. Bioorg. Med. Chem. 2016, 24, 27892793,  DOI: 10.1016/j.bmc.2016.04.042
    116. 116
      Parasar, B.; Chang, P. V. Chemical optogenetic modulation of inflammation and immunity. Chem. Sci. 2017, 8, 14501453,  DOI: 10.1039/C6SC03702J
    117. 117
      Tamura, R.; Balabanova, A.; Frakes, S. A.; Bargmann, A.; Grimm, J.; Koch, T. H.; Yin, H. H. Photoactivatable prodrug of doxazolidine targeting exosomes. J. Med. Chem. 2019, 62, 1959,  DOI: 10.1021/acs.jmedchem.8b01508
    118. 118
      Döbber, A.; Phoa, A. F.; Abbassi, R. H.; Stringer, B. W.; Day, B. W.; Johns, T. G.; Abadleh, M.; Peifer, C.; Munoz, L. Development and biological evaluation of a photoactivatable small molecule microtubule-targeting agent. ACS Med. Chem. Lett. 2017, 8, 395400,  DOI: 10.1021/acsmedchemlett.6b00483
    119. 119
      Perdicakis, B.; Montgomery, H. J.; Abbott, G. L.; Fishlock, D.; Lajoie, G. A.; Guillemette, J. G.; Jervis, E. Photocontrol of nitric oxide production in cell culture using a caged isoform selective inhibitor. Bioorg. Med. Chem. 2005, 13, 4757,  DOI: 10.1016/j.bmc.2004.10.002
    120. 120
      Abrahamse, H.; Hamblin, M. R. New photosensitizers for photodynamic therapy. Biochem. J. 2016, 473, 347364,  DOI: 10.1042/BJ20150942
    121. 121
      Detty, M. R.; Gibson, S. L.; Wagner, S. J. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J. Med. Chem. 2004, 47, 38973915,  DOI: 10.1021/jm040074b
    122. 122
      Hirohara, S.; Oka, C.; Totani, M.; Obata, M.; Yuasa, J.; Ito, H.; Tamura, M.; Matsui, H.; Kakiuchi, K.; Kawai, T.; Kawaichi, M.; Tanihara, M. Synthesis, photophysical properties, and biological evaluation of trans-bisthioglycosylated tetrakis(fluorophenyl)chlorin for photodynamic therapy. J. Med. Chem. 2015, 58, 86588670,  DOI: 10.1021/acs.jmedchem.5b01262
    123. 123
      Monro, S.; Colón, K. L.; Yin, H.; Roque, J., 3rd.; Konda, P.; Gujar, S.; Thummel, R. P.; Lilge, L.; Cameron, C. G.; McFarland, S. A. Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433. Chem. Rev. 2019, 119, 797,  DOI: 10.1021/acs.chemrev.8b00211
    124. 124
      Xu, P.; Jia, Y.; Yang, Y.; Chen, J.; Hu, P.; Chen, Z.; Huang, M. Photodynamic oncotherapy mediated by gonadotropin-releasing hormone receptors. J. Med. Chem. 2017, 60, 86678672,  DOI: 10.1021/acs.jmedchem.7b01216
    125. 125
      Thapa, P.; Li, M.; Bio, M.; Rajaputra, P.; Nkepang, G.; Sun, Y.; Woo, S.; You, Y. Far-red light-activatable prodrug of paclitaxel for the combined effects of photodynamic therapy and site-specific paclitaxel chemotherapy. J. Med. Chem. 2016, 59, 32043214,  DOI: 10.1021/acs.jmedchem.5b01971
    126. 126
      Battah, S.; Hider, R. C.; MacRobert, A. J.; Dobbin, P. S.; Zhou, T. Hydroxypyridinone and 5-aminolaevulinic acid conjugates for photodynamic therapy. J. Med. Chem. 2017, 60, 34983510,  DOI: 10.1021/acs.jmedchem.7b00346
    127. 127
      Feng, X.; Shi, Y.; Xie, L.; Zhang, K.; Wang, X.; Liu, Q.; Wang, P. Synthesis, characterization, and biological evaluation of a porphyrin-based photosensitizer and its isomer for effective photodynamic therapy against breast cancer. J. Med. Chem. 2018, 61, 71897201,  DOI: 10.1021/acs.jmedchem.8b00547
    128. 128
      Zhou, Y.; Cheung, Y. K.; Ma, C.; Zhao, S.; Gao, D.; Lo, P. C.; Fong, W. P.; Wong, K. S.; Ng, D. K. P. Endoplasmic reticulum-localized two-photon-absorbing boron dipyrromethenes as advanced photosensitizers for photodynamic therapy. J. Med. Chem. 2018, 61, 39523961,  DOI: 10.1021/acs.jmedchem.7b01907
    129. 129
      Cheruku, R. R.; Cacaccio, J.; Durrani, F.; Tabaczynski, W. A.; Watson, R.; Marko, A. J.; Kumar, R.; El-Khouly, M. E.; Fukuzumi, S.; Missert, J. R.; Yao, R.; Sajjad, M.; Chandra, D.; Guru, K.; Pandey, R. K. Epidermal growth factor receptor targeted multifunctional photosensitizers for bladder cancer imaging and photodynamic therapy. J. Med. Chem. 2019, 62, 2598,  DOI: 10.1021/acs.jmedchem.8b01927
    130. 130
      Blacklock, K. M.; Yachnin, B. J.; Woolley, G. A.; Khare, S. D. Computational design of a photocontrolled cytosine deaminase. J. Am. Chem. Soc. 2018, 140, 1417,  DOI: 10.1021/jacs.7b08709
    131. 131
      Zhu, M.; Zhou, H. Azobenzene-based small molecular photoswitches for protein modulation. Org. Biomol. Chem. 2018, 16, 84348445,  DOI: 10.1039/C8OB02157K
    132. 132
      (a) Quandt, G.; Höfner, G.; Pabel, J.; Dine, J.; Eder, M.; Wanner, K. T. First photoswitchable neurotransmitter transporter inhibitor: light-induced control of γ-aminobutyric acid transporter 1 (GAT1) activity in mouse brain. J. Med. Chem. 2014, 57, 68096821,  DOI: 10.1021/jm5008566 .
      (b) Lutz, T.; Wein, T.; Höfner, G.; Pabel, J.; Eder, M.; Dine, J.; Wanner, K. T. Development of new photoswitchable azobenzene based γ-aminobutyric acid (GABA) uptake inhibitors with distinctly enhanced potency upon photoactivation. J. Med. Chem. 2018, 61, 62116235,  DOI: 10.1021/acs.jmedchem.8b00629
    133. 133
      Nørager, N. G.; Poulsen, M. H.; Strømgaard, K. Controlling Ca2+ permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors with photochromic ion channel blockers. J. Med. Chem. 2018, 61, 80488053,  DOI: 10.1021/acs.jmedchem.8b00756
    134. 134
      Matera, C.; Gomila, A. M. J.; Camarero, N.; Libergoli, M.; Soler, C.; Gorostiza, P. Photoswitchable antimetabolite for targeted photoactivated chemotherapy. J. Am. Chem. Soc. 2018, 140, 1576415773,  DOI: 10.1021/jacs.8b08249
    135. 135
      Li, J.; Kong, H.; Huang, L.; Cheng, B.; Qin, K.; Zheng, M.; Yan, Z.; Zhang, Y. Visible light-initiated bioorthogonal photoclick cycloaddition. J. Am. Chem. Soc. 2018, 140, 1454214546,  DOI: 10.1021/jacs.8b08175
    136. 136
      Comer, E.; Beaudoin, J. A.; Kato, N.; Fitzgerald, M. E.; Heidebrecht, R. W.; Lee, Md, 4th.; Masi, D.; Mercier, M.; Mulrooney, C.; Muncipinto, G.; Rowley, A.; Crespo-Llado, K.; Serrano, A. E.; Lukens, A. K.; Wiegand, R. C.; Wirth, D. F.; Palmer, M. A.; Foley, M. A.; Munoz, B.; Scherer, C. A.; Duvall, J. R.; Schreiber, S. L. Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agents. J. Med. Chem. 2014, 57, 84968502,  DOI: 10.1021/jm500994n
    137. 137
      Kuttruff, C. A.; Haile, M.; Kraml, J.; Tautermann, C. S. Late-stage functionalization of drug-like molecules using diversinates. ChemMedChem 2018, 13, 983987,  DOI: 10.1002/cmdc.201800151
    138. 138
      Caro-Diaz, E. J. E.; Urbano, M.; Buzard, D. J.; Jones, R. M. C-H activation reactions as useful tools for medicinal chemists. Bioorg. Med. Chem. Lett. 2016, 26, 53785383,  DOI: 10.1016/j.bmcl.2016.06.036
    139. 139
      Sekizawa, H.; Amaike, K.; Itoh, Y.; Suzuki, T.; Itami, K.; Yamaguchi, J. Late-stage C-H coupling enables rapid identification of HDAC inhibitors: synthesis and evaluation of NCH-31 analogues. ACS Med. Chem. Lett. 2014, 5, 582586,  DOI: 10.1021/ml500024s
    140. 140
      Miyamura, S.; Araki, M.; Suzuki, T.; Yamaguchi, J.; Itami, K. Stereodivergent synthesis of arylcyclopropylamines by sequential C-H borylation and Suzuki-Miyaura coupling. Angew. Chem., Int. Ed. 2015, 54, 846851,  DOI: 10.1002/anie.201409186
    141. 141
      El Marrouni, A.; Campbell, M.; Perkins, J. J.; Converso, A. Development of a sp(2)-sp(3) stille cross-coupling for rapid synthesis of HIV NNRTI doravirine analogues. Org. Lett. 2017, 19, 30713074,  DOI: 10.1021/acs.orglett.7b01142
    142. 142
      Naret, T.; Khelifi, I.; Provot, O.; Bignon, J.; Levaique, H.; Dubois, J.; Souce, M.; Kasselouri, A.; Deroussent, A.; Paci, A.; Varela, P. F.; Gigant, B.; Alami, M.; Hamze, A. 1,1-Diheterocyclic ethylenes derived from quinaldine and carbazole as new tubulin polymerization inhibitors: synthesis, metabolism, and biological evaluation. J. Med. Chem. 2019, 62, 1902,  DOI: 10.1021/acs.jmedchem.8b01386
    143. 143
      Brown, D. G.; Boström, J. Analysis of past and present synthetic methodologies on medicinal chemistry: where have all the new reactions gone?. J. Med. Chem. 2016, 59, 44434458,  DOI: 10.1021/acs.jmedchem.5b01409
    144. 144
      Fier, P. S.; Maloney, K. M. NHC-Catalyzed deamination of primary sulfonamides: a platform for late-stage functionalization. J. Am. Chem. Soc. 2019, 141, 1441,  DOI: 10.1021/jacs.8b11800
    145. 145
      Uehling, M. R.; King, R. P.; Krska, S. W.; Cernak, T.; Buchwald, S. L. Pharmaceutical diversification via palladium oxidative addition complexes. Science 2019, 363, 405408,  DOI: 10.1126/science.aac6153
    146. 146
      Clark, J. R.; Feng, K.; Sookezian, A.; White, M. C. Manganese-catalysed benzylic C(sp(3))-H amination for late-stage functionalization. Nat. Chem. 2018, 10, 583591,  DOI: 10.1038/s41557-018-0020-0
    147. 147
      Margrey, K. A.; Czaplyski, W. L.; Nicewicz, D. A.; Alexanian, E. J. A general strategy for aliphatic C-H functionalization enabled by organic photoredox catalysis. J. Am. Chem. Soc. 2018, 140, 42134217,  DOI: 10.1021/jacs.8b00592
    148. 148
      Laudadio, G.; Govaerts, S.; Wang, Y.; Ravelli, D.; Koolman, H. F.; Fagnoni, M.; Djuric, S. W.; Noël, T. Selective C(sp3)-H aerobic oxidation enabled by decatungstate photocatalysis in flow. Angew. Chem., Int. Ed. 2018, 57, 40784082,  DOI: 10.1002/anie.201800818
    149. 149
      Liu, Z.; Li, J.; Li, S.; Li, G.; Sharpless, K. B.; Wu, P. SuFEx click chemistry enabled late-stage drug functionalization. J. Am. Chem. Soc. 2018, 140, 29192925,  DOI: 10.1021/jacs.7b12788
    150. 150
      Boström, J.; Brown, D. G.; Young, R. J.; Keserü, G. M. Expanding the medicinal chemistry synthetic toolbox. Nat. Rev. Drug Discovery 2018, 17, 709,  DOI: 10.1038/nrd.2018.116
    151. 151
      Roughley, S. D.; Jordan, A. M. The medicinal chemist’s toolbox: an analysis of reactions used in the pursuit of drug candidates. J. Med. Chem. 2011, 54, 34513479,  DOI: 10.1021/jm200187y
    152. 152
      Frédérich, M.; Pirotte, B.; Fillet, M.; de Tullio, P. Metabolomics as a challenging approach for medicinal chemistry and personalized medicine. J. Med. Chem. 2016, 59, 86498666,  DOI: 10.1021/acs.jmedchem.5b01335
    153. 153
      (a) Stepan, A. F.; Tran, T. P.; Helal, C. J.; Brown, M. S.; Chang, C.; O’Connor, R. E.; De Vivo, M.; Doran, S. D.; Fisher, E. L.; Jenkinson, S.; Karanian, D.; Kormos, B. L.; Sharma, R.; Walker, G. S.; Wright, A. S.; Yang, E. X.; Brodney, M. A.; Wager, T. T.; Verhoest, P. R.; Obach, R. S. Late-stage microsomal oxidation reduces drug-drug interaction and identifies phosphodiesterase 2A inhibitor PF-06815189. ACS Med. Chem. Lett. 2018, 9, 6872,  DOI: 10.1021/acsmedchemlett.7b00343 .
      (b) Obach, R. S.; Walker, G. S.; Sharma, R.; Jenkinson, S.; Tran, T. P.; Stepan, A. F. Lead diversification at the nanomole scale using liver microsomes and quantitative nuclear magnetic resonance spectroscopy: application to phosphodiesterase 2 inhibitors. J. Med. Chem. 2018, 61, 36263640,  DOI: 10.1021/acs.jmedchem.8b00116
    154. 154
      Clouthier, C. M.; Pelletier, J. N. Expanding the organic toolbox: a guide to integrating biocatalysis in synthesis. Chem. Soc. Rev. 2012, 41, 15851605,  DOI: 10.1039/c2cs15286j
    155. 155
      Segall, M. Advances in multiparameter optimization methods for de novo drug design. Expert Opin. Drug Discovery 2014, 9, 803817,  DOI: 10.1517/17460441.2014.913565
    156. 156
      Segall, M. D.; Yusof, I.; Champness, E. J. Avoiding missed opportunities by analyzing the sensitivity of our decisions. J. Med. Chem. 2016, 59, 42674277,  DOI: 10.1021/acs.jmedchem.5b01921
    157. 157
      Shultz, M. D. Two decades under the influence of the rule of five and the changing properties of approved oral drugs. J. Med. Chem. 2019, 62, 1701,  DOI: 10.1021/acs.jmedchem.8b00686
    158. 158
      Doak, B. C.; Zheng, J.; Dobritzsch, D.; Kihlberg, J. How beyond rule of 5 drugs and clinical candidates bind to their targets. J. Med. Chem. 2016, 59, 23122327,  DOI: 10.1021/acs.jmedchem.5b01286
    159. 159
      DeGoey, D. A.; Chen, H. J.; Cox, P. B.; Wendt, M. D. Beyond the rule of 5: lessons learned from AbbVie’s drugs and compound collection. J. Med. Chem. 2018, 61, 26362651,  DOI: 10.1021/acs.jmedchem.7b00717
    160. 160
      Raymer, B.; Bhattacharya, S. K. Lead-like drugs: A perspective. J. Med. Chem. 2018, 61, 10375,  DOI: 10.1021/acs.jmedchem.8b00407
    161. 161
      Johnson, T. W.; Gallego, R. A. Lipophilic efficiency as an important metric in drug design. J. Med. Chem. 2018, 61, 64016420,  DOI: 10.1021/acs.jmedchem.8b00077
    162. 162
      Wager, T. T.; Kormos, B. L.; Brady, J. T.; Will, Y.; Aleo, M. D.; Stedman, D. B.; Kuhn, M.; Chandrasekaran, R. Y. Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies. J. Med. Chem. 2013, 56, 97719779,  DOI: 10.1021/jm401485p
    163. 163
      (a) Shultz, M. D.; Majumdar, D.; Chin, D. N.; Fortin, P. D.; Feng, Y.; Gould, T.; Kirby, C. A.; Stams, T.; Waters, N. J.; Shao, W. Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. J. Med. Chem. 2013, 56, 70497059,  DOI: 10.1021/jm400826j .
      (b) Shultz, M. D.; Cheung, A. K.; Kirby, C. A.; Firestone, B.; Fan, J.; Chen, C. H.; Chen, Z.; Chin, D. N.; Dipietro, L.; Fazal, A.; Feng, Y.; Fortin, P. D.; Gould, T.; Lagu, B.; Lei, H.; Lenoir, F.; Majumdar, D.; Ochala, E.; Palermo, M. G.; Pham, L.; Pu, M.; Smith, T.; Stams, T.; Tomlinson, R. C.; Toure, B. B.; Visser, M.; Wang, R. M.; Waters, N. J.; Shao, W. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J. Med. Chem. 2013, 56, 64956511,  DOI: 10.1021/jm400807n
    164. 164
      Jiang, Z. Y.; Xu, L. L.; Lu, M. C.; Chen, Z. Y.; Yuan, Z. W.; Xu, X. L.; Guo, X. K.; Zhang, X. J.; Sun, H. P.; You, Q. D. Structure-activity and structure-property relationship and exploratory in vivo evaluation of the nanomolar Keap1-Nrf2 protein-protein interaction inhibitor. J. Med. Chem. 2015, 58, 64106421,  DOI: 10.1021/acs.jmedchem.5b00185
    165. 165
      (a) Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci. 2010, 1, 435449,  DOI: 10.1021/cn100008c .
      (b) Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Central nervous system multiparameter optimization desirability: application in drug discovery. ACS Chem. Neurosci. 2016, 7, 767775,  DOI: 10.1021/acschemneuro.6b00029 .
      (c) Wager, T. T.; Chappie, T.; Horton, D.; Chandrasekaran, R. Y.; Samas, B.; Dunn-Sims, E. R.; Hsu, C.; Nawreen, N.; Vanase-Frawley, M. A.; O’Connor, R. E.; Schmidt, C. J.; Dlugolenski, K.; Stratman, N. C.; Majchrzak, M. J.; Kormos, B. L.; Nguyen, D. P.; Sawant-Basak, A.; Mead, A. N. Dopamine D3/D2 receptor antagonist PF-4363467 attenuates opioid drug-seeking behavior without concomitant D2 side effects. ACS Chem. Neurosci. 2017, 8, 165177,  DOI: 10.1021/acschemneuro.6b00297
    166. 166
      Vilums, M.; Zweemer, A. J.; Yu, Z.; de Vries, H.; Hillger, J. M.; Wapenaar, H.; Bollen, I. A.; Barmare, F.; Gross, R.; Clemens, J.; Krenitsky, P.; Brussee, J.; Stamos, D.; Saunders, J.; Heitman, L. H.; Ijzerman, A. P. Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists. J. Med. Chem. 2013, 56, 77067714,  DOI: 10.1021/jm4011737
    167. 167
      Yu, Z.; van Veldhoven, J. P.; Louvel, J.; t Hart, I. M.; Rook, M. B.; van der Heyden, M. A.; Heitman, L. H.; IJzerman, A. P. Structure-affinity relationships (SARs) and Structure-kinetics relationships (SKRs) of Kv11.1 blockers. J. Med. Chem. 2015, 58, 59165929,  DOI: 10.1021/acs.jmedchem.5b00518
    168. 168
      Rai, G.; Brimacombe, K. R.; Mott, B. T.; Urban, D. J.; Hu, X.; Yang, S. M.; Lee, T. D.; Cheff, D. M.; Kouznetsova, J.; Benavides, G. A.; Pohida, K.; Kuenstner, E. J.; Luci, D. K.; Lukacs, C. M.; Davies, D. R.; Dranow, D. M.; Zhu, H.; Sulikowski, G.; Moore, W. J.; Stott, G. M.; Flint, A. J.; Hall, M. D.; Darley-Usmar, V. M.; Neckers, L. M.; Dang, C. V.; Waterson, A. G.; Simeonov, A.; Jadhav, A.; Maloney, D. J. Discovery and optimization of potent, cell-active pyrazole-based inhibitors of lactate dehydrogenase (LDH). J. Med. Chem. 2017, 60, 91849204,  DOI: 10.1021/acs.jmedchem.7b00941
    169. 169
      Brough, P. A.; Baker, L.; Bedford, S.; Brown, K.; Chavda, S.; Chell, V.; D’Alessandro, J.; Davies, N. G.; Davis, B.; Le Strat, L.; Macias, A. T.; Maddox, D.; Mahon, P. C.; Massey, A. J.; Matassova, N.; McKenna, S.; Meissner, J. W.; Moore, J. D.; Murray, J. B.; Northfield, C. J.; Parry, C.; Parsons, R.; Roughley, S. D.; Shaw, T.; Simmonite, H.; Stokes, S.; Surgenor, A.; Stefaniak, E.; Robertson, A.; Wang, Y.; Webb, P.; Whitehead, N.; Wood, M. Application of off-rate screening in the identification of novel pan-isoform inhibitors of pyruvate dehydrogenase kinase. J. Med. Chem. 2017, 60, 22712286,  DOI: 10.1021/acs.jmedchem.6b01478
    170. 170
      Klebe, G. Applying thermodynamic profiling in lead finding and optimization. Nat. Rev. Drug Discovery 2015, 14, 95110,  DOI: 10.1038/nrd4486
    171. 171
      Cusack, K. P.; Wang, Y.; Hoemann, M. Z.; Marjanovic, J.; Heym, R. G.; Vasudevan, A. Design strategies to address kinetics of drug binding and residence time. Bioorg. Med. Chem. Lett. 2015, 25, 20192027,  DOI: 10.1016/j.bmcl.2015.02.027
    172. 172
      Buch, I.; Giorgino, T.; De Fabritiis, G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 1018410189,  DOI: 10.1073/pnas.1103547108
    173. 173
      Perricone, U.; Gulotta, M. R.; Lombino, J.; Parrino, B.; Cascioferro, S.; Diana, P.; Cirrincione, G.; Padova, A. An overview of recent molecular dynamics applications as medicinal chemistry tools for the undruggable site challenge. MedChemComm 2018, 9, 920936,  DOI: 10.1039/C8MD00166A
    174. 174
      Mollica, L.; Theret, I.; Antoine, M.; Perron-Sierra, F.; Charton, Y.; Fourquez, J. M.; Wierzbicki, M.; Boutin, J. A.; Ferry, G.; Decherchi, S.; Bottegoni, G.; Ducrot, P.; Cavalli, A. Molecular dynamics simulations and kinetic measurements to estimate and predict protein-ligand residence times. J. Med. Chem. 2016, 59, 71677176,  DOI: 10.1021/acs.jmedchem.6b00632
    175. 175
      Krimmer, S. G.; Cramer, J.; Betz, M.; Fridh, V.; Karlsson, R.; Heine, A.; Klebe, G. Rational design of thermodynamic and kinetic binding profiles by optimizing surface water networks coating protein-bound ligands. J. Med. Chem. 2016, 59, 1053010548,  DOI: 10.1021/acs.jmedchem.6b00998
    176. 176
      Nasief, N. N.; Tan, H.; Kong, J.; Hangauer, D. Water mediated ligand functional group cooperativity: the contribution of a methyl group to binding affinity is enhanced by a COO(−) group through changes in the structure and thermodynamics of the hydration waters of ligand-thermolysin complexes. J. Med. Chem. 2012, 55, 82838302,  DOI: 10.1021/jm300472k
    177. 177
      Liu, L. Efficient hit and lead compound evaluation strategy based on off-rate screening by surface plasmon resonance. J. Med. Chem. 2014, 57, 28432844,  DOI: 10.1021/jm5003815
    178. 178
      Murray, J. B.; Roughley, S. D.; Matassova, N.; Brough, P. A. Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products. J. Med. Chem. 2014, 57, 28452850,  DOI: 10.1021/jm401848a
    179. 179
      Spagnuolo, L. A.; Eltschkner, S.; Yu, W.; Daryaee, F.; Davoodi, S.; Knudson, S. E.; Allen, E. K.; Merino, J.; Pschibul, A.; Moree, B.; Thivalapill, N.; Truglio, J. J.; Salafsky, J.; Slayden, R. A.; Kisker, C.; Tonge, P. J. Evaluating the contribution of transition-state destabilization to changes in the residence time of triazole-based InhA inhibitors. J. Am. Chem. Soc. 2017, 139, 34173429,  DOI: 10.1021/jacs.6b11148
    180. 180
      Kokh, D. B.; Amaral, M.; Bomke, J.; Grädler, U.; Musil, D.; Buchstaller, H. P.; Dreyer, M. K.; Frech, M.; Lowinski, M.; Vallee, F.; Bianciotto, M.; Rak, A.; Wade, R. C. Estimation of drug-target residence times by τ-random acceleration molecular dynamics simulations. J. Chem. Theory Comput. 2018, 14, 38593869,  DOI: 10.1021/acs.jctc.8b00230
    181. 181
      Cummins, D. J.; Bell, M. A. Integrating Everything: The molecule selection toolkit, a system for compound prioritization in drug discovery. J. Med. Chem. 2016, 59, 69997010,  DOI: 10.1021/acs.jmedchem.5b01338
    182. 182
      McEnaney, P. J.; Parker, C. G.; Zhang, A. X.; Spiegel, D. A. Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease. ACS Chem. Biol. 2012, 7, 11391151,  DOI: 10.1021/cb300119g
    183. 183
      Casi, G.; Neri, D. Antibody-drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents. J. Med. Chem. 2015, 58, 87518761,  DOI: 10.1021/acs.jmedchem.5b00457
    184. 184
      Murelli, R. P.; Zhang, A. X.; Michel, J.; Jorgensen, W. L.; Spiegel, D. A. Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer. J. Am. Chem. Soc. 2009, 131, 1709017092,  DOI: 10.1021/ja906844e
    185. 185
      (a) Parker, C. G.; Domaoal, R. A.; Anderson, K. S.; Spiegel, D. A. An antibody-recruiting small molecule that targets HIV gp120. J. Am. Chem. Soc. 2009, 131, 1639216394,  DOI: 10.1021/ja9057647 .
      (b) Parker, C. G.; Dahlgren, M. K.; Tao, R. N.; Li, D. T.; Douglass, E. F., Jr.; Shoda, T.; Jawanda, N.; Spasov, K. A.; Lee, S.; Zhou, N.; Domaoal, R. A.; Sutton, R. E.; Anderson, K. S.; Jorgensen, W. L.; Krystal, M.; Spiegel, D. A. Illuminating HIV gp120-ligand recognition through computationally-driven optimization of antibody-recruiting molecules. Chem. Sci. 2014, 5, 23112317,  DOI: 10.1039/C4SC00484A
    186. 186
      Genady, A. R.; Janzen, N.; Banevicius, L.; El-Gamal, M.; El-Zaria, M. E.; Valliant, J. F. Preparation and evaluation of radiolabeled antibody recruiting small molecules that target prostate-specific membrane antigen for combined radiotherapy and immunotherapy. J. Med. Chem. 2016, 59, 26602673,  DOI: 10.1021/acs.jmedchem.5b01881
    187. 187
      Liu, Z.; Chen, X. Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem. Soc. Rev. 2016, 45, 14321456,  DOI: 10.1039/C5CS00158G
    188. 188
      Matos, M. J. Learning from nature: the role of albumin in drug delivery. Future Med. Chem. 2018, 10, 983985,  DOI: 10.4155/fmc-2018-0053
    189. 189
      Kratz, F.; Muller-Driver, R.; Hofmann, I.; Drevs, J.; Unger, C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J. Med. Chem. 2000, 43, 12531256,  DOI: 10.1021/jm9905864
    190. 190
      Jafari, N.; Ahmed, R.; Gloyd, M.; Bloomfield, J.; Britz-McKibbin, P.; Melacini, G. Allosteric sensing of fatty acid binding by NMR: application to human serum albumin. J. Med. Chem. 2016, 59, 74577465,  DOI: 10.1021/acs.jmedchem.6b00410
    191. 191
      Shechter, Y.; Tsubery, H.; Fridkin, M. N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl](3)-gentamicin C(1) is a long-acting prodrug derivative. J. Med. Chem. 2002, 45, 42644270,  DOI: 10.1021/jm020042t
    192. 192
      Zheng, Y. R.; Suntharalingam, K.; Johnstone, T. C.; Yoo, H.; Lin, W.; Brooks, J. G.; Lippard, S. J. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J. Am. Chem. Soc. 2014, 136, 87908798,  DOI: 10.1021/ja5038269
    193. 193
      Bech, E. M.; Martos-Maldonado, M. C.; Wismann, P.; Sorensen, K. K.; van Witteloostuijn, S. B.; Thygesen, M. B.; Vrang, N.; Jelsing, J.; Pedersen, S. L.; Jensen, K. J. Peptide half-life extension: divalent, small-molecule albumin interactions direct the systemic properties of glucagon-like peptide 1 (GLP-1) analogues. J. Med. Chem. 2017, 60, 74347446,  DOI: 10.1021/acs.jmedchem.7b00787
    194. 194
      Kratz, F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin. Invest. Drugs 2007, 16, 855866,  DOI: 10.1517/13543784.16.6.855
    195. 195
      Zhang, H.; Wang, K.; Na, K.; Li, D.; Li, Z.; Zhao, D.; Zhong, L.; Wang, M.; Kou, L.; Luo, C.; Zhang, H.; Kan, Q.; Ding, H.; He, Z.; Sun, J. Striking a balance between carbonate/carbamate linkage bond- and reduction-sensitive disulfide bond-bearing linker for tailored controlled release: in situ covalent-albumin-binding gemcitabine prodrugs promote bioavailability and tumor accumulation. J. Med. Chem. 2018, 61, 49044917,  DOI: 10.1021/acs.jmedchem.8b00293
    196. 196
      http://www.thebodypro.com/content/81083/china-approves-albuvirtide-a-once-weekly-injectabl.html (accessed Apr 8, 2019).
    197. 197
      Chong, H.; Yao, X.; Zhang, C.; Cai, L.; Cui, S.; Wang, Y.; He, Y. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS One 2012, 7, e32599,  DOI: 10.1371/journal.pone.0032599
    198. 198
      (a) Bohn, P.; Le Fur, N.; Hagues, G.; Costentin, J.; Torquet, N.; Papamicaël, C.; Marsais, F.; Levacher, V. Rational design of central selective acetylcholinesterase inhibitors by means of a ″bio-oxidisable prodrug″ strategy. Org. Biomol. Chem. 2009, 7, 26122618,  DOI: 10.1039/b903041g .
      (b) Bohn, P.; Gourand, F.; Papamicaël, C.; Ibazizène, M.; Dhilly, M.; Gembus, V.; Alix, F.; Ţînţaş, M. L.; Marsais, F.; Barré, L.; Levacher, V. Dihydroquinoline carbamate derivatives as ″bio-oxidizable″ prodrugs for brain delivery of acetylcholinesterase inhibitors: [11C] Radiosynthesis and biological evaluation. ACS Chem. Neurosci. 2015, 6, 737744,  DOI: 10.1021/cn5003539 .
      (c) Peauger, L.; Azzouz, R.; Gembus, V.; Ţînţaş, M. L.; Sopková-de Oliveira Santos, J.; Bohn, P.; Papamicaël, C.; Levacher, V. Donepezil-based central acetylcholinesterase inhibitors by means of a ″bio-oxidizable″ prodrug strategy: design, synthesis, and in vitro biological evaluation. J. Med. Chem. 2017, 60, 59095926,  DOI: 10.1021/acs.jmedchem.7b00702 .
      (d) Azzouz, R.; Peauger, L.; Gembus, V.; Ţînţaş, M. L.; Sopková-de Oliveira Santos, J.; Papamicaël, C.; Levacher, V. Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ″bio-oxidizable″ prodrugs: Synthesis, biological evaluation and structure-activity relationship. Eur. J. Med. Chem. 2018, 145, 165190,  DOI: 10.1016/j.ejmech.2017.12.084
    199. 199
      Childress, E. S.; Alexopoulos, S. J.; Hoehn, K. L.; Santos, W. L. Small molecule mitochondrial uncouplers and their therapeutic potential. J. Med. Chem. 2018, 61, 46414655,  DOI: 10.1021/acs.jmedchem.7b01182
    200. 200
      Millard, M.; Gallagher, J. D.; Olenyuk, B. Z.; Neamati, N. A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. J. Med. Chem. 2013, 56, 91709179,  DOI: 10.1021/jm4012438
    201. 201
      (a) Ye, Y.; Zhang, T.; Yuan, H.; Li, D.; Lou, H.; Fan, P. Mitochondria-targeted lupane triterpenoid derivatives and their selective apoptosis-inducing anticancer mechanisms. J. Med. Chem. 2017, 60, 63536363,  DOI: 10.1021/acs.jmedchem.7b00679 .
      (b) Chang, W.; Liu, J.; Zhang, M.; Shi, H.; Zheng, S.; Jin, X.; Gao, Y.; Wang, S.; Ji, A.; Lou, H. Efflux pump-mediated resistance to antifungal compounds can be prevented by conjugation with triphenylphosphonium cation. Nat. Commun. 2018, 9, 5102,  DOI: 10.1038/s41467-018-07633-9
    202. 202
      Bauer, R. A. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discovery Today 2015, 20, 10611073,  DOI: 10.1016/j.drudis.2015.05.005
    203. 203
      Zhao, Z.; Liu, Q.; Bliven, S.; Xie, L.; Bourne, P. E. Determining cysteines available for covalent inhibition across the human kinome. J. Med. Chem. 2017, 60, 28792889,  DOI: 10.1021/acs.jmedchem.6b01815
    204. 204
      Akbar, A.; McNeil, N. M. R.; Albert, M. R.; Ta, V.; Adhikary, G.; Bourgeois, K.; Eckert, R. L.; Keillor, J. W. Structure-activity relationships of potent, targeted covalent inhibitors that abolish both the transamidation and GTP binding activities of human tissue transglutaminase. J. Med. Chem. 2017, 60, 79107927,  DOI: 10.1021/acs.jmedchem.7b01070
    205. 205
      Muth, F.; El-Gokha, A.; Ansideri, F.; Eitel, M.; Doring, E.; Sievers-Engler, A.; Lange, A.; Boeckler, F. M.; Lammerhofer, M.; Koch, P.; Laufer, S. A. Tri- and tetrasubstituted pyridinylimidazoles as covalent inhibitors of c-Jun N-terminal kinase 3. J. Med. Chem. 2017, 60, 594607,  DOI: 10.1021/acs.jmedchem.6b01180
    206. 206
      Shi, L.; Zhong, Z.; Li, X.; Zhou, Y.; Pan, Z. Discovery of an orally available janus kinase 3 selective covalent inhibitor. J. Med. Chem. 2019, 62, 1054,  DOI: 10.1021/acs.jmedchem.8b01823
    207. 207
      (a) Patricelli, M. P.; Janes, M. R.; Li, L. S.; Hansen, R.; Peters, U.; Kessler, L. V.; Chen, Y.; Kucharski, J. M.; Feng, J.; Ely, T.; Chen, J. H.; Firdaus, S. J.; Babbar, A.; Ren, P.; Liu, Y. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discovery 2016, 6, 316329,  DOI: 10.1158/2159-8290.CD-15-1105 .
      (b) Hansen, R.; Peters, U.; Babbar, A.; Chen, Y.; Feng, J.; Janes, M. R.; Li, L. S.; Ren, P.; Liu, Y.; Zarrinkar, P. P. The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors. Nat. Struct. Mol. Biol. 2018, 25, 454,  DOI: 10.1038/s41594-018-0061-5
    208. 208
      Brameld, K. A.; Owens, T. D.; Verner, E.; Venetsanakos, E.; Bradshaw, J. M.; Phan, V. T.; Tam, D.; Leung, K.; Shu, J.; LaStant, J.; Loughhead, D. G.; Ton, T.; Karr, D. E.; Gerritsen, M. E.; Goldstein, D. M.; Funk, J. O. Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido [2,3-d]pyrimidin-7(8H)-one (PRN1371) for the treatment of solid tumors. J. Med. Chem. 2017, 60, 65166527,  DOI: 10.1021/acs.jmedchem.7b00360
    209. 209
      Wolle, P.; Hardick, J.; Cronin, S. J. F.; Engel, J.; Baumann, M.; Lategahn, J.; Penninger, J.; Rauh, D. Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c Jun N-Terminal Kinase) pathway with covalent inhibitors. J. Med. Chem. 2019, 62, 2843,  DOI: 10.1021/acs.jmedchem.9b00102
    210. 210
      Lelais, G.; Epple, R.; Marsilje, T. H.; Long, Y. O.; McNeill, M.; Chen, B.; Lu, W.; Anumolu, J.; Badiger, S.; Bursulaya, B.; DiDonato, M.; Fong, R.; Juarez, J.; Li, J.; Manuia, M.; Mason, D. E.; Gordon, P.; Groessl, T.; Johnson, K.; Jia, Y.; Kasibhatla, S.; Li, C.; Isbell, J.; Spraggon, G.; Bender, S.; Michellys, P. Y. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a novel, potent, and wt sparing covalent inhibitor of oncogenic (L858R, ex19del) and resistant (T790M) EGFR nutants for the treatment of EGFR mutant non-small-cell lung cancers. J. Med. Chem. 2016, 59, 66716689,  DOI: 10.1021/acs.jmedchem.5b01985
    211. 211
      Horton, J. R.; Woodcock, C. B.; Chen, Q.; Liu, X.; Zhang, X.; Shanks, J.; Rai, G.; Mott, B. T.; Jansen, D. J.; Kales, S. C.; Henderson, M. J.; Cyr, M.; Pohida, K.; Hu, X.; Shah, P.; Xu, X.; Jadhav, A.; Maloney, D. J.; Hall, M. D.; Simeonov, A.; Fu, H.; Vertino, P. M.; Cheng, X. Structure-based engineering of irreversible inhibitors against histone lysine demethylase KDM5A. J. Med. Chem. 2018, 61, 10588,  DOI: 10.1021/acs.jmedchem.8b01219
    212. 212
      Liu, Y.; Xie, Z.; Zhao, D.; Zhu, J.; Mao, F.; Tang, S.; Xu, H.; Luo, C.; Geng, M.; Huang, M.; Li, J. Development of the first generation of disulfide-based subtype-selective and potent covalent pyruvate dehydrogenase kinase 1 (PDK1) inhibitors. J. Med. Chem. 2017, 60, 22272244,  DOI: 10.1021/acs.jmedchem.6b01245
    213. 213
      (a) McAllister, L. A.; O’Neil, S. V.; Fonseca, K. R.; Piro, J. R.; Cianfrogna, J. A.; Foley, T. L.; Gilbert, A. M.; Harris, A. R.; Helal, C. J.; Johnson, D. S.; Montgomery, J. I.; Nason, D. M.; Noell, S.; Pandit, J.; Rogers, B. N.; Samad, T. A.; Shaffer, C. L.; da Silva, R. G.; Uccello, D. P.; Webb, D.; Brodney, M. A. Discovery of trifluoromethyl glycol carbamates as potent and selective covalent monoacylglycerol lipase (MAGL) inhibitors for treatment of neuroinflammation. J. Med. Chem. 2018, 61, 30083026,  DOI: 10.1021/acs.jmedchem.8b00070 .
      (b) Butler, C. R.; Beck, E. M.; Harris, A.; Huang, Z.; McAllister, L. A.; Am Ende, C. W.; Fennell, K.; Foley, T. L.; Fonseca, K.; Hawrylik, S. J.; Johnson, D. S.; Knafels, J. D.; Mente, S.; Noell, G. S.; Pandit, J.; Phillips, T. B.; Piro, J. R.; Rogers, B. N.; Samad, T. A.; Wang, J.; Wan, S.; Brodney, M. A. Azetidine and piperidine carbamates as efficient, covalent inhibitors of monoacylglycerol lipase. J. Med. Chem. 2017, 60, 98609873,  DOI: 10.1021/acs.jmedchem.7b01531
    214. 214
      Kulkarni, P. M.; Kulkarni, A. R.; Korde, A.; Tichkule, R. B.; Laprairie, R. B.; Denovan-Wright, E. M.; Zhou, H.; Janero, D. R.; Zvonok, N.; Makriyannis, A.; Cascio, M. G.; Pertwee, R. G.; Thakur, G. A. Novel electrophilic and photoaffinity covalent probes for mapping the cannabinoid 1 receptor allosteric site(s). J. Med. Chem. 2016, 59, 4460,  DOI: 10.1021/acs.jmedchem.5b01303
    215. 215
      Doornbos, M. L. J.; Wang, X.; Vermond, S. C.; Peeters, L.; Pérez-Benito, L.; Trabanco, A. A.; Lavreysen, H.; Cid, J. M.; Heitman, L. H.; Tresadern, G.; IJzerman, A. P. Covalent allosteric probe for the metabotropic glutamate receptor 2: Design, synthesis, and pharmacological characterization. J. Med. Chem. 2019, 62, 223,  DOI: 10.1021/acs.jmedchem.8b00051
    216. 216
      Casimiro-Garcia, A.; Trujillo, J. I.; Vajdos, F.; Juba, B.; Banker, M. E.; Aulabaugh, A.; Balbo, P.; Bauman, J.; Chrencik, J.; Coe, J. W.; Czerwinski, R.; Dowty, M.; Knafels, J. D.; Kwon, S.; Leung, L.; Liang, S.; Robinson, R. P.; Telliez, J. B.; Unwalla, R.; Yang, X.; Thorarensen, A. Identification of cyanamide-based Janus kinase 3 (JAK3) covalent inhibitors. J. Med. Chem. 2018, 61, 10665,  DOI: 10.1021/acs.jmedchem.8b01308
    217. 217
      Chan, A. H.; Lee, W. G.; Spasov, K. A.; Cisneros, J. A.; Kudalkar, S. N.; Petrova, Z. O.; Buckingham, A. B.; Anderson, K. S.; Jorgensen, W. Covalent inhibitors for eradication of drug-resistant HIV-1 reverse transcriptase: from design to protein crystallography. Proc. Natl. Acad. Sci. U. S. A. 2017, 114, 97259730,  DOI: 10.1073/pnas.1711463114
    218. 218
      Shindo, N.; Fuchida, H.; Sato, M.; Watari, K.; Shibata, T.; Kuwata, K.; Miura, C.; Okamoto, K.; Hatsuyama, Y.; Tokunaga, K.; Sakamoto, S.; Morimoto, S.; Abe, Y.; Shiroishi, M.; Caaveiro, J. M. M.; Ueda, T.; Tamura, T.; Matsunaga, N.; Nakao, T.; Koyanagi, S.; Ohdo, S.; Yamaguchi, Y.; Hamachi, I.; Ono, M.; Ojida, A. Selective and reversible modification of kinase cysteines with chlorofluoroacetamides. Nat. Chem. Biol. 2019, 15, 250,  DOI: 10.1038/s41589-018-0204-3
    219. 219
      (a) Brouwer, A. J.; Jonker, A.; Werkhoven, P.; Kuo, E.; Li, N.; Gallastegui, N.; Kemmink, J.; Florea, B. I.; Groll, M.; Overkleeft, H. S.; Liskamp, R. M. Peptido sulfonyl fluorides as new powerful proteasome inhibitors. J. Med. Chem. 2012, 55, 109951003,  DOI: 10.1021/jm301443r .
      (b) Artschwager, R.; Ward, D.; Gannon, S.; Brouwer, A. J.; van de Langemheen, H.; Kowalski, H.; Liskamp, R. Potent and highly selective inhibitors of the proteasome trypsin-like site by incorporation of basic side chain containing amino acid derived sulfonyl fluorides. J. Med. Chem. 2018, 61, 53955411,  DOI: 10.1021/acs.jmedchem.8b00685
    220. 220
      Yang, F.; Zhu, M.; Zhang, J.; Zhou, H. Synthesis of biologically active boron-containing compounds. MedChemComm 2018, 9, 201211,  DOI: 10.1039/C7MD00552K
    221. 221
      (a) Smith, T. P.; Windsor, I. W.; Forest, K. T.; Raines, R. T. Stilbene boronic acids form a covalent bond with human transthyretin and inhibit its aggregation. J. Med. Chem. 2017, 60, 78207834,  DOI: 10.1021/acs.jmedchem.7b00952 .
      (b) Windsor, I. W.; Palte, M. J.; Lukesh, J. C., 3rd.; Gold, B.; Forest, K. T.; Raines, R. T. Sub-picomolar inhibition of hiv-1 protease with a boronic acid. J. Am. Chem. Soc. 2018, 140, 1401514018,  DOI: 10.1021/jacs.8b07366
    222. 222
      Nitsche, C.; Zhang, L.; Weigel, L. F.; Schilz, J.; Graf, D.; Bartenschlager, R.; Hilgenfeld, R.; Klein, C. D. Peptide-boronic acid inhibitors of flaviviral proteases: medicinal chemistry and structural biology. J. Med. Chem. 2017, 60, 511516,  DOI: 10.1021/acs.jmedchem.6b01021
    223. 223
      Zervosen, A.; Herman, R.; Kerff, F.; Herman, A.; Bouillez, A.; Prati, F.; Pratt, R. F.; Frère, J. M.; Joris, B.; Luxen, A.; Charlier, P.; Sauvage, E. Unexpected tricovalent binding mode of boronic acids within the active site of a penicillin-binding protein. J. Am. Chem. Soc. 2011, 133, 1083910848,  DOI: 10.1021/ja200696y
    224. 224
      (a) Powers, R. A.; Swanson, H. C.; Taracila, M. A.; Florek, N. W.; Romagnoli, C.; Caselli, E.; Prati, F.; Bonomo, R. A.; Wallar, B. J. Biochemical and structural analysis of inhibitors targeting the ADC-7 cephalosporinase of Acinetobacter baumannii. Biochemistry 2014, 53, 76707679,  DOI: 10.1021/bi500887n .
      (b) Caselli, E.; Romagnoli, C.; Vahabi, R.; Taracila, M. A.; Bonomo, R. A.; Prati, F. Click chemistry in lead optimization of boronic acids as β-lactamase inhibitors. J. Med. Chem. 2015, 58, 54455458,  DOI: 10.1021/acs.jmedchem.5b00341 .
      (c) Bouza, A. A.; Swanson, H. C.; Smolen, K. A.; VanDine, A. L.; Taracila, M. A.; Romagnoli, C.; Caselli, E.; Prati, F.; Bonomo, R. A.; Powers, R. A.; Wallar, B. J. Structure-based analysis of boronic acids as inhibitors of acinetobacter-derived cephalosporinase-7, a unique class C β-lactamase. ACS Infect. Dis. 2018, 4, 325336,  DOI: 10.1021/acsinfecdis.7b00152 .
      (d) Caselli, E.; Romagnoli, C.; Powers, R. A.; Taracila, M. A.; Bouza, A. A.; Swanson, H. C.; Smolen, K. A.; Fini, F.; Wallar, B. J.; Bonomo, R. A.; Prati, F. Inhibition of acinetobacter-derived cephalosporinase: exploring the carboxylate recognition site using novel β-lactamase inhibitors. ACS Infect. Dis. 2018, 4, 337348,  DOI: 10.1021/acsinfecdis.7b00153
    225. 225
      Mons, E.; Jansen, I. D. C.; Loboda, J.; van Doodewaerd, B. R.; Hermans, J.; Verdoes, M.; van Boeckel, C. A. A.; van Veelen, P. A.; Turk, B.; Turk, D.; Ovaa, H. The alkyne moiety as a latent electrophile in irreversible covalent small molecule inhibitors of Cathepsin K. J. Am. Chem. Soc. 2019, 141, 3507,  DOI: 10.1021/jacs.8b11027
    226. 226
      Palermo, G.; Branduardi, D.; Masetti, M.; Lodola, A.; Mor, M.; Piomelli, D.; Cavalli, A.; De Vivo, M. Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas. J. Med. Chem. 2011, 54, 66126623,  DOI: 10.1021/jm2004283
    227. 227
      Chatterjee, P.; Botello-Smith, W. M.; Zhang, H.; Qian, L.; Alsamarah, A.; Kent, D.; Lacroix, J. J.; Baudry, M.; Luo, Y. Can relative binding free energy predict selectivity of reversible covalent inhibitors?. J. Am. Chem. Soc. 2017, 139, 1794517952,  DOI: 10.1021/jacs.7b08938
    228. 228
      Scarpino, A.; Ferenczy, G. G.; Keseru, G. M. Comparative evaluation of covalent docking tools. J. Chem. Inf. Model. 2018, 58, 14411458,  DOI: 10.1021/acs.jcim.8b00228
    229. 229
      (a) Kathman, S. G.; Xu, Z.; Statsyuk, A. V. A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases. J. Med. Chem. 2014, 57, 49694974,  DOI: 10.1021/jm500345q .
      (b) Kathman, S. G.; Span, I.; Smith, A. T.; Xu, Z.; Zhan, J.; Rosenzweig, A. C.; Statsyuk, A. V. A small molecule that switches a ubiquitin ligase from a processive to a distributive enzymatic mechanism. J. Am. Chem. Soc. 2015, 137, 1244212445,  DOI: 10.1021/jacs.5b06839
    230. 230
      Johansson, H.; Tsai, Y. I.; Fantom, K.; Chung, C. W.; Kümper, S.; Martino, L.; Thomas, D. A.; Eberl, H. C.; Muelbaier, M.; House, D.; Rittinger, K. Fragment-based covalent ligand screening enables rapid discovery of inhibitors for the RBR E3 ubiquitin ligase HOIP. J. Am. Chem. Soc. 2019, 141, 2703,  DOI: 10.1021/jacs.8b13193
    231. 231
      Lavogina, D.; Lust, M.; Viil, I.; König, N.; Raidaru, G.; Rogozina, J.; Enkvist, E.; Uri, A.; Bossemeyer, D. Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. J. Med. Chem. 2009, 52, 308321,  DOI: 10.1021/jm800797n
    232. 232
      Gao, F.; Yan, X.; Shakya, T.; Baettig, O. M.; Ait-Mohand-Brunet, S.; Berghuis, A. M.; Wright, G. D.; Auclair, K. Synthesis and structure-activity relationships of truncated bisubstrate inhibitors of aminoglycoside 6′-N-acetyltransferases. J. Med. Chem. 2006, 49, 52735281,  DOI: 10.1021/jm060732n
    233. 233
      Bockman, M. R.; Kalinda, A. S.; Petrelli, R.; De la Mora-Rey, T.; Tiwari, D.; Liu, F.; Dawadi, S.; Nandakumar, M.; Rhee, K. Y.; Schnappinger, D.; Finzel, B. C.; Aldrich, C. C. Targeting mycobacterium tuberculosis biotin protein ligase (MtBPL) with nucleoside-based bisubstrate adenylation inhibitors. J. Med. Chem. 2015, 58, 73497369,  DOI: 10.1021/acs.jmedchem.5b00719
    234. 234
      Halby, L.; Menon, Y.; Rilova, E.; Pechalrieu, D.; Masson, V.; Faux, C.; Bouhlel, M. A.; David-Cordonnier, M. H.; Novosad, N.; Aussagues, Y.; Samson, A.; Lacroix, L.; Ausseil, F.; Fleury, L.; Guianvarc’h, D.; Ferroud, C.; Arimondo, P. B. Rational design of bisubstrate-type analogues as inhibitors of DNA methyltransferases in cancer cells. J. Med. Chem. 2017, 60, 46654679,  DOI: 10.1021/acs.jmedchem.7b00176
    235. 235
      Babault, N.; Allali-Hassani, A.; Li, F.; Fan, J.; Yue, A.; Ju, K.; Liu, F.; Vedadi, M.; Liu, J.; Jin, J. Discovery of bisubstrate inhibitors of nicotinamide N-methyltransferase (NNMT). J. Med. Chem. 2018, 61, 15411551,  DOI: 10.1021/acs.jmedchem.7b01422
    236. 236
      Cinelli, M. A.; Li, H.; Chreifi, G.; Poulos, T. L.; Silverman, R. B. Nitrile in the hole: Discovery of a small auxiliary pocket in neuronal nitric oxide synthase leading to the development of potent and selective 2-aminoquinoline Inhibitors. J. Med. Chem. 2017, 60, 39583978,  DOI: 10.1021/acs.jmedchem.7b00259
    237. 237
      Ye, S.; Loll, B.; Berger, A. A.; Mülow, U.; Alings, C.; Wahl, M. C.; Koksch, B. Fluorine teams up with water to restore inhibitor activity to mutant BPTI. Chem. Sci. 2015, 6, 52465254,  DOI: 10.1039/C4SC03227F
    238. 238
      Seo, J.; Igarashi, J.; Li, H.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Structure-based design and synthesis of N(omega)-nitro-L-arginine-containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water. J. Med. Chem. 2007, 50, 20892099,  DOI: 10.1021/jm061305c
    239. 239
      Fornabaio, M.; Spyrakis, F.; Mozzarelli, A.; Cozzini, P.; Abraham, D. J.; Kellogg, G. E. Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 3. The free energy contribution of structural water molecules in HIV-1 protease complexes. J. Med. Chem. 2004, 47, 45074516,  DOI: 10.1021/jm030596b
    240. 240
      (a) Chong, P. Y.; Shotwell, J. B.; Miller, J. F.; Price, D. J.; Maynard, A.; Voitenleitner, C.; Mathis, A.; Williams, S.; Pouliot, J.; Creech, K.; Wang, F.; Fang, J. M.; Zhang, H.; Tai, V.; Turner, E.; Kahler, K. M.; Crosby, R.; Peat, A. J. Design of N-benzoxaborole benzofuran GSK8175 - Optimization of human PK inspired by metabolites of a failed clinical HCV inhibitor. J. Med. Chem. 2019, 62, 3254,  DOI: 10.1021/acs.jmedchem.8b01719 .
      (b) Zhan, P.; Kang, D.; Liu, X. Resurrecting the condemned: Identification of N-benzoxaborole benzofuran GSK8175 as a clinical candidate with reduced metabolic liability. J. Med. Chem. 2019, 62, 3251,  DOI: 10.1021/acs.jmedchem.9b00415
    241. 241
      Spyrakis, F.; Ahmed, M. H.; Bayden, A. S.; Cozzini, P.; Mozzarelli, A.; Kellogg, G. E. The roles of water in the protein matrix: a largely untapped resource for drug discovery. J. Med. Chem. 2017, 60, 67816827,  DOI: 10.1021/acs.jmedchem.7b00057
    242. 242
      Gerstenberger, B. S.; Trzupek, J. D.; Tallant, C.; Fedorov, O.; Filippakopoulos, P.; Brennan, P. E.; Fedele, V.; Martin, S.; Picaud, S.; Rogers, C.; Parikh, M.; Taylor, A.; Samas, B.; O’Mahony, A.; Berg, E.; Pallares, G.; Torrey, A. D.; Treiber, D. K.; Samardjiev, I. J.; Nasipak, B. T.; Padilla-Benavides, T.; Wu, Q.; Imbalzano, A. N.; Nickerson, J. A.; Bunnage, M. E.; Muller, S.; Knapp, S.; Owen, D. R. Identification of a chemical probe for family VIII bromodomains through optimization of a fragment hit. J. Med. Chem. 2016, 59, 48004811,  DOI: 10.1021/acs.jmedchem.6b00012
    243. 243
      Kuhne, S.; Kooistra, A. J.; Bosma, R.; Bortolato, A.; Wijtmans, M.; Vischer, H. F.; Mason, J. S.; de Graaf, C.; de Esch, I. J.; Leurs, R. Identification of ligand binding hot spots of the histamine H1 receptor following structure-based fragment optimization. J. Med. Chem. 2016, 59, 90479061,  DOI: 10.1021/acs.jmedchem.6b00981
    244. 244
      Blanco, B.; Sedes, A.; Peon, A.; Otero, J. M.; van Raaij, M. J.; Thompson, P.; Hawkins, A. R.; Gonzalez-Bello, C. Exploring the water-binding pocket of the type II dehydroquinase enzyme in the structure-based design of inhibitors. J. Med. Chem. 2014, 57, 34943510,  DOI: 10.1021/jm500175z
    245. 245
      Wright, Z. V. F.; Wu, N. C.; Kadam, R. U.; Wilson, I. A.; Wolan, D. W. Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin. Bioorg. Med. Chem. Lett. 2017, 27, 37443748,  DOI: 10.1016/j.bmcl.2017.06.074
    246. 246
      Mosure, S.; Shang, J.; Eberhardt, J.; Brust, R.; Zheng, J.; Griffin, P. R.; Forli, S.; Kojetin, D. J. Structural basis of altered potency and efficacy displayed by a major in vivo metabolite of the anti-diabetic PPARγ drug pioglitazone. J. Med. Chem. 2019, 62, 2008,  DOI: 10.1021/acs.jmedchem.8b01573
    247. 247
      Thomaston, J. L.; Polizzi, N. F.; Konstantinidi, A.; Wang, J.; Kolocouris, A.; DeGrado, W. F. Inhibitors of the M2 proton channel engage and disrupt transmembrane networks of hydrogen-bonded waters. J. Am. Chem. Soc. 2018, 140, 15219,  DOI: 10.1021/jacs.8b06741
    248. 248
      Geist, L.; Mayer, M.; Cockcroft, X.-L.; Wolkerstorfer, B.; Kessler, D.; Engelhardt, H.; McConnell, D. B.; Konrat, R. Direct NMR probing of hydration shells of protein ligand interfaces and its application to drug design. J. Med. Chem. 2017, 60, 87088715,  DOI: 10.1021/acs.jmedchem.7b00845
    249. 249
      Murphy, R. B.; Repasky, M. P.; Greenwood, J. R.; Tubert-Brohman, I.; Jerome, S.; Annabhimoju, R.; Boyles, N. A.; Schmitz, C. D.; Abel, R.; Farid, R.; Friesner, R. A. WScore: A flexible and accurate treatment of explicit water molecules in ligand-receptor docking. J. Med. Chem. 2016, 59, 43644384,  DOI: 10.1021/acs.jmedchem.6b00131
    250. 250
      Peach, M. L.; Tan, N.; Choyke, S. J.; Giubellino, A.; Athauda, G.; Burke, T. R., Jr.; Nicklaus, M. C.; Bottaro, D. P. Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. J. Med. Chem. 2009, 52, 943951,  DOI: 10.1021/jm800791f
    251. 251
      Klüter, S.; Grutter, C.; Naqvi, T.; Rabiller, M.; Simard, J. R.; Pawar, V.; Getlik, M.; Rauh, D. Displacement assay for the detection of stabilizers of inactive kinase conformations. J. Med. Chem. 2010, 53, 357367,  DOI: 10.1021/jm901297e
    252. 252
      (a) Whelligan, D. K.; Solanki, S.; Taylor, D.; Thomson, D. W.; Cheung, K. M.; Boxall, K.; Mas-Droux, C.; Barillari, C.; Burns, S.; Grummitt, C. G.; Collins, I.; van Montfort, R. L.; Aherne, G. W.; Bayliss, R.; Hoelder, S. Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J. Med. Chem. 2010, 53, 76827698,  DOI: 10.1021/jm1008727 .
      (b) Colombano, G.; Caldwell, J. J.; Matthews, T. P.; Bhatia, C.; Joshi, A.; McHardy, T.; Mok, N. Y.; Newbatt, Y.; Pickard, L.; Strover, J.; Hedayat, S.; Walton, M. I.; Myers, S.; Jones, A. M.; Saville, H.; McAndrew, C.; Burke, R.; Eccles, S.; Davies, F.; Bayliss, R.; Collins, I. Binding to an unusual inactive kinase conformation by highly selective inhibitors of inositol-requiring enzyme 1α kinase-endoribonuclease. J. Med. Chem. 2019, 62, 2447,  DOI: 10.1021/acs.jmedchem.8b01721
    253. 253
      Prado, V.; Lence, E.; Maneiro, M.; Vazquez-Ucha, J. C.; Beceiro, A.; Thompson, P.; Hawkins, A. R.; Gonzalez-Bello, C. Targeting the motion of shikimate kinase: development of competitive inhibitors that stabilize an inactive open conformation of the enzyme. J. Med. Chem. 2016, 59, 54715487,  DOI: 10.1021/acs.jmedchem.6b00483
    254. 254
      Weisner, J.; Gontla, R.; van der Westhuizen, L.; Oeck, S.; Ketzer, J.; Janning, P.; Richters, A.; Mühlenberg, T.; Fang, Z.; Taher, A.; Jendrossek, V.; Pelly, S. C.; Bauer, S.; van Otterlo, W. A.; Rauh, D. Covalent-allosteric kinase inhibitors. Angew. Chem., Int. Ed. 2015, 54, 1031310316,  DOI: 10.1002/anie.201502142
    255. 255
      (a) Milroy, L. G.; Bartel, M.; Henen, M. A.; Leysen, S.; Adriaans, J. M.; Brunsveld, L.; Landrieu, I.; Ottmann, C. Stabilizer-guided inhibition of protein-protein interactions. Angew. Chem., Int. Ed. 2015, 54, 1572015724,  DOI: 10.1002/anie.201507976 .
      (b) Sijbesma, E.; Hallenbeck, K. K.; Leysen, S.; de Vink, P.; Skora, L.; Jahnke, W.; Brunsveld, L.; Arkin, M. R.; Ottmann, C. Site-directed fragment-based screening for the discovery of protein-protein interaction stabilizers. J. Am. Chem. Soc. 2019, 141, 3524,  DOI: 10.1021/jacs.8b11658 .
      (c) Andrei, S. A.; de Vink, P.; Sijbesma, E.; Han, L.; Brunsveld, L.; Kato, N.; Ottmann, C.; Higuchi, Y. Rationally designed semisynthetic natural product analogues for stabilization of 14–3-3 protein-protein interactions. Angew. Chem., Int. Ed. 2018, 57, 1347013474,  DOI: 10.1002/anie.201806584
    256. 256
      (a) Andrei, S. A.; Sijbesma, E.; Hann, M.; Davis, J.; O’Mahony, G.; Perry, M. W. D.; Karawajczyk, A.; Eickhoff, J.; Brunsveld, L.; Doveston, R. G.; Milroy, L. G.; Ottmann, C. Stabilization of protein-protein interactions in drug discovery. Expert Opin. Drug Discovery 2017, 12, 925940,  DOI: 10.1080/17460441.2017.1346608 .
      (b) Bier, D.; Thiel, P.; Briels, J.; Ottmann, C. Stabilization of protein-protein interactions in chemical biology and drug discovery. Prog. Biophys. Mol. Biol. 2015, 119, 1019,  DOI: 10.1016/j.pbiomolbio.2015.05.002 .
      (c) Giordanetto, F.; Schäfer, A.; Ottmann, C. Stabilization of protein-protein interactions by small molecules. Drug Discovery Today 2014, 19, 18121821,  DOI: 10.1016/j.drudis.2014.08.005 .
      (d) Thiel, P.; Kaiser, M.; Ottmann, C. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?. Angew. Chem., Int. Ed. 2012, 51, 20122018,  DOI: 10.1002/anie.201107616
    257. 257
      Verteramo, M. L.; Stenström, O.; Ignjatović, M. M.; Caldararu, O.; Olsson, M. A.; Manzoni, F.; Leffler, H.; Oksanen, E.; Logan, D. T.; Nilsson, U. J.; Ryde, U.; Akke, M. Interplay between Conformational Entropy and Solvation Entropy in Protein-Ligand Binding. J. Am. Chem. Soc. 2019, 141, 20122026,  DOI: 10.1021/jacs.8b11099
    258. 258
      Campos, K. R.; Coleman, P. J.; Alvarez, J. C.; Dreher, S. D.; Garbaccio, R. M.; Terrett, N. K.; Tillyer, R. D.; Truppo, M. D.; Parmee, E. R. The importance of synthetic chemistry in the pharmaceutical industry. Science 2019, 363, eaat0805,  DOI: 10.1126/science.aat0805
    259. 259
      (a) Nielsen, T. E.; Schreiber, S. L. Towards the optimal screening collection: a synthesis strategy. Angew. Chem., Int. Ed. 2008, 47, 4856,  DOI: 10.1002/anie.200703073 .
      (b) Gerry, C. J.; Schreiber, S. L. Chemical probes and drug leads from advances in synthetic planning and methodology. Nat. Rev. Drug Discovery 2018, 17, 333352,  DOI: 10.1038/nrd.2018.53
    260. 260
      Dömling, A.; Wang, W.; Wang, K. Chemistry and biology of multicomponent reactions. Chem. Rev. 2012, 112, 3083135,  DOI: 10.1021/cr100233r
    261. 261
      Wagner, B. K.; Schreiber, S. L. The power of sophisticated phenotypic screening and modern mechanism-of-action methods. Cell Chem. Biol. 2016, 23, 39,  DOI: 10.1016/j.chembiol.2015.11.008
    262. 262
      Churcher, I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?. J. Med. Chem. 2018, 61, 444452,  DOI: 10.1021/acs.jmedchem.7b01272
    263. 263
      (a) Murcko, M. A. What makes a great medicinal chemist? A personal perspective. J. Med. Chem. 2018, 61, 74197424,  DOI: 10.1021/acs.jmedchem.7b01445 .
      (b) Walters, W. P.; Green, J.; Weiss, J. R.; Murcko, M. A. What do medicinal chemists actually make? A 50-year retrospective. J. Med. Chem. 2011, 54, 64056416,  DOI: 10.1021/jm200504p
    264. 264
      Zhang, P.; Huang, H.; Banerjee, S.; Clarkson, G. J.; Ge, C.; Imberti, C.; Sadler, P. J. Nucleus-targeted organoiridium-albumin conjugate for photodynamic cancer therapy. Angew. Chem., Int. Ed. Engl. 2019, 58, 2350,  DOI: 10.1002/anie.201813002
    265. 265
      Hoffer, L.; Voitovich, Y. V.; Raux, B.; Carrasco, K.; Muller, C.; Fedorov, A. Y.; Derviaux, C.; Amouric, A.; Betzi, S.; Horvath, D.; Varnex, A.; Collette, Y.; Combes, S.; Roche, P.; Morelli, X. Integrated strategy for lead optimization based on fragment growing: The diversity-oriented-target-focused-synthesis approach. J. Med. Chem. 2018, 61, 57195732,  DOI: 10.1021/acs.jmedchem.8b00653
    266. 266
      Fleming, N. How artificial intelligence is changing drug discovery. Nature 2018, 557, S55S57,  DOI: 10.1038/d41586-018-05267-x
    267. 267
      Schneider, G. Automating drug discovery. Nat. Rev. Drug Discovery 2017, 17, 97113,  DOI: 10.1038/nrd.2017.232

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

STEP 1:
Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

MENDELEY PAIRING EXPIRED
Your Mendeley pairing has expired. Please reconnect

This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. Read the ACS privacy policy.

CONTINUE